

P R O S P E C T U S

2,000,000 SHARES  
[LOGO]

COMMON STOCK

-----  
ENZON, INC. IS OFFERING 2,000,000 SHARES OF ITS COMMON STOCK.

-----  
OUR COMMON STOCK IS QUOTED ON THE NASDAQ NATIONAL MARKET UNDER THE SYMBOL  
'ENZN.' ON MARCH 20, 2000, THE REPORTED LAST SALE PRICE OF OUR COMMON STOCK WAS  
\$44 1/2 PER SHARE.

-----  
INVESTING IN OUR COMMON STOCK INVOLVES RISKS. SEE 'RISK FACTORS' BEGINNING ON  
PAGE 9.

-----  
PRICE \$44 1/2 A SHARE  
-----

	PRICE TO PUBLIC -----	UNDERWRITING DISCOUNTS AND COMMISSIONS -----	PROCEEDS TO COMPANY -----
Per Share.....	\$44.50	\$2.67	\$41.83
Total.....	\$89,000,000	\$5,340,000	\$83,660,000

We have granted the underwriters the right to purchase up to an additional  
300,000 shares to cover over-allotments.

The Securities and Exchange Commission and state securities regulators have not  
approved or disapproved these securities, or determined if this prospectus is  
truthful or complete. Any representation to the contrary is a criminal offense.

Morgan Stanley & Co. Incorporated expects to deliver the shares to purchasers on  
March 24, 2000.

-----  
MORGAN STANLEY DEAN WITTER

CIBC WORLD MARKETS

SG COWEN

March 20, 2000

TABLE OF CONTENTS

	PAGE
	----
Prospectus Summary.....	5
Risk Factors.....	9
Use of Proceeds.....	21
Price Range of Common Stock.....	22
Dividend Policy.....	22
Capitalization.....	23
Dilution.....	24
Selected Consolidated Financial Data.....	25
Management's Discussion and Analysis of Financial Condition and Results of Operations.....	26
Business.....	31
Management.....	50
Principal Stockholders.....	53
Description of Capital Stock.....	55
Material U.S. Federal Tax Considerations for Non-U.S. Holders of Common Stock.....	59
Underwriters.....	61
Legal Matters.....	62
Experts.....	62
Where You Can Find More Information..	63
Index to Financial Statements.....	F-1

-----

In this prospectus, the 'Company,' 'we,' 'us' and 'our' refer to Enzon, Inc. You should rely only on the information contained in this prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus. We are offering to sell shares of our common stock and seeking offers to buy shares of our common stock only in states where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of common stock.

-----

FORWARD-LOOKING STATEMENTS

The statements incorporated by reference or contained in this prospectus discuss our future expectations, contain projections of our results of operations or financial condition, and include other 'forward-looking' information within the meaning of Section 27A of the Securities Act of 1933, as amended. Forward-looking statements that express our beliefs, plans, objectives, assumptions or future events or performance may involve estimates, assumptions, risks and uncertainties. Therefore, our actual results and performance may differ materially from those expressed in the forward-looking statements. Forward-looking statements often, although not always, include words or phrases such as the following:

- 'will likely result'
- 'are expected to'
- 'will continue'
- 'is anticipated'
- 'estimate'
- 'intends'
- 'plans'

'projection'

'outlook'

2

You should not unduly rely on forward-looking statements contained or incorporated by reference in this prospectus. Actual results or outcomes may differ materially from those predicted in our forward-looking statements due to the risks and uncertainties inherent in our business, including risks and uncertainties in:

clinical trial results

obtaining and maintaining regulatory approval

market acceptance of and continuing demand of our products

the impact of competitive products and pricing

our ability to obtain additional financing to support our operations

factors discussed in the documents listed below

You should read and interpret any forward-looking statement together with the following documents:

our most recent Annual Report on Form 10-K

our Quarterly Reports on Form 10-Q

the risk factors contained in this prospectus under the caption 'Risk Factors'

our other filings with the Securities and Exchange Commission

Any forward-looking statement speaks only as of the date on which that statement is made. We will not update any forward-looking statement to reflect events or circumstances that occur after the date on which such statement is made.

3

[THIS PAGE INTENTIONALLY LEFT BLANK]

4

#### PROSPECTUS SUMMARY

This summary contains basic information about us and this offering. Because it is a summary, it does not contain all of the information that you should consider before investing. You should read this entire prospectus carefully, including the section entitled 'Risk Factors' and our financial statements and the notes thereto before making an investment decision. Except as otherwise noted, all information in this prospectus assumes no exercise of the underwriters' over-allotment option. See 'Underwriters.'

## OUR COMPANY

We are a biopharmaceutical company that develops and commercializes enhanced therapeutics for life-threatening diseases through the application of our two proprietary platform technologies: PEG and single-chain antibodies. We apply our PEG, or polyethylene glycol, technology to improve the delivery, safety and efficacy of proteins and small molecules with known therapeutic efficacy. We apply our single-chain antibody, or SCA, technology to discover and produce antibody-like molecules that offer many of the therapeutic benefits of monoclonal antibodies while addressing some of their limitations.

## PEG PRODUCTS

PEG-Intron is a PEG-enhanced version of Schering-Plough's alpha interferon product, INTRON A. We have designed PEG-Intron to allow for less frequent dosing, to have an improved side effect profile and to yield greater efficacy as compared to INTRON A. Our worldwide partner for PEG-Intron, Schering-Plough, has filed applications in both Europe and the United States for approval of PEG-Intron in the treatment of hepatitis C. In February 2000, Schering-Plough announced that the European regulatory committee reviewing the PEG-Intron application issued a positive opinion recommending approval of PEG-Intron for the treatment of adult patients with chronic hepatitis C. Product approval by the European regulatory authority is typically issued three months from the time that such committee renders its opinion. In February 2000, the FDA accepted Schering-Plough's December 1999 application for PEG-Intron for standard review, which typically takes 12 months from the date of filing. Schering-Plough is conducting a Phase III clinical trial of PEG-Intron as combination therapy with REBETOL for hepatitis C and Phase III clinical trials of PEG-Intron for the treatment of chronic myelogenous leukemia and malignant melanoma. Earlier stage clinical trials of PEG-Intron are being conducted for other indications, including HIV. Schering-Plough's worldwide sales of INTRON A and REBETRON Combination Therapy for all indications in 1999 totaled \$1.1 billion.

PROTHECAN is a PEG-enhanced version of camptothecin, a compound in the class of molecules called topoisomerase inhibitors. Camptothecin has been shown in clinical testing to be potent against certain tumor types, but it possesses limited clinical utility due to significant side effects and poor solubility. We have shown in pre-clinical studies that PROTHECAN has reduced side effects compared to camptothecin as well as other topoisomerase inhibitors and that it preferentially accumulates in tumors. We have initiated a Phase I clinical trial of PROTHECAN in treating various types of cancers.

We have commercialized two products based on our PEG technology: ADAGEN for the treatment of a congenital enzyme deficiency disease called SCID, and ONCASPAR for the treatment of acute lymphoblastic leukemia. Each of these products is a PEG-enhanced version of a naturally occurring enzyme. Both products have been on the market for several years and have demonstrated the safe and effective application of our PEG technology.

## SINGLE-CHAIN ANTIBODIES

SCAs are genetically engineered proteins which possess the binding specificity and affinity of monoclonal antibodies and are designed to expand on the therapeutic and diagnostic applications possible with monoclonal antibodies. Preclinical studies have shown that SCAs allow for greater tissue penetration and faster clearance from the body. We believe that we possess strong intellectual property in the area of SCAs. To date, 11 SCAs have been or are being tested in early stage clinical trials. The

most clinically advanced SCAs based on our technology are being developed by our licensee, Alexion Pharmaceuticals, for complications arising during cardiopulmonary bypass and myocardial infarction.

## STRATEGY

To further realize the potential value of our PEG and SCA technologies, we intend to pursue the following strategic initiatives:

continue to identify proteins and small molecules of known therapeutic value that we believe can be improved by our PEG technology and develop PEG-enhanced versions of such compounds

enter into license agreements with third parties to apply our PEG technology to their existing compounds

in-license and discover therapeutic SCAs for our own proprietary development, focusing initially on cancer and cardiovascular therapeutics

enter into license agreements with third parties who are developing SCAs in order to ensure proper compensation for use of our intellectual property

#### CORPORATE INFORMATION

Enzon, Inc. was incorporated in Delaware in 1981. Our principal executive offices are located at 20 Kingsbridge Road, Piscataway, New Jersey, 08854. Our telephone number at this location is (732) 980-4500. Our web site is located at <http://www.enzon.com>. The information contained on our web site is not a part of this prospectus.

-----

ADAGEN'r', ONCASPAR'r' and PROTHECAN'r' are our registered trademarks. Other trademarks and trade names used in this prospectus are the property of their respective owners.

6

#### THE OFFERING

Common stock offered.....	2,000,000 shares
Common stock to be outstanding after the offering....	40,049,632 shares
Over-allotment option.....	300,000 shares
Use of proceeds.....	We intend to use the proceeds from this offering for:  research and development activities, including the development of additional PEG and SCA compounds  facility upgrades  clinical trials for our current product candidates  general corporate purposes, including working capital
Nasdaq National Market symbol.....	ENZN

The number of shares of our common stock to be outstanding after this offering, utilizing the actual number of outstanding shares, as of February 15, 2000, does not take into account the following as of that date:

3,205,136 shares of common stock issuable upon the exercise of outstanding options at a weighted average exercise price of \$6.23 per share

457,731 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of \$5.75 per share

61,364 shares of common stock issuable upon the conversion of outstanding shares of our Series A preferred stock

7

SUMMARY FINANCIAL DATA

The financial data set forth below should be read in conjunction with the sections entitled 'Selected Financial Data,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations,' and the financial statements and notes included or incorporated by reference in this prospectus. The as adjusted Balance Sheet Data column gives effect to our sale of 2,000,000 shares of common stock in this offering, at a public offering price of \$44.50 per share.

	YEAR ENDED JUNE 30,			SIX MONTHS ENDED DECEMBER 31,	
	1997	1998	1999	1998	1999
	----	----	----	----	----
	(UNAUDITED)				
	(IN THOUSANDS, EXCEPT PER SHARE DATA)				
STATEMENT OF OPERATIONS DATA:					
Revenues:					
Sales.....	\$11,596	\$12,313	\$12,856	\$ 6,718	\$ 6,617
Contract revenues.....	1,131	2,331	302	67	62
	-----	-----	-----	-----	-----
Total revenues.....	12,727	14,644	13,158	6,785	6,679
Expenses:					
Cost of sales.....	3,840	3,645	4,310	2,339	1,972
Research and development.....	8,520	8,654	6,836	3,423	3,590
Selling, general and administrative.....	5,528	6,426	8,133	3,643	5,136
	-----	-----	-----	-----	-----
Total expenses.....	17,888	18,725	19,279	9,405	10,698
Operating loss.....	(5,161)	(4,081)	(6,121)	(2,620)	(4,019)
Other income, net.....	604	464	1,202	635	559
	-----	-----	-----	-----	-----
Net loss.....	\$(4,557)	\$(3,617)	\$(4,919)	\$(1,985)	\$(3,460)
	-----	-----	-----	-----	-----
Net loss per share:					
Basic and diluted.....	\$ (0.16)	\$ (0.12)	\$ (0.14)	\$ (0.06)	\$ (0.09)
	-----	-----	-----	-----	-----
Weighted average number of common shares outstanding:					
Basic and diluted.....	29,046	31,092	35,699	35,182	36,835

AS OF  
DECEMBER 31, 1999

ACTUAL	AS ADJUSTED
-----	-----
(UNAUDITED)	
(IN THOUSANDS)	

BALANCE SHEET DATA:

Cash and cash equivalents.....	\$23,262	\$106,379
Working capital.....	21,108	104,225
Total assets.....	34,433	117,550
Long-term debt.....	--	--
Total stockholders' equity.....	22,980	106,097

## RISK FACTORS

This offering involves a high degree of risk. You should carefully consider the risks and uncertainties described below and the other information in this prospectus before deciding whether to purchase shares of our common stock. The risks described below are not the only ones facing our company. Additional risks not presently known to us or that we currently believe to be immaterial may also adversely affect our business. If any of the following risks actually occur, our business and operating results could be harmed. This could cause the trading price of our common stock to decline, and you may lose all or part of your investment.

### RISKS RELATED TO ENZON

#### WE HAVE A HISTORY OF LOSSES AND WE MAY NEVER BE PROFITABLE.

We have incurred substantial losses since our inception. As of December 31, 1999, we had an accumulated deficit of approximately \$126.8 million. We expect to incur operating losses for the foreseeable future. The size of these losses will depend primarily on the receipt and timing of regulatory approval of PEG-Intron and Schering-Plough's effective marketing of PEG-Intron, as well as on the rate of growth in our other product sales or royalty revenue and on the level of our expenses. Our two FDA-approved products are not generating significant revenues because neither product has become widely used due to a small patient population base and limitations on their indicated uses. Our ability to achieve long-term profitability will depend upon our or our licensees' ability to obtain regulatory approvals for additional product candidates. Even if our product candidates receive regulatory approval, we cannot assure you that our products will achieve market acceptance or will be commercialized successfully or that our operations will be profitable.

#### OUR NEAR TERM SUCCESS IS HEAVILY DEPENDENT ON FDA APPROVAL OF PEG-INTRON AND SCHERING-PLOUGH'S EFFECTIVE MARKETING OF PEG-INTRON.

Under our agreement with Schering-Plough, pursuant to which we applied our PEG technology to develop a modified form of Schering-Plough's INTRON A, we will receive royalties on worldwide sales of PEG-Intron, if any. Schering-Plough is responsible for conducting and funding the clinical studies, obtaining regulatory approval and marketing the product worldwide on an exclusive basis. In November 1999, Schering-Plough announced that it had submitted a Marketing Authorization Application to the European Agency for the Evaluation of Medicinal Products, or EMEA, seeking marketing approval of PEG-Intron in Europe for the treatment of hepatitis C. In February 2000, Schering-Plough announced that the Committee for Proprietary Medicinal Products of the EMEA issued an opinion recommending approval of the application. Product approval by the EMEA is typically issued three months from the time the Committee renders its opinion. In December 1999, Schering-Plough completed submission of a Biologics License Application, or BLA, to the FDA seeking marketing approval of PEG-Intron for the treatment of hepatitis C. Schering-Plough had requested priority review status from the FDA of this BLA. In February 2000, the FDA accepted Schering-Plough's BLA for PEG-Intron for standard review, rather than priority review. Standard review typically takes 12 months from the date of filing. We have not had access to and do not know the results of the Phase III clinical trial that were included in Schering-Plough's BLA, nor have we been able to review the BLA. If Schering-Plough does not receive marketing approval from the FDA or the EMEA in a timely manner, or at all, it will have a material adverse effect on our business, financial condition and results of operation.

Schering-Plough currently markets INTRON A together with REBETOL as combination therapy for the treatment of hepatitis C and INTRON A as a stand-alone treatment for hepatitis C. If the current BLA is approved by the FDA, Schering-Plough will be able to market PEG-Intron only as a stand-alone or monotherapy treatment for hepatitis C. Schering-Plough is conducting a Phase III clinical trial of PEG-Intron as combination therapy with REBETOL for hepatitis C and Phase III clinical trials of PEG-Intron for the treatment of chronic myelogenous leukemia and malignant melanoma. If those trials are successful, PEG-Intron may be the subject of future BLAs for those indications. We cannot assure you that Schering-Plough will seek or obtain marketing approval to sell PEG-Intron for these additional indications or for combination therapy. Although

obligated under our agreement to use commercial efforts to market PEG-Intron, we cannot assure you that Schering-Plough will be successful in marketing PEG-Intron or that Schering-Plough will not continue to market INTRON A, either as a stand-alone product or in combination therapy with REBETOL, even if PEG-Intron receives FDA approval. The amount and timing of resources dedicated by Schering-Plough to the development and marketing of PEG-Intron is not within our control. If Schering-Plough breaches or terminates its agreement with us, or fails to work diligently toward FDA approval of the product for additional indications, the commercialization of PEG-Intron could be slowed or blocked completely. Our revenues will be negatively affected if Schering-Plough continues to market INTRON A in competition with PEG-Intron or if it cannot meet the manufacturing demands of the market. If Schering-Plough does not use commercial efforts to market PEG-Intron, or it otherwise breaches the agreement, a dispute may arise between us. A dispute would be both expensive and time-consuming and may result in delays in the development and commercialization of PEG-Intron, which would likely have a material adverse affect on our business, financial condition and results of operations.

THERE IS CURRENTLY PATENT LITIGATION, WHICH COULD HAVE A SIGNIFICANT ADVERSE IMPACT ON OUR BUSINESS.

Hoffmann-La Roche has sued Schering-Plough and claimed that the PEG technology used in PEG-Intron infringes a patent held by Hoffmann-La Roche. The litigation is at a very early stage, and we cannot predict its outcome. Prior to the commencement of this litigation we obtained an opinion of patent counsel that the patent held by Hoffmann-La Roche is invalid. However, this opinion is not binding on any court or the U.S. Patent and Trademark Office. We cannot assure you that the patent opinion will prove to be correct and that a court would find any of the claims of such patents to be invalid or that the product developed by us or our collaborator does not infringe such patents. If this litigation is not resolved favorably for Schering-Plough and Schering-Plough is prevented from marketing PEG-Intron, we would not receive any royalties on sales of PEG-Intron. This would have a material adverse effect on our business, financial condition and results of operations.

In December 1998, we filed a patent infringement suit against Shearwater Polymers, a company that has reportedly developed a Branched PEG, or U-PEG, used in Hoffmann-La Roche's Pegasys product, a PEG-modified version of its alpha-interferon product called Roferon-A. We believe that Pegasys utilizes a type of Branched PEG, for which we have been granted a patent in the United States and have similar patents pending in Europe, Japan and Canada. Shearwater has filed a counterclaim in this litigation alleging that our Branched PEG patent is invalid and unenforceable. While an adverse outcome in the litigation will not prevent Schering-Plough from commercializing PEG-Intron, if we are not successful in our infringement suit or if our patent is held to be invalid, we may not be able to preclude Shearwater from selling its Branched PEG or preclude Hoffmann-La Roche from commercializing Pegasys if it obtains regulatory approval. If we are unable to enforce our patent rights in this area against others, it may have a material adverse effect on our business, financial condition and results of operations.

During the course of our litigation proceedings with Shearwater Polymers and Schering-Plough's litigation with Hoffmann-La Roche, interim information about the status of each of these litigations may be released. Although these interim releases may differ from the final determinations in these litigations, such information may have a material adverse effect on the market price of our common stock.

WE ARE SUBJECT TO EXTENSIVE REGULATION. COMPLIANCE WITH THESE REGULATIONS CAN BE COSTLY, TIME CONSUMING AND SUBJECT US TO UNANTICIPATED DELAYS IN DEVELOPING OUR PRODUCTS.

The manufacturing and marketing of pharmaceutical products in the United States and abroad are subject to stringent governmental regulation. The sale of any of our products for use in humans in the United States will require the prior approval of the FDA. Similar approvals by comparable agencies are required



in most foreign countries. The FDA has established mandatory procedures and safety standards that apply to the clinical testing, manufacture and marketing of pharmaceutical products. Obtaining FDA approval for a new therapeutic product may take several years and involve substantial expenditures. ADAGEN was approved by the FDA in 1990. ONCASPAR was approved in the United

10

States and in Germany in 1994, and in Canada in 1997, in each case for patients with acute lymphoblastic leukemia who are hypersensitive to native forms of L-asparaginase. ONCASPAR was approved in Russia in April 1993 for therapeutic use in a broad range of cancers. Except for these approvals, none of our other products has been approved for sale and use in humans in the United States or elsewhere.

We cannot assure you that we or our licensees will be able to obtain FDA or other relevant marketing approval for any of our other products. In addition, any approved products are subject to continuing regulation. If we or our licensees fail to comply with applicable requirements it could result in:

criminal penalties,

civil penalties,

fines,

recall or seizure,

injunctions requiring suspension of production,

orders requiring ongoing supervision by the FDA, or

refusal by the government to approve marketing or export applications or to allow us to enter into supply contracts.

If we or our licensees fail to obtain or maintain requisite governmental approvals or fail to obtain or maintain approvals of the scope requested, it will delay or preclude us or our licensees or marketing partners from marketing our products. It could also limit the commercial use of our products. Any such failure or limitation may have a material adverse affect on our business, financial condition and results of operations.

WE HAVE EXPERIENCED PROBLEMS COMPLYING WITH THE FDA'S REGULATIONS FOR MANUFACTURING OUR PRODUCTS, AND WE MAY NOT BE ABLE TO RESOLVE THESE PROBLEMS.

Manufacturers of drugs also must comply with the applicable FDA good manufacturing practice regulations, which include quality control and quality assurance requirements as well as the corresponding maintenance of records and documentation. Manufacturing facilities are subject to ongoing periodic inspection by the FDA and corresponding state agencies, including unannounced inspections, and must be licensed as part of the product approval process before they can be used in commercial manufacturing. We or our present or future suppliers may be unable to comply with the applicable good manufacturing practice regulations and other FDA regulatory requirements.

During 1998, we began to experience manufacturing problems with one of our FDA-approved products, ONCASPAR. The problems were due to increased levels of white particulates in batches of ONCASPAR, which resulted in an increased rejection rate for this product. During fiscal 1999, we agreed with the FDA to temporary labeling and distribution restrictions for ONCASPAR and instituted additional inspection and labeling procedures prior to distribution. During May 1999, the FDA required us to limit distribution of ONCASPAR to only those patients who are hypersensitive to native L-asparaginase. In November 1999, the FDA withdrew this distribution restriction.

Recently, we have noticed an unacceptable level of black particulates in a batch of ADAGEN filled by our third-party contract filler. We believe these particulates are caused by the filling process, and our third-party filler has taken steps to resolve this issue. Because we use the same outside filler for ADAGEN and ONCASPAR, this problem could affect ONCASPAR as well.

In July 1999, the FDA conducted an inspection of our manufacturing facility in connection with our product license for ADAGEN. Following that inspection, the FDA documented several deviations from Current Good Manufacturing Practices, known as cGMP, in a Form 483 report. We provided the FDA with a corrective action plan. In November 1999, the FDA issued a warning letter citing the same cGMP deviations listed in the July 1999 Form 483, but it also stated that the FDA was satisfied with our proposed corrective actions. As a result of the deviations, the FDA decided not to approve product

11

export requests from us for both ADAGEN and ONCASPAR until it determines that all noted ADAGEN cGMP deviations have been corrected.

In January 2000, the FDA conducted another inspection of our manufacturing facility relating to the ONCASPAR product license and as a follow-up to the July 1999 inspection relating to ADAGEN. Following this most recent inspection, the FDA issued a Form 483 report, citing deviations from cGMP in the manufacture of ONCASPAR and two cGMP deviations for ADAGEN. We have responded to the FDA with a corrective action plan to the January 2000 Form 483. However, we cannot assure you that the FDA will not issue a warning letter with respect to the manufacture of ONCASPAR or that the FDA will approve product export requests that we may make in the future.

While we expect to resolve these manufacturing problems by the second quarter of the calendar year, we cannot be certain that the solution will be acceptable to the FDA. If we cannot satisfactorily resolve these problems, the FDA may not permit us to continue to distribute ONCASPAR or ADAGEN. If we cannot market and distribute ONCASPAR or ADAGEN for an extended period, future sales of the products may suffer, which could adversely affect our financial results.

Rhone-Poulenc Rorer, or RPR, which has the exclusive right to sell ONCASPAR in North America, has asserted that we should be responsible for its lost profits while ONCASPAR is under the temporary labeling and distribution restrictions resulting from the white particulate problem. RPR contends that its lost profits through December 31, 1999 were \$5.2 million. We are also currently in discussions with RPR related to a disagreement over the purchase price we charged RPR for ONCASPAR under our supply agreement with it. RPR has asserted that we have overcharged it in the amount of \$2.3 million. We believe our costing of ONCASPAR complies with the supply agreement. Although we do not agree with RPR's claims, the ultimate resolution of either matter could have a material adverse effect on our financial position.

Schering-Plough will be responsible for the manufacture of PEG-Intron.

OUR CLINICAL TRIALS COULD TAKE LONGER TO COMPLETE AND COST MORE THAN WE EXPECT.

We will need to conduct clinical studies of all of our product candidates. These studies are costly, time consuming and unpredictable. Any unanticipated costs or delays in our clinical studies could harm our business, financial condition and results of operations.

Schering-Plough is conducting clinical trials of our lead product candidate, PEG-Intron, which is in Phase III trials as combination therapy with REBETOL for treatment of hepatitis C and as stand-alone therapy for two cancer indications. We are currently conducting early stage clinical trials of our next PEG product, PROTHECAN. Clinical trials can be very costly and time-consuming. The rate of completion of clinical trials depends upon many factors, including the rate of enrollment of patients. If we or Schering-Plough are unable to accrue sufficient clinical patients in our respective trials during the appropriate period, such trials may be delayed and will likely incur significant additional costs. In addition, FDA or institutional review boards may require us to delay, restrict, or discontinue our clinical trials on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.

The cost of human clinical trials varies dramatically based on a number of factors, including:

the order and timing of clinical indications pursued,  
the extent of development and financial support from corporate collaborators,  
the number of patients required for enrollment,  
the difficulty of obtaining clinical supplies of the product candidate, and  
the difficulty in obtaining sufficient patient populations and clinicians.

All statutes and regulations governing the conduct of clinical trials are subject to change in the future, which could affect the cost of our clinical trials. Any unanticipated costs or delays in our clinical studies could harm our business, financial condition and results of operations.

In some cases, we rely on corporate collaborators or academic institutions to conduct some or all aspects of clinical trials involving our product candidates. We will have less control over the timing and

12

other aspects of these clinical trials than if we conducted them entirely on our own. We cannot assure you that these trials will commence or be completed as we expect or that they will be conducted successfully.

IF PRE-CLINICAL AND CLINICAL TRIALS DO NOT YIELD POSITIVE RESULTS, OUR PRODUCTS WILL FAIL.

If pre-clinical and clinical testing of one or more of our product candidates do not demonstrate the safety and efficacy of the desired indications, those potential products will fail. Numerous unforeseen events may arise during, or as a result of, the testing process, including the following:

the results of pre-clinical studies may be inconclusive, or they may not be indicative of results that will be obtained in human clinical trials,

potential products may not have the desired effect or may have undesirable side effects or other characteristics that preclude regulatory approval or limit their commercial use if approved,

results attained in early human clinical trials may not be indicative of results that are obtained in later clinical trials, and

after reviewing test results, we or our corporate collaborators may abandon projects which we might previously have believed to be promising.

Clinical testing is very costly and can take many years. The failure to adequately demonstrate the safety and efficacy of a therapeutic product under development would delay or prevent regulatory approval, which could adversely affect our business and financial performance.

EVEN IF WE OBTAIN REGULATORY APPROVAL FOR OUR PRODUCTS, THEY MAY NOT BE ACCEPTED IN THE MARKETPLACE.

The commercial success of our products will depend upon their acceptance by the medical community and third-party payors as clinically useful, cost-effective and safe. Even if our products obtain regulatory approval, we cannot assure you that they will achieve market acceptance of any kind. The degree of market acceptance will depend on many factors, including:

the receipt, timing and scope of regulatory approvals,

the timing of market entry in comparison with potentially competitive products,

the availability of third-party reimbursement, and

the establishment and demonstration in the medical community of the clinical safety, efficacy and cost-effectiveness of drug candidates, as

well as their advantages over existing technologies and therapeutics.

If any of our products do not achieve market acceptance, we will likely lose our entire investment in that product.

WE DEPEND ON OUR COLLABORATIVE PARTNERS. IF WE LOSE OUR COLLABORATIVE PARTNERS OR THEY DO NOT APPLY ADEQUATE RESOURCES TO OUR COLLABORATIONS, OUR PRODUCT DEVELOPMENT AND FINANCIAL PERFORMANCE MAY SUFFER.

We rely heavily and will depend heavily in the future on collaborations with corporate partners, primarily pharmaceutical companies, for one or more of the research, development, manufacturing, marketing and other commercialization activities relating to many of our product candidates. If we lose our collaborative partners, or if they do not apply adequate resources to our collaborations, our product development and financial performance may suffer.

The amount and timing of resources dedicated by our collaborators to their collaborations with us is not within our control. If any collaborator breaches or terminates its agreements with us, or fails to conduct its collaborative activities in a timely manner, the commercialization of our product candidates could be slowed or blocked completely. We cannot assure you that our collaborative partners will not change their strategic focus or pursue alternative technologies or develop alternative products as a means for developing treatments for the diseases targeted by these collaborative programs. Our

13

collaborators could develop competing products. In addition, our revenues will be affected by the effectiveness of our corporate partners in marketing any successfully developed products.

We cannot assure you that our collaborations will be successful. Disputes may arise between us and our collaborators as to a variety of matters, including financing obligations under our agreements and ownership of intellectual property rights. These disputes may be both expensive and time-consuming and may result in delays in the development and commercialization of products.

WE ARE DEPENDENT UPON A SINGLE OUTSIDE SUPPLIER FOR EACH OF THE CRUCIAL RAW MATERIALS NECESSARY TO THE MANUFACTURE OF EACH OF OUR PRODUCTS AND PRODUCT CANDIDATES.

We cannot assure you that sufficient quantities of our raw material requirements will be available to support the continued research, development or manufacture of our products. We purchase the unmodified compounds utilized in our approved products and products under development from outside suppliers. We may be required to enter into supply contracts with outside suppliers for certain unmodified compounds. We do not produce the unmodified adenosine deaminase used in the manufacture of ADAGEN or the unmodified forms of L-asparaginase used in the manufacture of ONCASPAR. We have a supply contract with an outside supplier for the supply of each of these unmodified compounds. If we experience a delay in obtaining or are unable to obtain any unmodified compound, including unmodified adenosine deaminase or unmodified L-asparaginase, on reasonable terms, or at all, it could have a material adverse effect on our business, financial condition and results of operations.

If we are required to obtain an alternate source for an unmodified compound utilized in a product, the FDA and relevant foreign regulatory agencies will likely require that we perform additional testing to demonstrate that the alternate material is biologically and chemically equivalent to the unmodified compound previously used in our clinical trials. This testing could delay or stop development of a product, limit commercial sales of an approved product and cause us to incur significant additional expenses. If we are unable to demonstrate that the alternate material is chemically and biologically equivalent to the previously used unmodified compound, we will likely be required to repeat some or all of the pre-clinical and clinical trials conducted for the compound. The marketing of an FDA approved drug could be disrupted while such tests are conducted. Even if the alternate material is shown to be chemically and biologically equivalent to the previously used compound, the FDA or relevant foreign regulatory agency may require that we conduct additional

clinical trials with the alternate material.

THE UNITED STATES AND FOREIGN PATENTS UPON WHICH OUR ORIGINAL PEG TECHNOLOGY WAS BASED HAVE EXPIRED. WE DEPEND ON PATENTS AND PROPRIETARY RIGHTS, WHICH MAY OFFER ONLY LIMITED PROTECTION AGAINST POTENTIAL INFRINGEMENT AND THE DEVELOPMENT BY OUR COMPETITORS OF COMPETITIVE PRODUCTS.

Research Corporation Technologies, Inc. held the patent upon which our original PEG technology was based and had granted us a license under such patent. Research Corporation's patent contained broad claims covering the attachment of PEG to polypeptides. However, this United States patent and its corresponding foreign patents have expired. Based upon the expiration of the Research Corporation patent, other parties will be permitted to make, use or sell products covered by the claims of the Research Corporation patent, subject to other patents, including those which we hold. We have obtained several patents with claims covering improved methods of attaching or linking PEG to therapeutic compounds. We cannot assure you that any of these patents will enable us to prevent infringement or that competitors will not develop alternative methods of attaching PEG to compounds potentially resulting in competitive products outside the protection that may be afforded by our patents. We are aware that others have also filed patent applications and have been granted patents in the United States and other countries with respect to the application of PEG to proteins and other compounds. We cannot assure that the expiration of the Research Corporation patent or other patents related to PEG that have been granted to third parties will not have a material adverse effect on our business, financial condition and results of operations.

The pharmaceutical industry places considerable importance on obtaining patent and trade secret protection for new technologies, products and processes. Our success depends, in part, on our ability to

14

develop and maintain a strong patent position for our products and technologies both in the United States and in other countries. We have been licensed, and been issued, a number of patents in the United States and other countries, and we have other patent applications pending to protect our proprietary technology. Although we believe that our patents provide certain protection from competition, we cannot assure you that such patents will be of substantial protection or commercial benefit to us, will afford us adequate protection from competing products, or will not be challenged or declared invalid. In addition we cannot assure you that additional United States patents or foreign patent equivalents will be issued to us. The scope of patent claims for biotechnological inventions is uncertain and our patents and patent applications are subject to this uncertainty.

To facilitate development of our proprietary technology base, we may need to obtain licenses to patents or other proprietary rights from other parties. If we are unable to obtain such licenses, our product development efforts may be delayed or blocked.

We are aware that certain organizations are engaging in activities that infringe certain of our PEG and SCA technology patents. We cannot assure you that we will be able to enforce our patent and other rights against such organizations.

We expect that there will continue to be significant litigation in the biotechnology and pharmaceutical industries regarding patents and other proprietary rights. We have become involved in patent litigation, and we may likely become involved in additional patent litigation in the future. We may incur substantial costs in asserting any patent rights and in defending suits against us related to intellectual property rights. Such disputes could substantially delay our product development or commercialization activities, and could have a material adverse effect on our business, financial condition and results of operations. As discussed in 'Business -- Legal Proceedings,' there are two pending litigation matters either involving or affecting our products and patents. The adverse disposition of either of these litigations will adversely affect our business, financial condition and results of operations.

We also rely on trade secrets, know-how and continuing technological

advancements to protect our proprietary technology. We have entered into confidentiality agreements with our employees, consultants, advisors and collaborators. However, these parties may not honor these agreements and we may not be able to successfully protect our rights to unpatented trade secrets and know-how. Others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets and know-how.

WE HAVE LIMITED SALES AND MARKETING EXPERIENCE, WHICH MAKES US DEPENDENT ON OUR MARKETING PARTNERS.

Other than ADAGEN, which we market on a worldwide basis to a small patient population, we have not engaged in the direct commercial marketing of any of our products and therefore we do not have significant experience in sales, marketing or distribution. For some of our products, we have provided exclusive marketing rights to our corporate partners in return for milestone payments and royalties to be received on sales. To the extent that we enter into licensing arrangements for the marketing and sale of our products, any revenues we receive will depend primarily on the efforts of these third parties. We will not control the amount and timing of marketing resources that such third parties devote to our products. In addition, if we market products directly, significant additional expenditures and management resources would be required to increase the size of our internal sales force. In any sales or marketing effort, we would compete with many other companies that currently have extensive and well-funded sales operations. Our marketing and sales efforts may be unable to compete successfully against other such companies.

WE MAY NEED TO OBTAIN ADDITIONAL FINANCING TO MEET OUR FUTURE CAPITAL NEEDS AND THIS FINANCING MAY NOT BE AVAILABLE WHEN WE NEED IT.

Our current development projects require substantial capital. We may require substantial additional funds to conduct research activities, pre-clinical studies, clinical trials and other activities relating to the successful commercialization of potential products. In addition, we may seek to acquire

15

additional technologies. We do not expect to achieve significant sales or royalty revenue from our current FDA-approved products, ADAGEN and ONCASPAR. In addition, we cannot be sure that we will obtain significant revenue from PEG-Intron in the near future, or ever. Additional funds from other sources may not be available on acceptable terms, if at all. If adequate funds are unavailable from operations or additional sources of financing, we may have to delay, reduce the scope of or eliminate one or more of our research or development programs which would materially and adversely affect our business, financial condition and operations.

While we believe that the net proceeds of this offering, together with our cash, cash equivalents and investments, will be adequate to satisfy our capital needs for the foreseeable future, our actual capital requirements will depend on many factors, including:

- the level of revenues we receive from our FDA-approved products and product candidates,
- continued progress of our research and development programs,
- our ability to establish additional collaborative arrangements,
- changes in our existing collaborative relationships,
- progress with pre-clinical studies and clinical trials,
- the time and costs involved in obtaining regulatory clearance for our products,
- the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims,
- competing technological and market developments, and

our ability to market and distribute our products and establish new collaborative and licensing arrangements.

We may seek to raise any necessary additional funds through equity or debt financings, collaborative arrangements with corporate partners or other sources which may be dilutive to existing stockholders. We cannot assure you that we will be able to obtain additional funds on acceptable terms, if at all. If adequate funds are not available, we may be required to:

delay, reduce the scope or eliminate one or more of our development projects,

obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves, or

license rights to technologies, product candidates or products on terms that are less favorable to us than might otherwise be available.

WE DEPEND ON KEY PERSONNEL AND MAY NOT BE ABLE TO RETAIN THESE EMPLOYEES OR RECRUIT ADDITIONAL QUALIFIED PERSONNEL, WHICH WOULD HARM OUR BUSINESS.

Because of the specialized scientific nature of our business, we are highly dependent upon qualified scientific, technical and managerial personnel. There is intense competition for qualified personnel in the pharmaceutical field. Therefore, we may not be able to attract and retain the qualified personnel necessary for the development of our business. The loss of the services of existing personnel, as well as the failure to recruit additional key scientific, technical and managerial personnel in a timely manner would harm our research and development programs and our business.

THE FAILURE OF COMPUTER SYSTEMS TO BE YEAR 2000 COMPLIANT COULD NEGATIVELY IMPACT OUR BUSINESS.

In 1999, we completed a review of our business systems, including computer systems and manufacturing equipment, and queried our customers and vendors as to their progress in identifying and addressing problems that their systems may face in correctly interrelating and processing date information in the year 2000. To date, we have not experienced any significant problems related to the year 2000 problem, either in our systems or the systems of our vendors or customers. The failure of our computer systems to be year 2000 compliant could negatively impact our business.

#### RISKS RELATED TO OUR INDUSTRY

WE FACE RAPID TECHNOLOGICAL CHANGE AND INTENSE COMPETITION, WHICH COULD HARM OUR BUSINESS AND RESULTS OF OPERATIONS.

The biopharmaceutical industry is characterized by rapid technological change. Our future success will depend on our ability to maintain a competitive position with respect to technological advances. Rapid technological development by others may result in our products and technologies becoming obsolete.

We face intense competition from established biotechnology and pharmaceutical companies, as well as academic and research institutions that are pursuing competing technologies and products. We know that competitors are developing or manufacturing various products that are used for the prevention, diagnosis or treatment of diseases that we have targeted for product development. Many of our competitors have substantially greater research and development capabilities and experiences and greater manufacturing, marketing and financial resources than we do. Accordingly, our competitors may develop technologies and products that are superior to those we or our collaborators are developing and render our technologies and products or those of our collaborators obsolete and noncompetitive. In addition, many of our competitors have much more experience than we do in pre-clinical testing and human clinical trials of new drugs, as well as obtaining FDA and other regulatory approval. If

we cannot compete effectively, our business and financial performance would suffer.

#### WE MAY BE SUED FOR PRODUCT LIABILITY.

Because our products and product candidates are new treatments, with limited, if any, past use on humans, their use during testing or after approval could expose us to product liability claims. We maintain product liability insurance coverage in the total amount of \$10.0 million for claims arising from the use of our products in clinical trials prior to FDA approval and for claims arising from the use of our products after FDA approval. We cannot assure you that we will be able to maintain our existing insurance coverage or obtain coverage for the use of our other products in the future. Also, this insurance coverage and our resources may not be sufficient to satisfy any liability resulting from product liability claims and a product liability claim may have a material adverse effect on our business, financial condition or results of operations.

SALES OF OUR PRODUCTS COULD BE ADVERSELY AFFECTED IF THE COSTS FOR THESE PRODUCTS ARE NOT REIMBURSED BY THIRD-PARTY PAYORS.

In recent years, there have been numerous proposals to change the health care system in the United States. Some of these proposals have included measures that would limit or eliminate payments for medical procedures and treatments or subject the pricing of pharmaceuticals to government control. In addition, government and private third-party payors are increasingly attempting to contain health care costs by limiting both the coverage and the level of reimbursement of drug products. Consequently, significant uncertainty exists as to the reimbursement status of newly-approved health care products.

Our ability to commercialize our products will depend, in part, on the extent to which reimbursement for the cost of the products and related treatments will be available from third-party payors. If we or any of our collaborators succeeds in bringing one or more products to market, we cannot assure you that third-party payors will establish and maintain price levels sufficient for realization of an appropriate return on our investment in product development. In addition, lifetime limits on benefits included in most private health plans may force patients to self-pay for treatment. For example, patients who receive ADAGEN are expected to require injections for their entire lives. The cost of this treatment may exceed certain plan limits and cause patients to self-fund further treatment. Furthermore, inadequate third-party coverage may lead to reduced market acceptance of our products. Significant changes in the health care system in the United States or elsewhere could have a material adverse effect on our business and financial performance.

17

#### RISKS RELATED TO THIS OFFERING

THE PRICE OF OUR COMMON STOCK HAS BEEN, AND MAY CONTINUE TO BE, VOLATILE.

Historically, the market price of our common stock has fluctuated over a wide range and it is likely that the price of our common stock will fluctuate in the future. The market price of our common stock could be impacted due to a variety of factors, including:

the results of pre-clinical testing and clinical trials by us, our corporate partners or our competitors,

announcements of technical innovations or new products by us, our corporate partners or our competitors,

the status of corporate collaborations and supply arrangements entered into by us, our corporate partners or our competitors,

regulatory approvals of our products or those of our competitors,

changes in government regulation,

developments in the patents or other proprietary rights owned or licensed



by us or our competitors,

public concern as to the safety and efficacy of products developed by us or others,

litigation, and

general market conditions in our industry.

In addition, due to one or more of the foregoing factors in one or more future quarters, our results of operations may fall below the expectations of securities analysts and investors. In that event, the market price of our common stock could be materially and adversely affected.

The stock market has recently experienced extreme price and volume fluctuations. These fluctuations have especially affected the market price of the stock of many high technology and healthcare-related companies. Such fluctuations have often been unrelated to the operating performance of these companies. Nonetheless, these broad market fluctuations may negatively affect the market price of our common stock.

EVENTS WITH RESPECT TO OUR SHARE CAPITAL COULD CAUSE THE PRICE OF OUR COMMON STOCK TO DECLINE.

Sales of substantial amounts of our common stock in the open market, or the availability of such shares for sale, could adversely affect the price of our common stock. Based upon the number of shares of common stock outstanding as of February 15, 2000, we expect to have 40,049,632 shares of common stock outstanding, excluding shares reserved for issuance upon the exercise of outstanding stock options and warrants, and the conversion of outstanding preferred stock (or 40,349,632 shares of common stock outstanding if the underwriters' over-allotment option is exercised in full) upon the completion of this offering. The following securities that may be exercised for, or are convertible into, shares of our common stock were issued and outstanding as of February 15, 2000:

Options. Stock options to purchase 3,205,136 shares of our common stock at a weighted average exercise price of approximately \$6.23 per share; of this total, 2,647,536 were exercisable at a weighted average exercise price of \$3.88 per share as of such date.

Warrants. Various warrants to purchase 457,731 shares of our common stock, all of which were exercisable, at a weighted average exercise price of \$5.75 per share as of such date.

Series A preferred stock. 27,000 shares of our Series A preferred stock are outstanding, all of which were convertible into 61,364 shares of our common stock as of such date.

The shares of our common stock that may be issued under the warrants and options are either currently registered with the SEC, or will be registered with the SEC before the shares are purchased by the holders of the warrants and options. The shares of common stock that may be issued upon

conversion of the Series A preferred stock are eligible for sale without any volume limitation pursuant to Rule 144(k) under the Securities Act of 1933, as amended.

We and each of our directors and officers have agreed that, without the prior written consent of Morgan Stanley & Co. Incorporated on behalf of the underwriters, none of us will, during the period ending 90 days after the date of this prospectus, sell or otherwise dispose of any shares of our common stock, subject to certain exceptions. We cannot predict whether future sales of our common stock or the availability of our common stock for sale will adversely affect the market price for our common stock or our ability to raise capital by offering equity securities.

COMMON AND PREFERRED STOCK MAY HAVE AN ADVERSE EFFECT ON THE MARKET PRICE FOR OUR COMMON STOCK AND MAY IMPAIR OUR ABILITY TO RAISE ADDITIONAL FUNDS.

There are demand and/or piggyback registration rights on 457,731 shares of our common stock underlying warrants outstanding as of February 15, 2000. We have granted Schering-Plough piggyback registration rights with respect to 847,489 shares of our common stock. In addition, two persons affiliated with Evolution Capital have piggyback and demand registration rights with respect to the shares underlying their warrants to purchase 200,000 shares of our common stock. The demand rights give these warrant holders a one-time right to require us to register, upon their request, that number of shares underlying such warrants. We granted the Carson Group, Inc. and two of its principals, piggyback registration rights with respect to the shares underlying their warrants to purchase an aggregate of 51,504 shares of our common stock as consideration for finder's services that were provided to us. Transferees of Clearwater Fund IV were also granted piggyback registration rights under a registration rights agreement with us with respect to the 206,227 shares of common stock issuable under warrants they hold, 200,000 of which shares are currently covered by an effective registration statement. Absent any contractual limitations, the holders of these rights could cause a significant number of shares of our common stock to be registered and sold in the public market. Such sales, or the perception that these sales could occur, may have an adverse effect on the market price for our common stock and could impair our ability to raise capital through an offering of equity securities. We have obtained waivers of all such piggyback registration rights applicable to this offering.

We originally registered the resale of approximately 3,983,000 shares of our common stock owned by stockholders who purchased such shares in a private placement of our common stock that closed in July 1998. We are required to maintain the effectiveness of this registration statement until the earlier of the date that all of the shares are sold or July 2000.

We originally registered the resale of approximately 4,122,317 shares of our common stock owned by stockholders who purchased such shares in a private placement of our common stock that closed in January and March 1996. We are required to maintain the effectiveness of this registration statement until the earlier of the date that all of the shares are sold or March 15, 2004.

INVESTORS IN THIS OFFERING WILL SUFFER IMMEDIATE AND SUBSTANTIAL DILUTION.

We expect that the public offering price of our common stock in this offering will be substantially higher than the net tangible book value per share of our outstanding common stock. As of December 31, 1999, our net tangible book value was \$20.8 million and on a pro forma basis our net tangible book value after this offering will be \$103.9 million, based on the public offering price of \$44.50. The amount of the increase in net tangible book value attributable to the investors in this offering will be \$2.09 per share of common stock. Investors of our common stock in this offering will experience immediate and substantial dilution of \$41.85 per share of common stock.

OUR CHARTER DOCUMENTS AND DELAWARE LAW MAY DISCOURAGE A TAKEOVER OF OUR COMPANY.

Provisions of our certificate of incorporation, bylaws and Delaware law could make it more difficult for a third party to acquire or merge with us, even if doing so would be beneficial to our stockholders.

19

Our board of directors has the authority to issue up to 3,000,000 shares of our preferred stock, par value \$0.01 per share, and to determine the price and terms, including preferences and voting rights, of those shares without stockholder approval. Although we have no current plans to issue additional shares of our preferred stock, any such issuance could:

have the effect of delaying, deferring or preventing a change in control of our company,

discourage bids for our common stock at a premium over the market price, or

adversely affect the market price of and the voting and other rights of the holders of our common stock.

In addition, certain provisions of our certificate of incorporation establishing a classified board of directors, and our agreements with our executive officers that provide significant payments to them following a change in control of our company, could each have the effect of discouraging potential takeover attempts.

20

#### USE OF PROCEEDS

Our net proceeds from the sale of our common stock in this offering, based on the public offering price of \$44.50 per share and after deducting the underwriting discount and estimated offering expenses payable by us, will be approximately \$83.1 million, or \$95.7 million if the underwriters' over-allotment option is exercised in full.

We intend to use the net proceeds from this offering to fund:

development of additional PEG and SCA compounds,  
facility upgrades,  
clinical trials for our current product candidates, and  
general corporate purposes, including working capital.

In addition, a portion of the net proceeds may be used for acquisitions of businesses, products and technologies that are complementary to ours. We currently have no agreements with respect to any material acquisitions as of the date of this prospectus. The amounts and timing of our actual expenditures for each purpose may vary significantly depending on numerous factors, including:

the status of our product development efforts,  
regulatory approvals,  
competition,  
marketing, and  
sales activities and the market acceptance of any products we introduce.

Pending the use of the net proceeds for the above purposes, we will invest the funds in short-term, interest-bearing, investment-grade securities.

21

#### PRICE RANGE OF COMMON STOCK

Our common stock is quoted on the Nasdaq National Market under the symbol 'ENZN.' The following table sets forth the high and low sale prices for the periods indicated, as reported on the Nasdaq National Market. The prices shown represent inter-dealer prices, without retail mark-up, markdown or commission, and may not represent actual transactions.

COMMON STOCK PRICE	
-----	
HIGH	LOW

	----	---
YEAR ENDED JUNE 30, 1998		
First Quarter.....	\$ 5.19	\$ 2.00
Second Quarter.....	7.25	4.75
Third Quarter.....	7.19	5.13
Fourth Quarter.....	6.88	4.56
YEAR ENDED JUNE 30, 1999		
First Quarter.....	7.44	3.63
Second Quarter.....	14.63	4.88
Third Quarter.....	17.88	12.63
Fourth Quarter.....	21.00	11.25
YEAR ENDING JUNE 30, 2000		
First Quarter.....	34.81	19.63
Second Quarter.....	47.25	25.50
Third Quarter (through March 20, 2000).....	72.75	38.00

There were approximately 2,110 record holders of our common stock as of February 15, 2000. On March 20, 2000, the reported last sale price on the Nasdaq National Market for our common stock was \$44.50 per share.

DIVIDEND POLICY

We have never declared or paid any cash dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future. We currently intend to retain future earnings to fund the development and growth of our business. Holders of the Series A preferred stock are entitled to an annual dividend of \$2.00 per share, payable semiannually, but only when and if declared by our board of directors, out of funds legally available. As of February 15, 2000 there were 27,000 shares of Series A preferred stock issued and outstanding. Dividends on the Series A preferred stock are cumulative and accrue and accumulate but will not be paid, except in liquidation or upon conversion, until such time as the board of directors deems it appropriate in light of our then current financial condition. No dividends are to be paid or set apart for payment on our common stock, nor are any shares of common stock to be redeemed, retired or otherwise acquired for valuable consideration unless we have paid in full or made appropriate provision for the payment in full of all dividends which have then accumulated on the Series A preferred stock.

CAPITALIZATION

The following table sets forth our unaudited actual and as adjusted capitalization as of December 31, 1999, as described below. The as adjusted column gives effect to the sale of 2,000,000 shares of our common stock in this offering, at the public offering price of \$44.50 per share and after deducting the underwriting discount and estimated offering expenses. This table should be read in conjunction with 'Selected Consolidated Financial Data' and our financial statements and related notes, which are included elsewhere in this prospectus.

	AS OF DECEMBER 31, 1999	
	----- ACTUAL	AS ADJUSTED -----
	(UNAUDITED)	
	(IN THOUSANDS)	
Cash and cash equivalents.....	\$ 23,262	\$ 106,379
Long-term debt.....	\$ --	\$ --
Stockholders' equity:		

Preferred stock, \$.01 par value; 3,000,000 shares authorized; 27,000 shares issued and outstanding actual and as adjusted (liquidation preference \$1,189,000).....	--	--
Common stock, \$.01 par value; 60,000,000 shares authorized; 37,209,146 shares issued and outstanding actual and 39,209,146 shares issued and outstanding as adjusted.....	372	392
Additional paid-in capital.....	149,372	232,469
Accumulated deficit.....	(126,764)	(126,764)
	-----	-----
Total stockholders' equity.....	22,980	106,097
	-----	-----
Total capitalization.....	\$ 22,980	\$ 106,097
	-----	-----
	-----	-----

During the period from January 1, 2000 through February 15, 2000, we issued 840,486 additional shares of common stock in connection with the exercise of stock options and warrants. The number of shares of our common stock to be outstanding after this offering, utilizing the actual outstanding shares as of February 15, 2000, does not take into account the following as of that date:

3,205,136 shares of common stock issuable upon the exercise of outstanding options at a weighted average exercise price of \$6.23 per share,

457,731 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of \$5.75 per share, and

61,364 shares of common stock issuable upon the conversion of outstanding shares of our Series A preferred stock.

DILUTION

Our net tangible book value as of December 31, 1999 was \$20.8 million, or \$0.56 per common share. Net tangible book value per common share represents the amount of our stockholders' equity, less intangible assets and our preferred stock liquidation value, divided by the total number of shares of common stock outstanding as of December 31, 1999. After giving effect to the sale of the 2,000,000 shares of common stock offered in this prospectus at the public offering price of \$44.50 per share and after deducting the estimated underwriting discounts and offering expenses, our pro forma net tangible book value as of December 31, 1999 would have been \$103.9 million, or \$2.65 per share of common stock. This represents an immediate increase in net tangible book value of \$2.09 per share to existing shareholders and an immediate dilution of \$41.85 per share to new investors purchasing shares in this offering. The following table illustrates this per share dilution:

Public offering price per common share.		\$44.50
Net tangible book value per share before the offering.....	\$0.56	
Increase per share attributable to new investors.....	2.09	
	-----	
Pro forma net tangible book value per share after this offering.....		2.65
		-----
Dilution per share to new investors.....		\$41.85
		-----
		-----

Dilution is determined by subtracting pro forma net tangible book value per common share from the public offering price per share.



(IN THOUSANDS)

(UNAUDITED)

BALANCE SHEET DATA:

Cash and cash equivalents.....	\$ 8,103	\$12,666	\$ 8,316	\$ 6,478	\$24,674	\$23,262
Working capital.....	4,523	9,743	6,281	4,161	23,662	21,108
Total assets.....	19,184	21,964	16,005	13,741	34,916	34,433
Long-term debt.....	--	--	--	--	--	--
Total stockholders' equity.....	8,298	12,914	8,542	6,927	25,575	22,980

25

MANAGEMENT'S DISCUSSION AND ANALYSIS OF  
FINANCIAL CONDITION AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS

OVERVIEW

We are a biopharmaceutical company that develops and commercializes enhanced therapeutics for life-threatening diseases through the application of our two proprietary platform technologies: PEG and single-chain antibodies. We apply our PEG, or polyethylene glycol, technology to improve the delivery, safety and efficacy of proteins and small molecules with known therapeutic efficacy. We apply our single-chain antibody technology to discover and produce antibody-like molecules that offer many of the therapeutic benefits of monoclonal antibodies while addressing some of their limitations. To date, we have devoted substantially all of our resources to research and develop products both internally and in cooperation with our strategic partners.

Substantially all of our revenues were generated from sales of our products and royalties on the sale of our products by others, and contract revenues. Our revenues, as well as our results of operations, have fluctuated and we expect continued fluctuation from period to period due to the level of revenues from our FDA-approved products and contract revenues, the status of development of our products and expenses related to manufacturing. We have incurred significant operating losses since our inception in 1981 and, as of December 31, 1999, had an accumulated deficit of approximately \$126,764,000.

SIX MONTHS ENDED DECEMBER 31, 1999 AND 1998

Revenues. Revenues for the six months ended December 31, 1999 decreased by \$107,000 to \$6,679,000 as compared to \$6,786,000 for the same period last year. The components of revenues are sales, which consist of sales of our products and royalties on the sale of these products by others, and contract revenues. Sales decreased by 1% to \$6,617,000 for the six months ended December 31, 1999, as compared to \$6,718,000 for the prior year. This decrease was due to a decline in ONCASPAR revenues. This decrease in ONCASPAR revenues was offset in part by an increase in ADAGEN sales of approximately 11%, resulting from an increase in patients receiving ADAGEN treatment. Net sales of ADAGEN, which we market, were \$6,042,000 for the six months ended December 31, 1999 and \$5,428,000 for the six months ended December 31, 1998. The decline in ONCASPAR revenues was due to declines in manufacturing and royalty revenues resulting from difficulties encountered in our manufacturing process and the resulting changes in labeling and distribution discussed below. We had export sales of \$2,007,000 for the six months ended December 31, 1999 and \$1,723,000 for the six months ended December 31, 1998. Of these amounts, sales in Europe were \$1,748,000 for the six months ended December 31, 1999 and \$1,487,000 for the six months ended December 31, 1998.

Cost of Sales. Cost of sales, as a percentage of sales, improved to 30% for the six months ended December 31, 1999 as compared to 35% for the six months ended December 31, 1998. This improvement was primarily due to a charge taken last year related to the write-off of ONCASPAR finished goods on hand and in the distribution pipeline. The prior year's write-off of ONCASPAR finished goods was attributable to the manufacturing problems discussed below.

Research and Development. Research and development expenses increased by 5%

to \$3,590,000 for the six months ended December 31, 1999 from \$3,423,000 in the same period last year. The increase was due to increased payroll and related expenses as well as the acquisition of certain patent rights. Our research and development expenses are focused on the clinical development of PEG-camptothecin which is in Phase I clinical trials, as well as pre-clinical development of other PEG compounds.

Selling, General and Administrative. Selling, general and administrative expenses for the six months ended December 31, 1999 increased by 41% to \$5,136,000, as compared to \$3,644,000 in the prior year. The increase was primarily due to increased legal fees related to litigation and ongoing arbitration proceedings, increased patent filing and defense costs, and increased ONCASPAR marketing and distribution costs.

26

Net Loss. Our net loss for the six months ended December 31, 1999 increased to \$3,460,000 from the net loss of \$1,985,000 for the six months ended December 31, 1998 primarily due to the decrease in revenues and the increase in expenses discussed above.

#### FISCAL YEARS ENDED JUNE 30, 1999, 1998 AND 1997

Revenues. The components of our revenues are sales, which consist of sales of our products and royalties on the sale of these products by others, and contract revenues. Our revenues for the year ended June 30, 1999 decreased to \$13,158,000 as compared to \$14,644,000 for the year ended June 30, 1998 due to a decrease in contract revenue. Our sales increased by 4% to \$12,856,000 for the year ended June 30, 1999 as compared to \$12,313,000 for the year ended June 30, 1998. The increase was due to an increase in ADAGEN sales of approximately 11%, resulting from an increase in patients receiving ADAGEN treatment. Net sales of ADAGEN, which we market, were \$11,246,000 for the year ended June 30, 1999 and \$10,107,000 for the year ended June 30, 1998. We market our other approved product, ONCASPAR, through marketing agreements in the U.S. and Canada with RPR and in Europe with MEDAC. ONCASPAR revenues are comprised of manufacturing revenues, as well as royalties on sales of ONCASPAR by RPR. ONCASPAR revenues for fiscal 1999 decreased due to a decline in manufacturing and royalty revenues resulting from difficulties encountered in our manufacturing process and the resulting changes in labeling and distribution described below.

During 1998, we began to experience manufacturing problems with ONCASPAR. The problems were due to an increase in the levels of particulates in batches of ONCASPAR which resulted in an increased rejection rate for this product. During fiscal 1999, as a result of these manufacturing problems, we agreed with the FDA to temporary labeling and distribution restrictions for ONCASPAR. RPR stopped distributing ONCASPAR and we took over distribution of ONCASPAR directly to patients on an as-needed basis. We also instituted additional inspection and labeling procedures prior to distribution of the product. In addition, during May 1999, the FDA required us to limit distribution of the product to only those patients who are hypersensitive to native L-asparaginase. In November 1999, the FDA lifted this distribution restriction.

We have been able to manufacture several batches of ONCASPAR, which contain acceptable levels of particulates, and anticipate a final resolution of the problem during the fourth quarter of fiscal 2000. It is expected that RPR will resume distribution of ONCASPAR at that time. We cannot assure you that this solution will be acceptable to the FDA or RPR. If we are unable to resolve this problem or the other manufacturing problems discussed in the risk factor entitled 'We have experienced problems complying with the FDA's regulations for manufacturing our products, and we may not be able to resolve these problems,' the FDA may not permit us to continue to distribute ONCASPAR or ADAGEN. An extended disruption in the marketing and distribution of ONCASPAR or ADAGEN may have a material adverse effect on future sales of the products.

We expect sales of ADAGEN to increase at rates comparable to those achieved during the last two years as additional patients are treated. We also anticipate ONCASPAR sales will remain at reduced levels until the manufacturing problem is resolved and RPR resumes normal distribution of the product. We cannot assure you that any particular sales levels of ADAGEN or ONCASPAR will be achieved or maintained.



Contract revenue for the year ended June 30, 1999 decreased to \$302,000, as compared to \$2,331,000 for the year ended June 30, 1998. The decrease was principally due to the fact that we received milestone payments in 1998 under our licensing agreement for PEG-Intron with Schering-Plough and we did not receive any such payments in 1999. During the year ended June 30, 1998, we recognized \$2,200,000 in milestone payments we received when Schering-Plough advanced PEG-Intron into a Phase III clinical trial. On November 9, 1999, Schering-Plough announced that it had submitted a Marketing Authorization Application to the European Agency for the Evaluation of Medicinal Products seeking marketing approval for PEG-Intron Powder for Injection for the treatment of hepatitis C in Europe. Schering-Plough announced that on December 23, 1999, it submitted a Biologics License Application to the FDA seeking similar marketing approval in the U.S. for PEG-Intron. The FDA accepted this application in February 2000, which entitled us to a \$1,000,000 milestone payment.

27

During the years ended June 30, 1999 and 1998, we had export sales of \$3,075,000 and \$2,641,000, respectively. Of these amounts, sales in Europe were \$2,559,000 for the year ended June 30, 1999 and \$2,117,000 for the year ended June 30, 1998.

Our revenues for the year ended June 30, 1998 increased to \$14,644,000 as compared to \$12,727,000 for fiscal 1997. Our sales increased by 6% to \$12,313,000 for the year ended June 30, 1998 as compared to \$11,596,000 for the prior year. The increase was due to an increase in ADAGEN sales of approximately 13%, resulting from an increase in patients receiving ADAGEN treatment. Net sales of ADAGEN, which we market, were \$10,107,000 for the year ended June 30, 1998 and \$8,935,000 for the year ended June 30, 1997. ONCASPAR revenues in 1998 decreased due to a decline in manufacturing revenue resulting from difficulties encountered in our manufacturing process, previously discussed. The decrease in manufacturing revenue was partially offset by increased royalties due to an increase in sales of ONCASPAR by RPR.

Contract revenue for the year ended June 30, 1998 increased to \$2,331,000, as compared to \$1,131,000 for the year ended June 30, 1997. The increase was principally due to an increase in milestone payments we received under our licensing agreement for PEG-Intron with Schering-Plough. During the year ended June 30, 1998, we recognized \$2,200,000 in milestone payments received as a result of Schering-Plough advancing PEG-Intron into a Phase III clinical trial. During the prior year, we received a \$1,000,000 milestone payment under the same licensing agreement with Schering-Plough.

During the years ended June 30, 1998 and 1997, we had export sales of \$2,641,000 and \$2,377,000, respectively. Our sales in Europe were \$2,117,000 for the year ended June 30, 1998 and \$1,937,000 for the year ended June 30, 1997.

Cost of Sales. Cost of sales, as a percentage of sales, increased to 34% for the year ended June 30, 1999 as compared to 30% for the year ended June 30, 1998. The increase was primarily due to a charge taken in the first quarter 1999 related to a write-off of ONCASPAR finished goods on hand and in the distribution pipeline, as well as increased ONCASPAR production costs. The increased write-off of ONCASPAR finished goods was attributable to the manufacturing problems previously discussed.

Cost of sales, as a percentage of sales, decreased to 30% for the year ended June 30, 1998 as compared to 33% for the year ended June 30, 1997. The decrease was primarily due to the prior year's expense of excess ONCASPAR raw material and purchase commitments related to our supply agreement for this material. During the fiscal year ended June 1998, we amended our supply agreement for this material which extended the period available for us to accept delivery of our remaining purchase commitment through 1999, in exchange for a \$1,300,000 advance payment of the remaining purchase commitment. See Note 10 to the Consolidated Financial Statements included elsewhere in this prospectus.

Research and Development. Research and development expenses for the year ended June 30, 1999 decreased by 21% to \$6,836,000 from \$8,654,000 for the year ended June 30, 1998. The decrease in research and development expenses resulted from (1) a decrease in facility costs resulting from the elimination of a leased

facility and the consolidation of research and development operations and (2) a decline in clinical trial costs. The decrease in clinical trial costs was a result of the completion of a Phase Ib clinical trial for PEG-hemoglobin in 1998. Research and development expenses are expected to increase to previous levels as a result of the commencement of Phase I clinical trials for PROTHECAN (PEG-camptothecin).

Research and development expenses for the year ended June 30, 1998 remained relatively unchanged at \$8,654,000 as compared to \$8,520,000 for the year ended June 30, 1997. Our research and development efforts were focused on the continued development of our third generation Pro Drug/Transport Technology, which included pre-clinical activities for PROTHECAN, as well as clinical trial costs for PEG-hemoglobin.

Selling, General and Administrative. Selling, general and administrative expenses for the year ended June 30, 1999 increased by 27% to \$8,133,000, as compared to \$6,426,000 for the year ended June 30, 1998. The increase was primarily due to an increase in marketing and distribution costs for ONCASPAR. Due to the changes in distribution previously discussed, we were responsible for all

28

marketing and distribution for this product in 1999. During the prior year, these costs were the responsibility of RPR.

Selling, general and administrative expenses for the year ended June 30, 1998 increased by 16% to \$6,426,000 as compared to \$5,528,000 for the year ended June 30, 1997. The increase was due to increased investor and public relations activities, as well as consulting fees related to the development of a strategic business plan for our SCA technology.

Other Income/Expense. Other income/expense increased by \$737,000 to \$1,201,000 for the year ended June 30, 1999, as compared to \$464,000 for the year ended June 30, 1998. The increase was attributable to an increase in interest income due to an increase in interest bearing investments.

Other income/expense decreased by \$141,000 to \$464,000 for the year ended June 30, 1998 as compared to \$605,000 for the year ended June 30, 1997. The decrease was due principally to a decline in interest income due to a decrease in interest bearing investments.

Net Loss. Our net loss for the year ended June 30, 1999 increased to \$4,919,000 from our net loss of \$3,617,000 for the year ended June 30, 1998 due to the decrease in revenues and the increase in the cost of sales and selling, general and administrative expenses for the year ended June 30, 1999 discussed above. Our net loss for the year ended June 30, 1998 decreased to \$3,617,000 from our net loss of \$4,557,000 for the year ended June 30, 1997 due to the increase in revenues and the decrease in cost of sales for the year ended June 30, 1998 discussed above.

#### LIQUIDITY AND CAPITAL RESOURCES

Our total cash reserves, including cash and cash equivalents as of December 31, 1999 were \$23,262,000 as compared to \$24,674,000, as of June 30, 1999. The decrease in total cash reserves was due to the payment of approximately \$1,542,000 in cumulative accrued dividends on 80,000 shares of Series A preferred stock during the quarter ended December 31, 1999. The 80,000 shares of Series A preferred stock were converted into 181,818 shares of our common stock during the six months ended December 31, 1999. We invest our excess cash in a portfolio of high-grade marketable securities and United States government-backed securities.

To date, our sources of cash have been the proceeds from the sale of our stock through public offerings and private placements, sales of ADAGEN, sales of ONCASPAR, sales of our products for research purposes, contract research and development fees, technology transfer and license fees and royalty advances. Our current sources of liquidity are our cash, cash equivalents and interest earned on such cash reserves, sales of ADAGEN, sales of ONCASPAR, sales of our products for research purposes and license fees.

Under our amended license agreement with RPR, we received a payment of \$3,500,000 in advance royalties in January 1995. Royalties due under the amended license agreement will be offset against an original credit of \$5,970,000, which represents the royalty advance plus reimbursement of certain amounts due RPR under the original agreement and interest expense, before cash payments will be made under the agreement. The royalty advance is shown as a long-term liability. The corresponding current portion is included in accrued expenses on the consolidated balance sheets. We will reduce the advance as royalties are recognized under the agreement. Through December 31, 1999, an aggregate of \$4,369,000 in royalties payable by RPR has been offset against the original credit.

As of December 31, 1999, we had 27,000 shares of Series A preferred stock outstanding. These preferred shares are convertible into approximately 61,364 shares of common stock. Dividends accrue on the remaining outstanding shares of Series A preferred stock at a rate of \$54,000 per year. As of December 31, 1999, there were accrued and unpaid dividends totaling \$514,000 on the shares of Series A preferred stock outstanding. We have the option to pay these dividends in either cash or common stock.

We are currently in discussions with RPR related to our supply agreement with them. RPR has asserted that we have overcharged them under the supply agreement in the amount of \$2,329,000. We believe our costing and pricing of ONCASPAR complies with the supply agreement. RPR has also asserted that we should be responsible for its lost profits while ONCASPAR is under the temporary

29

labeling and distribution modifications. RPR contends that its lost profits through December 31, 1999 were \$5,194,000. We do not agree with RPR's claims. We do not believe the ultimate resolution of either matter will have a material adverse effect on our financial results or operations, though it could have a material adverse effect on our financial position.

We are being sued, in the United States District Court for the District of New Jersey, by LBC Capital Resources, Inc., a former financial advisor. LBC is asserting that under the May 2, 1995 letter agreement between us and LBC Capital Resources Inc., LBC was entitled to a commission in connection with our January and March 1996 private placements, comprised of \$500,000 and warrants to purchase approximately 1,000,000 shares of our common stock at an exercise price of \$2.50 per share. LBC has claimed \$3,000,000 in compensatory damages, plus punitive damages, counsel fees and costs for the alleged breach of the letter agreement. We have entered into an agreement with LBC, known as the Stipulation of Damages, which provides that if we are found liable to LBC in this suit, the damages for these claims would be limited to \$2,750,000 in cash. LBC has also asserted that it is entitled to an additional fee of \$175,000 and warrants to purchase 250,000 shares of our common stock to the extent the warrants issued to investors in the private placements are exercised. We believe that no compensation is due to LBC under this letter agreement and deny any liability under the letter agreement. We intend to defend this lawsuit vigorously and believe the ultimate resolution of this matter will not have a material adverse effect on our financial position. However, if we were required to issue warrants to LBC we would be required to incur a non-cash expense for each warrant issued equal to the difference between the exercise price of the warrants (\$2.50) and the current market price of our common stock.

We believe that the net proceeds from this offering, together with our existing resources, should be sufficient to fund our capital and operational requirements for the foreseeable future. However, there could be changes that could change this estimate. We will require substantial funds to conduct research and development activities, pre-clinical studies, clinical trials and other activities relating to the development and commercialization of our potential products. In addition, our cash requirements may vary materially from those now planned because of results of:

continued progress of our research and development programs,  
our ability to establish additional collaborative arrangements,

changes in our existing collaborative relationships,  
progress with pre-clinical studies and clinical trials,  
the time and costs involved in obtaining regulatory clearance for our products,  
the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims,  
competing technological and market developments, and  
our ability to market and distribute our products and establish new collaborative and licensing arrangements.

We may seek additional financing, such as through future offerings of equity or debt securities or agreements with collaborators with respect to the development and commercialization of products, to fund future operations. We cannot assure you, however, that we will be able to obtain additional funds on acceptable terms, if at all.

In management's opinion, the effect of inflation on our past operations has not been significant.

#### YEAR 2000

In 1999, we completed a review of our business systems, including computer systems and manufacturing equipment, and queried our customers and vendors as to their progress in identifying and addressing problems that their systems may face in correctly interrelating and processing data information in the year 2000. To date, we have not experienced any significant problems related to the year 2000 problem, either in our systems or the systems of our vendors or customers.

## BUSINESS

### OVERVIEW

We are a biopharmaceutical company that develops and commercializes enhanced therapeutics for life-threatening diseases through the application of our two proprietary platform technologies: PEG and single-chain antibodies. We apply our PEG, or polyethylene glycol, technology to improve the delivery, safety and efficacy of proteins and small molecules with known therapeutic efficacy. We apply our single-chain antibody, or SCA, technology to discover and produce antibody-like molecules that offer many of the therapeutic benefits of monoclonal antibodies while addressing some of their limitations.

PEG-Intron is a PEG-enhanced version of Schering-Plough's alpha interferon product, INTRON A. We have designed PEG-Intron to have an improved side effect profile, to yield greater efficacy as compared to INTRON A and to allow once per week dosing as compared to three times per week for INTRON A. Our worldwide partner for PEG-Intron, Schering-Plough, has filed applications in both Europe and the United States for approval of PEG-Intron in the treatment of hepatitis C. In February 2000, Schering-Plough announced that the European regulatory committee reviewing the PEG-Intron application issued a positive opinion recommending approval of PEG-Intron for the treatment of adult patients with chronic hepatitis C. Product approval by the European regulatory authority is typically issued three months from the time that such committee renders its opinion. In February 2000, the FDA accepted Schering-Plough's December 1999 application for PEG-Intron for standard review, which typically takes 12 months from the date of its filing. Schering-Plough is also conducting a Phase III clinical trial of PEG-Intron as combination therapy with REBETOL for hepatitis C and Phase III clinical trials of PEG-Intron for the treatment of chronic myelogenous leukemia and malignant melanoma. Earlier stage clinical trials of PEG-Intron are being conducted for other indications, including the treatment of HIV infection. Schering-Plough's worldwide sales of INTRON A and REBETON Combination Therapy for all indications in 1999 totaled \$1.1 billion.

PROTHECAN is a PEG-enhanced version of camptothecin, a compound in the class of molecules called topoisomerase inhibitors. Camptothecin has been shown in clinical testing to be potent against certain tumor types, but it possesses limited clinical utility due to significant side effects and poor solubility. We have shown in pre-clinical studies that PROTHECAN has reduced side effects compared to other topoisomerase inhibitors and preferentially accumulates in tumors. We have initiated a Phase I clinical trial of PROTHECAN in treating various types of cancers. Two topoisomerase inhibitors, topotecan and irinotecan, are currently approved and marketed for the treatment of ovarian and colorectal cancers, respectively. Total 1998 worldwide sales of these two products were approximately \$360 million. In addition to PEG-Intron and PROTHECAN, we have other PEG-enhanced product candidates in pre-clinical development.

We have commercialized two products based on our PEG technology: ADAGEN for the treatment of a congenital enzyme deficiency disease called SCID and ONCASPAR for the treatment of acute lymphoblastic leukemia. Each of these products is a PEG-enhanced version of a naturally occurring enzyme. Both products have been on the market for several years and have demonstrated the safe and effective application of our PEG technology.

SCAs are genetically engineered proteins which possess the binding specificity and affinity of monoclonal antibodies and are designed to expand on the therapeutic and diagnostic applications possible with monoclonal antibodies. Preclinical studies have shown that SCAs allow for greater tissue penetration and faster clearance from the body. We intend to use our strong intellectual property position for our SCAs to issue additional licenses to third parties developing SCAs. We also intend to develop PEG-enhanced therapeutic SCAs internally, focusing initially on cancer and cardiovascular therapeutics. To date, 11 SCAs have been or are being tested in early stage clinical trials. The most clinically advanced SCAs based on our technology are being developed by our licensee, Alexion Pharmaceuticals, for complications arising during cardiopulmonary bypass and myocardial infarction.

We intend to continue to commercialize our proprietary products and technologies both internally and in cooperation with our strategic partners. We have more than 15 strategic alliances and license relationships for the development of products using our proprietary technologies.

#### PEG TECHNOLOGY

Our proprietary PEG technology involves chemically attaching PEG to therapeutic proteins or small molecules for the purpose of enhancing therapeutic value. PEG is a relatively non-reactive and non-toxic polymer that is frequently used in food and pharmaceutical products. We have demonstrated, both in our marketed products and our products under development, that for some proteins and small molecules, we can impart significant pharmacologic advantages over the unmodified forms of the compound by modifying a compound using our PEG technology.

These advantages include:

- extended circulating life,
- lower toxicity,
- increased drug stability, and
- enhanced drug solubility.

[Graphic Insert]

A DEPICTION OF A PEG-ENHANCED MOLECULE.

For many years, we have applied our PEG technology to enhance the pharmacologic characteristics of potential or existing protein therapeutics. When we modify proteins with our PEG technology, it often causes these proteins

to have properties, such as improved circulating life and reduced toxicities, that significantly improve their therapeutic performance. In some cases, PEG can render a protein therapeutically effective, where the unmodified form had not been effective. For example, proteins are often limited in their use as therapeutics because they frequently induce an immunologic response. When PEG is attached, it disguises the compound and reduces recognition by the patient's immune system. As a result, many of the favorable characteristics listed above are achieved. Given such improvement, frequency of dosing can be reduced without diminishing potency, or higher doses can be given to achieve a more powerful therapeutic impact.

We recently developed a next generation PEG technology that allows us to apply PEG to small molecules. Like proteins, many small molecules of potentially significant therapeutic value possess undesired pharmacologic characteristics such as poor solubility, limited half life and propensity to induce an immunologic response. The attachment of PEG to small molecules not only disguises the molecule, thereby lowering potential immunogenicity and extending its circulatory life, but also greatly increases the solubility of these compounds. We attach PEG to small molecules by means of a covalent bond that is designed to temporarily inactivate the compound, and then deteriorate over time, releasing the compound in the proximity of targeted tissue. By inactivating and then reactivating the compound in the body we create a Pro Drug version of such compounds. These attributes may significantly enhance the therapeutic value of new chemicals, drugs already marketed by others and off-patent drugs with otherwise limited utility. We believe that this technology has broad usefulness and that it can be applied to a wide range of small molecules, such as:

- cancer chemotherapy agents,
- antibiotics,
- anti-fungals, and
- immunosuppressants.

32

We also believe that we will be able to use this PEG technology to impart Pro Drug attributes to proteins and peptides, including enzymes and growth factors.

We have significant expertise and intellectual property in the methods by which PEG can be attached to a compound, the selection of appropriate sites on the compound to which PEG is attached, and the amount and type of PEG used. If PEG is attached to the wrong site on the protein, it can result in a loss of the protein's activity or therapeutic effect. Similarly, inappropriate linkers or the incorrect type or amount of PEG applied to a compound will typically fail to produce the desired outcome. Given our expertise, we are able to tailor the PEG technology to produce the desired results for the particular substance being modified.

#### PEG PRODUCTS

##### PEG-INTRON

PEG-Intron is a PEG-enhanced version of Schering-Plough's recombinant alpha-interferon product called INTRON A. We have modified the INTRON A compound by attaching PEG to it, with the goal of imparting upon the drug enhanced characteristics, such as reduced toxicity, extended circulating life and the ability to administer higher doses without causing additional side effects. We have developed PEG-Intron in conjunction with Schering-Plough. Schering-Plough currently markets INTRON A for 16 major antiviral and oncology indications worldwide. The largest indications for INTRON A are hepatitis C and certain types of cancer. Schering-Plough has been conducting clinical trials of PEG-Intron in hepatitis C and cancer, as well as some other potential indications. Schering-Plough has submitted applications for marketing approval in both Europe and the U.S. for use of PEG-Intron as stand-alone therapy in treating hepatitis C.

Commencing in late 1998, Schering-Plough began selling INTRON A in combination therapy with REBETOL for the treatment of hepatitis C.

Schering-Plough has reported that the 1999 worldwide sales of INTRON A, as a stand-alone therapy for all indications and as combination therapy with REBETOL, were approximately \$1.1 billion. Sales of INTRON A as a stand-alone therapy for the treatment of hepatitis C represent a portion of these combined sales. To date, the only application filed by Schering-Plough for marketing approval of PEG-Intron is as stand-alone therapy for the treatment of hepatitis C.

#### Hepatitis C

According to an article published in the New England Journal of Medicine, approximately 3.9 million people in the U.S. are infected with the hepatitis C virus. Approximately 2.7 million of these people are characterized as having chronic hepatitis C infection. We believe that the number of people infected with the hepatitis C virus in Europe is comparable to that in the U.S. According to the World Health Organization, there were approximately 170 million chronic cases of hepatitis C worldwide. A substantial number of people in the U.S. who were infected with hepatitis C more than 10 years ago are thought to have contracted the virus through blood transfusions. Prior to 1992, the blood supply was not screened for the hepatitis C virus. In addition, the majority of people infected with the virus are thought to be unaware of the infection because the hepatitis C virus can incubate for up to 10 years before patients become symptomatic. We estimate that fewer than 100,000 patients are currently being treated in the U.S. for hepatitis C.

The current standard of care for hepatitis C infection is alpha-interferon administered three times per week for one year in combination with ribavirin, another antiviral drug. The alpha-interferon plus ribavirin therapy was approved in the U.S. for the treatment of hepatitis C in December 1998. Prior to such approval, hepatitis C infection was typically treated with alpha-interferon alone. In clinical studies, alpha-interferon stand-alone therapy for 48 weeks has reduced viral loads below the detectable levels in 10% to 15% of patients treated. In clinical studies, alpha-interferon plus ribavirin in combination therapy has reduced viral loads below detectable levels in 31% to 38% of patients treated. The clinical efficacy of alpha-interferon, both as a stand-alone or combination therapy, has been limited by serious side effects, which include flu-like symptoms, gastro-intestinal disorders and depression, in addition to

33

the undesirable dosing requirements. The requirement of three times per week dosing for the treatment of hepatitis C has also limited patient compliance.

We expect that PEG-Intron will have an improved side effect profile, greater efficacy and allow for less frequent dosing as compared to unmodified INTRON A. We expect that PEG-Intron will be administered once per week, as opposed to up to three times per week for current hepatitis C regimens utilizing unmodified INTRON A.

In November 1999, Schering-Plough announced that it had submitted a Marketing Authorization Application to the European Agency for the Evaluation of Medicinal Products, or EMEA, seeking marketing approval in Europe for PEG-Intron (PEG-interferon alfa-2b) Powder for Injection. In February 2000, Schering-Plough announced that the Committee for Proprietary Medicinal Products of the EMEA issued an opinion recommending approval of that application. Product approval by the EMEA is typically issued three months from the time that the Committee renders its opinion. Approval of this application for PEG-Intron will allow Schering-Plough to market PEG-Intron throughout the European Union. In December 1999, Schering-Plough submitted a Biologics License Application, or BLA, to the FDA seeking marketing approval for PEG-Intron Powder for Injection for the treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease. In February 2000, the FDA accepted Schering-Plough's BLA for PEG-Intron for standard review. Under the Prescription Drug Users Fee Act, the FDA is required to act on the application within 12 months from the date of its filing on December 23, 1999. According to Schering-Plough, the BLA proposes administration of PEG-Intron Powder by injection once weekly for one year.

Under our licensing agreement with Schering-Plough, we are entitled to milestone payments and royalties on worldwide sales of PEG-Intron. The FDA's

acceptance in February 2000 of the BLA filing submitted by Schering-Plough entitled us to a \$1.0 million milestone payment. Schering-Plough has been responsible for the clinical development of PEG-Intron. We have not had access to the results of the Phase III clinical trial that were included in Schering-Plough's BLA and its European Marketing Authorization Application, nor have we been able to review the BLA or the European Marketing Authorization Application.

Schering-Plough is also continuing its development of PEG-Intron as combination therapy with REBETOL (ribavirin, USP) for hepatitis C. In January 1999, Schering-Plough announced the initiation of a multi-national Phase III clinical trial for this combination therapy.

#### Cancer

INTRON A is also used extensively in the treatment of cancer. Of the 16 indications for which INTRON A is approved throughout the world, 12 are cancer indications. Currently, INTRON A is approved in the U.S. for three cancer indications and used in some cases for other indications on an off-label basis.

Schering-Plough is currently conducting two Phase III clinical trials of PEG-Intron for two cancer indications, malignant melanoma and chronic myelogenous leukemia. In addition, Schering-Plough is conducting early stage trials of PEG-Intron for various solid tumors and other forms of leukemia. The following is a list of approved and potential cancer indications for which INTRON A may be prescribed in the U.S.

CANCER TYPE	STATUS	ANNUAL U.S. INCIDENCE
Malignant melanoma (Stage II, III, IV)	Approved	44,200
Follicular NHL (low grade)	Approved	11,000
Chronic myelogenous leukemia	Approved	4,300
AIDS-related Kaposi's sarcoma	Approved	3,200
Bladder cancer	Potential	54,200
Renal cell carcinoma	Potential	31,000

If the ongoing Phase III clinical trials of PEG-Intron in malignant melanoma and chronic myelogenous leukemia demonstrate not only that the product is effective, but also that it has an improved side effect profile compared to unmodified INTRON A, we anticipate that higher doses of PEG-Intron may be used, as compared to unmodified INTRON A. The ability to administer higher doses of alpha-interferon could lead to increased efficacy, as well as permit the use of PEG-Intron for additional indications or usage. Published data from a Phase I clinical trial of PEG-Intron in various cancer types showed that some patients who previously did not respond to unmodified INTRON A treatment did respond to PEG-Intron. In that trial, PEG-Intron was administered once per week as opposed to up to five times per week, which is a typical therapy regimen using unmodified INTRON A, and we expect that the once per week dosing regimen may be used in treating various cancer types.

#### Potential Other Indications

We believe that PEG-Intron may be applied in treating other diseases, including HIV. A Phase I clinical trial of PEG-Intron has been conducted for HIV. In this study, 58% of the 30 patients had substantial reductions in their levels of HIV after adding a weekly injection of PEG-Intron to their combination treatments.

#### PROTHECAN

PROTHECAN is a PEG-enhanced version of a small molecule called camptothecin, which is an anticancer compound in the class of drugs called topoisomerase inhibitors. Camptothecin, which was originally developed at the National Institutes of Health and is now off patent, is believed be a potent



topoisomerase inhibitor.

For many years camptothecin has been known to be a very effective oncolytic agent but its drug delivery problems have limited its use. Recently, two camptothecin derivatives, topotecan and irinotecan, have been approved by the FDA for the treatment of ovarian and colorectal cancers, respectively. While these two new products are more soluble than camptothecin, their efficacy rate is relatively low. Despite their limitations, these two products together achieved 1998 worldwide sales of approximately \$360 million.

We believe that by adjusting the way PEG is covalently attached to camptothecin, the PEG attachment can be used to inactivate the compound's toxic mechanism, which allows it to circulate in the bloodstream for long periods of time. This allows the compound to accumulate in the proximity of tumor sites. Preliminary animal tests have shown that camptothecin modified with our PEG technology preferentially accumulates in tumors. The covalent bond used in the camptothecin to attach PEG to the drug is designed to deteriorate over time, resulting in the PEG falling off and allowing the compound once again to become active.

We are currently conducting a Phase I clinical trial of PROTHECAN in treating various types of cancers.

#### ADAGEN

ADAGEN, our first FDA-approved PEG product, is used to treat patients afflicted with a type of Severe Combined Immunodeficiency Disease, or SCID, also known as the 'Bubble Boy Disease,' which is caused by the chronic deficiency of the adenosine deaminase enzyme, or ADA. ADAGEN represents the first successful application of enzyme replacement therapy for an inherited disease. SCID results in children being born without fully functioning immune systems, leaving them susceptible to a wide range of infectious diseases. Currently, the only alternative to ADAGEN treatment is a well-matched bone marrow transplant. Injections of unmodified ADA are not effective because of its short circulating life (less than 30 minutes) and the potential for immunogenic reactions to a bovine-sourced enzyme. The attachment of PEG to ADA allows ADA to achieve its full therapeutic effect by increasing its circulating life and masking the ADA to avoid immunogenic reactions.

We are marketing ADAGEN on a worldwide basis and selling it in the United States. A European firm is distributing ADAGEN in Europe and Japan. Currently, 65 patients in nine countries are

35

receiving ADAGEN therapy. We believe many newborns with ADA-deficient SCID go undiagnosed and we are therefore focusing our marketing efforts for ADAGEN on new patient identification. Our sales of ADAGEN for the fiscal years ended June 30, 1999, 1998 and 1997 were \$11.2 million, \$10.1 million and \$8.9 million, respectively.

#### ONCASPAR

ONCASPAR, our second FDA-approved product, is a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase. It is currently approved in the U.S., Canada and Germany, and is used in conjunction with other chemotherapeutics to treat patients with acute lymphoblastic leukemia who are hypersensitive, or allergic, to native, or unmodified, forms of L-asparaginase. RPR has the exclusive license to market ONCASPAR in the U.S. and Canada, and MEDAC GmbH has the exclusive right to market ONCASPAR in Europe.

L-asparaginase is an enzyme which depletes the amino acid asparagine upon which certain leukemic cells are dependent for survival. Other companies market unmodified L-asparaginase in the U.S. for pediatric acute lymphoblastic leukemia and in Europe to treat adult acute lymphoblastic leukemia and non-Hodgkins lymphoma, as well as pediatric acute lymphoblastic leukemia.

The therapeutic value of unmodified L-asparaginase is limited by its short half-life, which requires every-other-day injections, and its propensity to cause a high incidence of allergic reactions. We believe that ONCASPAR offers

significant therapeutic advantages over unmodified L-asparaginase. ONCASPAR has a significantly increased half-life in blood, allowing every-other-week administration, and it causes fewer allergic reactions. Based upon the current use of unmodified L-asparaginase, we believe that ONCASPAR may be used in other cancer indications, including potentially lymphoma.

#### OTHER PEG PRODUCTS

Our PEG technology may be applicable to other potential products. We are currently conducting pre-clinical studies for additional PEG-enhanced compounds. We will continue to seek opportunities to develop other PEG-enhanced products. In 1998, we concluded a second Phase I clinical trial for a hemoglobin-based oxygen carrier, PEG-hemoglobin, for use as a radiosensitizer, in conjunction with radiation treatment of solid hypoxic tumors. We intend to continue to develop this product only in conjunction with a partner that will fund the development costs. To date, we have been unable to conclude an agreement with such a partner. We do not intend to conduct any clinical trials on our own.

#### SCA PROTEINS

##### GENERAL

Antibodies are proteins produced by the immune system in response to the presence in the body of bacteria, viruses or other disease causing agents. Antibodies of identical molecular structure that bind to a specific target are called monoclonal antibodies. Over the past few years, several monoclonal antibodies have been approved for therapeutic use and have achieved significant clinical and commercial success. Much of the clinical utility of monoclonal antibodies results from the affinity and specificity with which they bind to their targets, as well as a long circulating life due to their relatively large size. Monoclonal antibodies, however, are not well suited for use in indications where a short half-life is advantageous or where their large size inhibits them physically from reaching the area of potential therapeutic activity.

SCAs are genetically engineered proteins designed to expand on the therapeutic and diagnostic applications possible with monoclonal antibodies. SCAs have the binding specificity and affinity of monoclonal antibodies and, in their native form, are about one-fifth to one-sixth of the size of a monoclonal antibody, typically giving them very short half lives. We believe that human SCAs offer the following benefits compared to most monoclonal antibodies:

faster clearance from the body,

greater tissue penetration for both diagnostic imaging and therapy,

36

more specific localization to target sites in the body,

a significant decrease in immunogenic problems when compared with mouse-based antibodies,

easier and more cost effective scale-up for manufacturing when compared with monoclonal antibodies,

enhanced screening capabilities which allow for the more rapid assessment of SCA proteins of desired specificity using high throughput screening methods, and

a better opportunity to be used orally, intranasally, transdermally or by inhalation.

[GRAPH]

Monoclonal Antibody

[GRAPH]

Single-Chain Antibody

#### COMPARISON OF A STANDARD MONOCLONAL ANTIBODY AND A SINGLE-CHAIN ANTIBODY.

In addition to these benefits, fully human SCAs can be isolated directly from human SCA libraries without the need for costly and time consuming 'humanization' procedures. SCAs are also readily produced through intracellular

expression (inside cells) allowing for their use in gene therapy applications where SCA molecules act as specific inhibitors of cell function.

We, along with numerous other academic and industrial laboratories, have demonstrated through in vitro testing the binding specificity of dozens of SCAs. We, in collaboration with the National Cancer Institute, have shown in published preclinical studies that SCAs localize to specific tumors and rapidly penetrate the tumors.

#### SCAS UNDER DEVELOPMENT

We believe that we have a strong patent position in the area of SCAs. We also believe that all products made by or incorporating SCA-based proteins or genes will require a license under our patents. We have granted licenses to a number of corporations and intend to issue additional licenses. We also intend to develop our own SCAs, focusing primarily on PEG-enhanced SCAs. To date, we have granted SCA product licenses to more than fifteen companies, including Bristol-Myers Squibb, Baxter Healthcare and the Gencell Division of RPR. These product licenses generally provide for upfront

37

payments, milestone payments and royalties on sales of any SCA products developed. The following table sets forth a number of our licensees and summarizes their research and development efforts to date:

RESEARCH COLLABORATOR	STATUS	INDICATION/USE
Alexion Pharmaceuticals	Phase IIb	Cardiopulmonary bypass and myocardial infarction
Cell Genesys	Phase I/II	Colon cancer
Seattle Genetics	Phase I	Cancer
MorphoSys	Research	Phage display
Cambridge Antibody Technology	Research	Phage display
Baxter Healthcare Corporation	Research	Cancer
Bristol-Myers Squibb	Research	All therapeutics
Gencell Division of RPR	Research	Gene therapy

Currently, there are 11 SCA proteins that have either completed Phase I or II clinical trials or are in early research stages by various organizations, including our licensees and academic institutions. Some of the areas being explored are cancer therapy, cardiovascular indications and AIDS. We believe that those organizations that have not yet licensed this technology from us will need a license from us to commercialize these products. However, we cannot assure you that this will prove to be the case. Set forth below are some examples of research being conducted in the SCA area.

Alexion Pharmaceuticals. Our licensee, Alexion Pharmaceuticals, Inc., is developing an SCA directed against complement protein C5, which is a component of the body's normal defense against foreign pathogens. Inappropriate complement activation during cardiopulmonary bypass and myocardial infarction can lead to clinical problems. In Phase I trials during cardiopulmonary bypass, this SCA improved cardiac and neurological function and reduced blood loss. Alexion and its partner, Procter & Gamble, are currently conducting a 1,000 patient Phase IIb study to evaluate this SCA in patients undergoing cardiopulmonary bypass surgery and are initiating two additional 1,000 patient Phase II trials to evaluate this SCA in heart attack patients.

Cell Genesys. Another application of our SCA technology is in the area of T-Bodies. T-Body technology involves the expression of an SCA protein in a T-Cell that has been removed from the body and genetically modified. T-Cells, a type of lymphocyte cell, represent an important component of the immune system responsible for cell-mediated immunity and represent one of the body's natural defenses against foreign materials such as cancer cells and infectious organisms. Using SCA technology, T-Cells can be modified through molecular biology methods to express an SCA on the cell surface that can then recognize

and bind to a specific antigen, thereby targeting the T-Cell to a specific location. Cell Genesys, our licensee, has had success in applying T-Bodies in preclinical studies with a T-Body SCA directed to various forms of cancer. In its recently completed Phase I/II trial, Cell Genesys reported that the treatment could be safely administered in an outpatient setting although no antitumor activity was observed.

Cambridge Antibody Technology and MorphoSys. Cambridge Antibody Technology Ltd., or CAT, and MorphoSys are using antibody engineering, with phage display library technology, for the isolation of high specificity antibody binding regions. Using phage display technology, it is possible to conveniently isolate a fully human high-affinity SCA specific to virtually any target antigen. CAT and MorphoSys are leaders in the development of combinatorial antibody libraries, also referred to as phage display. CAT and MorphoSys currently have several licensing agreements with global pharmaceutical and biotechnology companies to apply their library to the identification and isolation of high specificity antibody proteins. Any companies working with CAT or MorphoSys will be required to negotiate a license with us for any SCAs that they might wish to commercialize.

Seattle Genetics. Seattle Genetics is developing a single-chain immunotoxin targeted to cancers. It recently started Phase I clinical trials in patients with carcinoma of its lead product candidate SGN-10, a single-chain version of Bristol-Myers' monoclonal antibody called BR 96. Preclinical data indicates that this SCA may have potent activity against a wide variety of solid tumor cancers. Single-chain immunotoxins combine an SCA that has specificity for a particular antigen on certain types of cancer

38

cells with a toxin protein that would not otherwise bind to those tumor cells. SGN-10 has an SCA component that binds with high specificity to a particular carbohydrate that is expressed on the cell surface of many forms of solid tumors, including breast, lung, ovarian, prostate, colorectal and pancreatic cancers.

Dana-Farber Cancer Institute and University of Alabama. Scientists at the Dana-Farber Cancer Institute and the University of Alabama are conducting research utilizing SCA proteins called intrabodies. Intrabodies are SCAs produced inside the cell via gene therapy. The Dana-Farber Cancer Institute is studying the use of a very specific intrabody for the treatment of HIV infection. The University of Alabama is studying a separate intrabody for ovarian cancer targeted to the erbB-2 receptor. Pre-clinical data generated from these studies have revealed that SCAs produced through intracellular expression can provide an important therapeutic response. The University of Alabama has completed a Phase I trial and the Dana-Farber Cancer Institute expects to initiate its trial shortly. Because the Dana-Farber Cancer Institute and the University of Alabama are academic research institutions, we have not required them to license our technologies.

#### INTERNAL DEVELOPMENT

We are evaluating the feasibility of in-licensing SCA proteins that are already in clinical development. We are also developing several new technology platforms combining our proprietary SCA and PEG technologies. We have shown that it is possible to increase the half life of an SCA, by a factor of two- to twenty-fold, by attaching PEG to it. We can modify these properties of a PEG-SCA by varying the size of the PEG, the amount and shape of PEG and the attachment site. We intend to pursue the expansion of PEG-SCA technologies and develop SCA therapeutics that may be important in the treatment of cardiovascular disease, cancer, transplantation and acute phases of certain chronic diseases such as arthritis.

#### STRATEGIC ALLIANCES AND LICENSES

In addition to internal product development, we seek to enter into joint development and licensing arrangements with other pharmaceutical and biopharmaceutical companies to expand the pipeline of products utilizing our proprietary PEG and SCA protein technologies. We believe that our technologies can be used to improve products that are already on the market or that are under

development to produce therapeutic products that provide a safer, more effective and more convenient therapy. Currently, our partners have two products in late stages of the approval process, PEG-Intron and Human Serum Albumin, as well as several SCA compounds in Phase I and Phase II clinical trials.

#### SCHERING-PLOUGH AGREEMENT

In November 1990, we entered into an agreement with Schering-Plough. Under this agreement, Schering-Plough agreed to apply our PEG technology to develop a modified form of Schering-Plough's INTRON A. Schering-Plough is responsible for conducting and funding the clinical studies, obtaining regulatory approval and marketing the product worldwide on an exclusive basis and we will receive royalties on worldwide sales of PEG-Intron, if any. The royalty percentage to which we are entitled will be lower in any country where a polyethylene glycol/interferon-a product is being marketed by a third party in competition with PEG-Intron, where such third party is not Hoffmann-La Roche.

In June 1999, we amended our agreement with Schering-Plough, which resulted in an increase in the effective royalty rate that we receive for PEG-Intron sales. In exchange, we relinquished our option to retain exclusive U.S. manufacturing rights for this product. In addition, we granted Schering-Plough a non-exclusive license under some of our PEG patents relating to Branched, or U-PEG, technology. This license gives Schering-Plough the ability to sublicense rights under these patents to any party developing a competing interferon product.

In February 2000, we earned a \$1.0 million milestone payment when the FDA accepted the BLA for PEG-Intron filed by Schering-Plough. We are entitled to an additional \$2.0 million milestone

39

payment upon the approval of the BLA, if and when such approval occurs. Our agreement with Schering-Plough terminates, on a country-by-country basis, upon the later of:

the termination of Schering-Plough's obligation to pay us royalties in such country under the agreement, which obligation runs until the later of the date the last patent to contain a claim covering PEG-Intron expires in the country or 15 years after the first commercial sale of PEG-Intron in such country, or

the expiration of the last to expire of our U-PEG patents or the patents owned or assigned to us under the agreement, including any patent extension or other extension of market exclusivity obtained relating to the patents.

Schering has the right to terminate this agreement at any time if we fail to maintain the requisite liability insurance.

#### RHONE-POULENC RORER LICENSE AGREEMENTS

We have entered into an amended license agreement with RPR under which we have granted RPR an exclusive license to sell in the United States ONCASPAR and any other asparaginase or PEG-asparaginase product developed by us or RPR during the term of the amended license agreement. Under the amended license agreement, we have received an advanced royalty payment of \$3.5 million and are entitled to a base royalty of 23.5% on net sales of ONCASPAR up to agreed-upon amounts, until 2008. Additionally, the amended license agreement provides for a super royalty of 43.5% on net sales of ONCASPAR which exceed certain agreed-upon amounts until 2008, with the limitation that the total royalties earned for any year shall not exceed 33% of RPR's net sales of ONCASPAR.

The payment of base royalties to us under the amended license agreement will be offset by an original credit of \$5.9 million, which represents the royalty advance plus reimbursement of certain amounts due to RPR under the original license agreement and interest expense. Super royalties will be paid to us when earned. The royalty advance is shown as a long term liability, with the corresponding current portion included in accrued expenses on our consolidated balance sheets as of December 31, 1999 and 1998. The royalty advance will be reduced as base royalties are recognized under the agreement.

The amended license agreement prohibits RPR from making, using or selling an asparaginase product in the U.S. or a competing PEG-asparaginase product anywhere in the world until the later of the expiration of the agreement or, if the agreement is terminated earlier, five years after termination. The agreement terminates in December 2008 but automatically renews for additional one-year periods unless either party notifies the other in writing that it intends not to renew the agreement at least three months prior to the end of the current term. It can be terminated earlier by either party due to a default by the other. In addition, RPR may terminate the agreement at any time upon one year's prior notice to us or if we are unable to supply product for more than 60 days under our supply agreement with RPR. When the amended license agreement terminates, all rights we granted to RPR under the agreement will revert to us. Under its supply agreement with us, RPR is required to purchase from us all of its product requirements for sales of ONCASPAR in North America. If we are unable to supply product to RPR under the supply agreement for more than 60 days for any reason other than a force majeure event, RPR may terminate the supply agreement and we will be required to exclusively license RPR the know-how required to manufacture ONCASPAR for the period of time during which the agreement would have continued had the license agreement not been terminated.

We are currently in discussions with RPR related to a disagreement over the purchase price of ONCASPAR under the supply agreement. RPR has asserted that we have overcharged RPR under the supply agreement in the amount of \$2.3 million. We believe our costing and pricing of ONCASPAR to RPR complies with the supply agreement. RPR has also asserted that we should be responsible for its lost profits while ONCASPAR is under the temporary labeling and distribution modifications described above. RPR contends that its lost profits through December 31, 1999 were \$5.2 million.

Under separate license agreements, RPR has exclusive rights to sell ONCASPAR in Canada and Mexico. These agreements provide for RPR to seek to obtain marketing approval of ONCASPAR in Canada and Mexico and for us to receive royalties on net sales of ONCASPAR in these countries, if

40

any. These agreements expire 10 years after the first commercial sale of ONCASPAR in each country, but automatically renew for consecutive five-year periods unless either party elects to terminate at least three months prior to the end of the current term. RPR may terminate these agreements on one year's prior notice to us.

We also have a license agreement with RPR for the Pacific Rim region, specifically, Australia, New Zealand, Japan, Hong Kong, Korea, China, Taiwan, the Philippines, Indonesia, Malaysia, Singapore, Thailand, Laos, Cambodia and Vietnam. Under the license agreement, RPR is responsible for obtaining approvals for indications in the licensed territories. Our supply agreement for the Pacific Rim region provides for RPR to purchase ONCASPAR for the region from us at established prices, which increase over the term of the agreement. The license agreement also provides for minimum purchase requirements for the first four years of the agreement. These agreements expire on a country-by-country basis 10 years after the first commercial sale of ONCASPAR in each country, but automatically renew for consecutive five-year periods unless either party elects to terminate at least three months prior to the end of the current term. RPR may terminate these agreements on one year's prior notice to us.

#### MEDAC LICENSE AGREEMENT

We have also granted an exclusive license to MEDAC to sell ONCASPAR and any PEG-asparaginase product developed by us or MEDAC during the term of the agreement in Western Europe, Turkey and Russia. Our supply agreement with MEDAC provides for MEDAC to purchase ONCASPAR from us at certain established prices, which increase over the initial five-year term of the agreement. Under the license agreement, MEDAC is responsible for obtaining additional approvals and indications in the licensed territories, beyond the currently approved hypersensitive indication in Germany. Under the agreement, MEDAC is required to meet certain minimum purchase requirements. The MEDAC license terminates in October 2001, but automatically renews for successive two-year periods unless either party elects to terminate at least nine months prior to the end of the

current term. MEDAC may terminate the agreement after providing us with one year's prior notice.

#### GREEN CROSS AGREEMENTS

We have two license agreements with the Green Cross Corporation for the development of a recombinant human serum albumin, or rHSA, as a blood volume expander. Green Cross was acquired by Yoshitomi Pharmaceutical Industries, Ltd. in April 1998. Green Cross has reported that it filed for approval of this product in Japan in November 1997. The agreements, which were assigned to us in connection with our acquisition of Genex Corporation in 1991, entitle us to a royalty on sales of an rHSA product sold by Green Cross in much of Asia and North and South America. Currently, Green Cross is only developing this product for the Japanese market. A binding arbitration was recently concluded regarding the royalty rate required under the agreements. Green Cross had filed documents in the arbitration taking the position that no royalty was due to us. We disputed that position, and in February 2000, the arbitrators awarded us a 1% royalty on Yoshitomi sales of rHSA in Japan, South East Asia, India, China, Australia, New Zealand and North and South America for a period of 15 years after the first commercial sale of Yoshitomi's rHSA following market approval of that product in Japan or the United States.

#### MARKETING

Other than ADAGEN, which we market on a worldwide basis to a small patient population, we do not engage in the direct commercial marketing of any of our products and therefore do not have an established sales force. For some of our products, we have provided exclusive marketing rights to our corporate partners in return for royalties on sales.

We expect to evaluate whether to create a sales force to market certain products in the United States or to continue to enter into licensing and marketing agreements with others for United States and foreign markets. These agreements generally provide that our licensees or marketing partners will conduct all or a significant portion of the marketing of these products. In addition, under these

agreements, our licensee or marketing partners may have all or a significant portion of the development and regulatory approval responsibilities.

#### RAW MATERIALS AND MANUFACTURING

In the manufacture of our products, we couple activated forms of PEG with unmodified proteins. We do not have a long-term supply agreement for the raw polyethylene glycol that we use to manufacture the PEG we require. Instead, we maintain a level of inventory which we believe should provide us sufficient time to find an alternate supplier of PEG, in the event it becomes necessary, without materially disrupting our business.

During 1998, we began to experience manufacturing problems with one of our FDA-approved products, ONCASPAR. The problems were due to increased levels of white particulates in batches of ONCASPAR, which resulted in an increased rejection rate for this product. During fiscal 1999, we agreed with the FDA to temporary labeling and distribution modifications for ONCASPAR and instituted additional inspection and labeling procedures prior to distribution. During May 1999, the FDA required us to limit distribution of ONCASPAR to only those patients who are hypersensitive to native L-asparaginase. In November 1999, the FDA withdrew this distribution restriction.

Recently, we have noticed an unacceptable level of black particulates in batch of ADAGEN filled by our third-party contract filler. We believe these particulates are caused by the filling process, and our outside filler has taken steps to resolve this issue. Because we use the same filler for ADAGEN and ONCASPAR, this problem could affect our manufacture of ONCASPAR.

In July 1999, the FDA conducted an inspection of our manufacturing facility in connection with our product license for ADAGEN. Following that inspection, the FDA documented several deviations from Current Good Manufacturing Practices,

known as cGMP, in a Form 483 report. We provided the FDA with a corrective action plan. In November 1999, the FDA issued a warning letter citing the same cGMP deviations listed in the July 1999 Form 483, but it also stated that the FDA was satisfied with our proposed corrective actions. As a result of the deviations, the FDA decided not to approve product export requests from us for both ADAGEN and ONCASPAR until it determines that all noted ADAGEN cGMP deviations have been corrected.

In January 2000, the FDA conducted another inspection of our manufacturing facility relating to the ONCASPAR product license and as a follow-up to the July 1999 inspection relating to ADAGEN. Following this most recent inspection, the FDA issued a Form 483 report, citing deviations from cGMP in the manufacture of ONCASPAR and two cGMP deviations for ADAGEN. We have responded to the FDA with a corrective action plan to the January 2000 Form 483.

#### RESEARCH AND DEVELOPMENT

Our primary source of new products is our internal research and development activities. Research and development expenses for the fiscal years ended June 30, 1999, 1998 and 1997 were approximately \$6.8 million, \$8.7 million and \$8.5 million, respectively.

Our research and development activities during fiscal 1999 concentrated primarily on pre-clinical work on PROTHECAN, our first product to use our Pro Drug/Transport Technology, and continued research and development of our proprietary technologies. As a result of our clinical trials for PROTHECAN we expect our research and expenses for fiscal 2000 to be at the levels for fiscal 1998 and 1997.

#### PATENTS

We have licensed, and been issued, a number of patents in the United States and other countries and have other patent applications pending to protect our proprietary technology. Although we believe that our patents provide adequate protection for the conduct of our business, we cannot assure you that such patents:

will be of substantial protection or commercial benefit to us,

42

will afford us adequate protection from competing products, or

will not be challenged or declared invalid.

We also cannot assure you that additional United States patents or foreign patent equivalents will be issued to us.

The patent covering our original PEG technology, which we had licensed from Research Corporation Technologies, Inc., contained broad claims covering the attachment of PEG to polypeptides. However, this United States patent and its corresponding foreign patents have expired. Based upon the expiration of the Research Corporation patent, other parties will be permitted to make, use, or sell products covered by the claims of the Research Corporation patent, subject to other patents, including those which we hold. We have obtained and intend to continue to pursue patents with claims covering improved methods of attaching or linking PEG to therapeutic compounds. We also have obtained patents relating to the specific composition of the PEG-modified compounds that we have identified or created. We will continue to seek such patents as we develop additional PEG-enhanced products. We cannot assure you that any of these patents will enable us to prevent infringement or that competitors will not develop competitive products outside the protection that may be afforded by our patents.

We are aware that others have also filed patent applications and have been granted patents in the United States and other countries with respect to the application of PEG to proteins and other compounds. Owners of any such patents may seek to prevent us or our collaborators from selling our products. In January 2000, Hoffmann-La Roche filed lawsuits in both the U.S. and France against Schering-Plough alleging that PEG-Intron infringes certain patents held by Hoffmann-La Roche. The validity and scope of Hoffmann-La Roche's patents in



this segment of the industry could be judicially determined during these proceedings. If Schering-Plough does not prevail in this litigation, Hoffmann-La Roche may completely block Schering-Plough from commercializing PEG-Intron. Among other things, the outcome will likely depend not only upon whether the Hoffmann-La Roche patents are determined valid and infringed, but upon the reasoning behind such determinations. Prior to the commencement of this litigation we obtained an opinion of patent counsel that the patent held by Hoffmann-La Roche is invalid. We are also aware of certain patents held by Biopure Corporation that are relevant to PEG-hemoglobin. We have obtained an opinion of counsel that no valid claims of such Biopure patents would be infringed by the sale of PEG-hemoglobin. These opinions have been relied upon by us and our collaborators in continuing to pursue development of these products; however, these opinions are not binding on any court or the U.S. Patent and Trademark Office. We cannot assure you that the patent opinions will prove to be correct and that a court would find any of the claims of such patents to be invalid or that the product developed by us or our collaborator does not infringe such patents.

We also believe that there are PEG-modified products being developed by third parties that infringe on one or more of our current PEG technology patents. On December 7, 1998, we filed a patent infringement suit against Shearwater Polymers Inc., a company that reportedly has developed a Branched PEG, or U-PEG, used in Hoffmann-La Roche's Pegasys product, a PEG-modified version of its alpha-interferon product called Roferon-A. According to published reports, Pegasys utilizes a type of Branched PEG for which we have been granted a patent in the U.S. and have a similar patent pending in Europe. Shearwater has filed a counterclaim in this litigation alleging that our Branched PEG patent is invalid and unenforceable.

In the field of SCA proteins, we have several United States and foreign patents and pending patent applications, including a patent granted in August 1990 covering the genes needed to encode SCA proteins. Creative BioMolecules, Inc., or Creative, provoked an interference with this patent and on June 28, 1991, the United States Patent and Trademark Office entered summary judgment terminating the interference proceeding and upholding our patent. Creative subsequently lost its appeal of this decision in the United States Court of Appeals and did not file a petition for review of this decision by the United States Supreme Court within the required time period.

In November 1993, Creative signed collaborative agreements with us in the field of our SCA protein technology and Creative's Biosynthetic Antibody Binding Site protein technology. Under the

agreements, each company is free, under a non-exclusive, worldwide license, to develop and sell products utilizing the technology claimed by both companies' antibody engineering patents, without paying royalties to the other. Each company is also free to market products in collaboration with third parties, but the third parties will be required to pay royalties on products covered by the patents which will be shared by the companies, except in certain instances. We have the exclusive right to market licenses under both companies' patents other than to Creative's collaborators. In addition, the agreements provide for the release and discharge by each company of the other from any and all claims based on past infringement of the technology which is the subject of the agreements. The agreement also provides for any future disputes between the companies regarding new patents in the area of engineered monoclonal antibodies to be resolved pursuant to agreed-upon procedures.

The degree of patent protection to be afforded to biotechnological inventions is uncertain and our products are subject to this uncertainty. We are aware of certain issued patents and patent applications, and there may be other patents and applications, containing subject matter which we or our licensees or collaborators may require in order to research, develop or commercialize at least some of our products. We cannot assure you that we will be able to obtain a license to such subject matter on acceptable terms, or at all.

In addition to the litigation described above, we expect that there may be significant litigation in the industry regarding patents and other proprietary rights and, to the extent we become involved in such litigation, it could

consume a substantial amount of our resources. An adverse decision in any such litigation could subject us to significant liabilities. In addition, we rely heavily on our proprietary technologies for which pending patent applications have been filed and on unpatented know-how developed by us. Insofar as we rely on trade secrets and unpatented know-how to maintain our competitive technological position, we cannot assure you that others may not independently develop the same or similar technologies. Although we have taken steps to protect our trade secrets and unpatented know-how, third parties nonetheless may gain access to such information.

#### GOVERNMENT REGULATION

The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements on the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval and promotion of our products. All of our products will require regulatory approval before commercialization. In particular, therapeutic products for human use are subject to rigorous pre-clinical and clinical testing and other requirements of the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, implemented by the FDA, as well as similar statutory and regulatory requirements of foreign countries. Obtaining these marketing approvals and subsequently complying with ongoing statutory and regulatory requirements is costly and time consuming. Any failure by us or our collaborators, licensors or licensees to obtain, or any delay in obtaining, regulatory approval or in complying with other requirements, could adversely affect the commercialization of products that we are then developing and our ability to receive product or royalty revenues.

The steps required before a new drug or biological product may be distributed commercially in the United States generally include:

- conducting appropriate pre-clinical laboratory evaluations of the product's chemistry, formulation and stability, and animal studies to assess the potential safety and efficacy of the product,

- submitting the results of these evaluations and tests to the FDA, along with manufacturing information and analytical data, in an Investigational New Drug Application, or IND,

- making the IND effective after the resolution of any safety or regulatory concerns of FDA,

- obtaining approval of Institutional Review Boards, or IRBs, to introduce the drug or biological product into humans in clinical studies,

44

- conducting adequate and well-controlled human clinical trials that establish the safety and efficacy of the drug or biological product candidate for the intended use, typically in the following three sequential, or slightly overlapping stages:

- Phase I. The drug or biologic is initially introduced into healthy human subjects or patients and tested for safety, dose tolerance, absorption, metabolism, distribution and excretion,

- Phase II. The drug or biologic is studied in patients to identify possible adverse effects and safety risks, to determine dose tolerance and the optimal dosage, and to collect initial efficacy data,

- Phase III. The drug or biologic is studied in an expanded patient population at multiple clinical study sites, to confirm efficacy and safety at the optimized dose, by measuring a primary endpoint established at the outset of the study,

- submitting the results of preliminary research, pre-clinical studies, and clinical studies as well as chemistry, manufacturing and control information on the drug or biological product to the FDA in a New Drug

Application, or NDA, for a drug product, or BLA for a biological product, and

obtaining FDA approval of the NDA or BLA prior to any commercial sale or shipment of the drug or biological product.

An NDA or BLA must contain, among other things, data derived from nonclinical laboratory and clinical studies which demonstrate that the product meets prescribed standards of safety, purity and potency, and a full description of manufacturing methods. The biological product may not be marketed in the U.S. until a biological license is issued.

The approval process can take a number of years and often requires substantial financial resources. The results of pre-clinical studies and initial clinical trials are not necessarily predictive of the results from large-scale clinical trials, and clinical trials may be subject to additional costs, delays or modifications due to a number of factors, including the difficulty in obtaining enough patients, clinical investigators, drug supply, or financial support. The FDA has issued regulations intended to accelerate the approval process for the development, evaluation and marketing of new therapeutic products intended to treat life-threatening or severely debilitating diseases, especially where no alternative therapies exist. If applicable, this procedure may shorten the traditional product development process in the United States. Similarly, products that represent a substantial improvement over existing therapies may be eligible for priority review with a target lapsed approval time of six months. Nonetheless, approval may be denied or delayed by the FDA or additional trials may be required. The FDA also may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the agency has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs. Upon approval, a drug product may be marketed only in those dosage forms and for those indications approved in the NDA or BLA, although information about off-label indications may be distributed in certain circumstances.

In addition to obtaining FDA approval for each indication to be treated with each product, each domestic drug product manufacturing establishment must register with the FDA, list its drug products with the FDA, comply with Current Good Manufacturing Practices and permit and pass inspections by the FDA. Moreover, the submission of applications for approval may require additional time to complete manufacturing stability studies. Foreign establishments manufacturing drug products for distribution in the United States also must list their products with the FDA and comply with Current Good Manufacturing Practices. They also are subject to periodic inspection by the FDA or by local authorities under agreement with the FDA.

Any products manufactured or distributed by us pursuant to FDA approvals are subject to extensive continuing regulation by the FDA, including record-keeping requirements and a requirement to report adverse experiences with the drug. In addition to continued compliance with standard regulatory requirements, the FDA also may require post-marketing testing and surveillance to monitor the safety and efficacy of the marketed product. Adverse experiences with the product must be reported to the FDA. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product are discovered following approval.

45

The Federal Food, Drug, and Cosmetic Act also mandates that drug products be manufactured consistent with Current Good Manufacturing Practices. In complying with the FDA's regulations on Current Good Manufacturing Practices, manufacturers must continue to spend time, money and effort in production, record-keeping, quality control, and auditing to ensure that the marketed product meets applicable specifications and other requirements. The FDA periodically inspects drug product manufacturing facilities to ensure compliance with Current Good Manufacturing Practices. Failure to comply subjects the manufacturer to possible FDA action, such as:

warning letters,

suspension of manufacturing,

seizure of the product,  
voluntary recall of a product,  
injunctive action, or  
possible civil or criminal penalties.

To the extent we rely on third parties to manufacture our compounds and products, those third parties will be required to comply with Current Good Manufacturing Practices.

Even after FDA approval has been obtained, and often as a condition to expedited approval, further studies, including post-marketing studies, may be required. Results of post-marketing studies may limit or expand the further marketing of the products. If we propose any modifications to the product, including changes in indication, manufacturing process, manufacturing facility or labeling, an NDA or BLA supplement may be required to be submitted to the FDA.

Products manufactured in the United States for distribution abroad will be subject to FDA regulations regarding export, as well as to the requirements of the country to which they are shipped. These latter requirements are likely to cover the conduct of clinical trials, the submission of marketing applications, and all aspects of product manufacture and marketing. Such requirements can vary significantly from country to country. As part of our strategic relationships our collaborators may be responsible for the foreign regulatory approval process of our products, although we may be legally liable for noncompliance.

We are also subject to various federal, state and local laws, rules, regulations and policies relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research work. Although we believe that our safety procedures for handling and disposing of such materials comply with current federal, state and local laws, rules, regulations and policies, the risk of accidental injury or contamination from these materials cannot be entirely eliminated.

We cannot predict the extent of government regulation which might result from future legislation or administrative action cannot be accurately predicted. In this regard, although the Food and Drug Administration Modernization Act of 1997 modified and created requirements and standards under the Federal Food, Drug, and Cosmetic Act with the intent of facilitating product development and marketing, the FDA is still in the process of developing regulations implementing the Food and Drug Administration Modernization Act of 1997. Consequently, the actual effect of these developments on our business is uncertain and unpredictable.

Moreover, we anticipate that Congress, state legislatures and the private sector will continue to review and assess controls on health care spending. Any such proposed or actual changes could cause us or our collaborators to limit or eliminate spending on development projects and may otherwise impact us. We cannot predict the likelihood, nature or extent of adverse governmental regulation that might result from future legislative or administrative action, either in the United States or abroad. Additionally, in both domestic and foreign markets, sales of our proposed products will depend, in part, upon the availability of reimbursement from third-party payors, such as government health administration authorities, managed care providers, private health insurers and other organizations. Significant uncertainty often exists as to the reimbursement status of newly approved health care products. In addition, third-party payors are increasingly challenging the price and cost-effectiveness of

medical products and services. There can be no assurance that our proposed products will be considered cost-effective or that adequate third-party reimbursement will be available to enable us to maintain price levels sufficient

to realize an appropriate return on our investment in product research and development.

ADAGEN was approved by the FDA in March 1990. ONCASPAR was approved for marketing in the U.S. and Germany in 1994 and in Canada in December 1997 for patients with acute lymphoblastic leukemia who are hypersensitive to native forms of L-asparaginase, and in Russia in April 1993 for therapeutic use in a broad range of cancers. Except for these approvals, none of our other products has been approved for sale and use in humans in the U.S. or elsewhere.

With respect to patented products, delays imposed by the government approval process may materially reduce the period during which we will have the exclusive right to exploit them.

#### COMPETITION

Competition in the biopharmaceutical industry is intense and based significantly on scientific and technological factors. These factors include the availability of patent and other protection of technology and products, the ability to commercialize technological developments and the ability to obtain governmental approval for testing, manufacturing and marketing. We compete with specialized biopharmaceutical firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations. These companies, as well as academic institutions, governmental agencies and private research organizations, also compete with us in recruiting and retaining highly qualified scientific personnel and consultants.

We are aware that other companies are conducting research on chemically modified therapeutic proteins and that certain companies are modifying pharmaceutical products, including proteins, by attaching PEG. Other than our ONCASPAR and ADAGEN products, we are not aware of any PEG-modified therapeutic proteins that are currently available commercially for therapeutic use. Nevertheless, other drugs or treatments that are currently available or that may be developed in the future, and which treat the same diseases as those that our products are designed to treat, may compete with our products.

Prior to the development of ADAGEN, the only treatment available to patients afflicted with ADA-deficient SCID was a bone marrow transplant. Completing a successful transplant depends upon finding a matched donor, the probability of which is low. More recently, researchers at the National Institutes of Health, or NIH, have been attempting to treat SCID patients with gene therapy, which if successfully developed, would compete with, and could eventually replace ADAGEN as a treatment. The patients in these trials are also receiving ADAGEN treatment in addition to the gene therapy. The theory behind gene therapy is that cultured T-lymphocytes that are genetically engineered and injected back into the patient will express adenosine deaminase, the deficient enzyme in people afflicted with ADA-deficient SCID, permanently and at normal levels. To date, patients in gene therapy clinical trials have not been able to stop ADAGEN treatment and, therefore, the trials have been inconclusive.

Current standard treatment of patients with acute lymphoblastic leukemia includes administering unmodified L-asparaginase along with the drugs vincristine, prednisone and daunomycin. Studies have shown that long-term treatment with L-asparaginase increases the disease-free survival in high risk patients. ONCASPAR, our PEG-modified L-asparaginase product, is used to treat patients with acute lymphoblastic leukemia who are hypersensitive to unmodified forms of L-asparaginase. Currently, there is one unmodified form of L-asparaginase (Elspar) available in the United States and several available in Europe. We believe that ONCASPAR has two advantages over these unmodified forms of L-asparaginase: increased circulating blood life and generally reduced immunogenicity.

The current market for INTRON A, Schering-Plough's interferon alpha-2b product, is highly competitive, with Hoffmann-La Roche, Amgen, Inc. and several other companies selling similar products. We believe that PEG-Intron may have several potential advantages over the interferon products currently on the market, including:

- once per week dosing versus the current three times per week dosing,
- an improved side effect profile, and
- increased efficacy.

It has also been reported that Hoffmann-La Roche's Pegasys product also has a potentially longer lasting version of its interferon product, Roferon-A, in Phase III clinical trials. We believe that this product infringes a patent which covers one of our second generation PEG technologies, called Branched PEG. We have initiated patent infringement litigation against the supplier of the PEG technology used in Hoffmann-La Roche's Pegasys, Shearwater Polymers Inc., and are seeking to block this product from entering the market.

There are several technologies which compete with our SCA protein technology, including chimeric antibodies, humanized antibodies, human monoclonal antibodies, recombinant antibody Fab fragments, low molecular weight peptides and mimetics. These competing technologies can be categorized into two areas:

those modifying monoclonal antibodies to minimize immunological reaction to a foreign protein, which is the strategy employed with chimerics, humanized antibodies and human monoclonal antibodies, and

those creating smaller portions of monoclonal antibodies, which are more specific to the target and have fewer side effects, as is the case with Fab fragments and low molecular weight peptides.

We believe that the smaller size of our SCA proteins should permit better penetration into the tumor, result in rapid clearance from the blood and cause a significant decrease in the immunogenic problems associated with conventional monoclonal antibodies. A number of organizations have active programs in SCA proteins. We believe that our patent position on SCA proteins will likely require companies that have not licensed our SCA protein patents to obtain licenses from us in order to commercialize their products, but there can be no assurance that this will prove to be the case.

#### EMPLOYEES

As of December 31, 1999, we employed 82 persons, including 15 persons with Ph.D. degrees. At that date, 37 employees were engaged in research and development activities, 25 were engaged in manufacturing, and 20 were engaged in administration and management. None of our employees is covered by a collective bargaining agreement. All of our employees are covered by confidentiality agreements. We consider our relations with our employees to be good.

#### FACILITIES

We lease approximately 56,000 square feet of research and development and office space in Piscataway, New Jersey. This lease will terminate in June 2007. Our manufacturing facilities are located in South Plainfield, New Jersey and occupy approximately 24,000 square feet. This lease will terminate in March 2007. We believe that our facilities are well maintained and adequate for our present and future anticipated needs.

#### LEGAL PROCEEDINGS

We are being sued, in the United States District Court for the District of New Jersey, by LBC Capital Resources, Inc., a former financial advisor. LBC is asserting that under the May 2, 1995 letter agreement between us and LBC, LBC was entitled to a commission in connection with our January and March 1996 private placements, comprised of \$500,000 and warrants to purchase approximately 1,000,000 shares of our common stock at an exercise price of \$2.50 per share. LBC has claimed \$3.0 million in compensatory damages, plus punitive damages, counsel fees and costs for the alleged breach of the letter agreement. We have entered into an agreement with LBC, known as the Stipulation of Damages, which provides that if we are found liable to LBC in this suit, the damages for these claims would be limited to \$2.75 million in cash. LBC has also asserted that it is entitled to an additional fee of \$175,000 and warrants to purchase 250,000 shares of our common stock to the extent any of the warrants issued to investors in the private placements are exercised. We believe that no such compensation is due to LBC under this letter agreement and deny any liability under the letter agreement. We intend to defend this lawsuit vigorously and believe the ultimate resolution of this matter will not have a material adverse effect on our

financial position. However, if we were required to issue warrants to LBC we would be required to incur a non-cash expense for each warrant issued equal to the difference between the exercise price of the warrants (\$2.50) and the then current market price of our common stock.

In December 1998, we filed a patent infringement suit against Shearwater Polymers Inc., a company that has reportedly developed a Branched PEG, or U-PEG, used in Hoffmann-La Roche's Pegasys product, a PEG-modified version of its alpha-interferon product called Roferon-A. We believe that Pegasys utilizes a type of Branched PEG for which we have been granted a patent in the U.S. and have similar patents pending in Europe, Japan and Canada. Shearwater has filed a counter-claim in this litigation alleging that our Branched PEG patent is invalid and unenforceable.

In January 2000, Hoffmann-La Roche filed lawsuits in both the U.S. and France against Schering-Plough alleging that PEG-Intron infringes certain patents held by Hoffmann-La Roche. The validity and scope of Hoffmann-La Roche's patents in this segment of the industry could be judicially determined during these proceedings. If Schering-Plough does not prevail in this litigation, Hoffmann-La Roche may completely block Schering-Plough from commercializing PEG-Intron. Among other things, the outcome will likely depend not only upon whether the patents are determined valid and infringed, but also upon the reasoning behind such determinations. We are presently unable to predict either the effect or degree of effect this litigation will have on our business and financial condition.

We have two research and license agreements with the Green Cross Corporation regarding rHSA. We were recently involved in an arbitration to resolve the amount of royalties to which we are entitled under these agreements. In April 1998, Yoshitomi Pharmaceutical Industries, Ltd., the successor to Green Cross' business, filed documents in such arbitration seeking a declaratory judgment that under its agreement with us no royalties are payable. In February 2000, the arbitrators awarded us a 1% royalty on Yoshitomi sales of rHSA in Japan, South East Asia, India, China, Australia, New Zealand and North and South America for a period of 15 years after the first commercial sale of Yoshitomi's rHSA following market approval of that product in Japan or the United States.

MANAGEMENT

DIRECTORS, EXECUTIVE OFFICERS AND OTHER KEY EMPLOYEES

Our directors, executive officers and other key employees, including their ages, are as follows as of February 15, 2000:

NAME	AGE	POSITION
----	---	-----
Peter G. Tombros(1).....	57	President, Chief Executive Officer and Director
Kenneth J. Zuerblis.....	40	Vice President, Finance and Chief Financial Officer
John A. Caruso.....	55	Vice President, Administration, General Counsel and Secretary
Randy H. Thurman(1) (2).....	50	Chairman of the Board
David S. Barlow(2) (4).....	43	Director
Rolf A. Classon(2) (3).....	54	Director
Dr. Rosina B. Dixon(2) (4) (5)....	57	Director
Dr. David W. Golde(4) (5).....	59	Director
Robert LeBuhn(1) (3) (5).....	67	Director
A. M. 'Don' MacKinnon(3).....	75	Director
Dr. Josef Bossart.....	48	Vice President, Business Development and President,

		SCA Ventures
Joseph Fischer.....	51	Vice President, Manufacturing
Dr. Jeffrey McGuire.....	49	Vice President, Research and Development and Chief Scientific Officer

-----

- (1) Member of the Executive Committee of our Board of Directors.
- (2) Member of the Compensation Committee of our Board of Directors.
- (3) Member of the Finance and Audit Committee of our Board of Directors.
- (4) Member of the Scientific Advisory Committee of our Board of Directors.
- (5) Member of the Corporate Governance Committee of our Board of Directors.

Peter G. Tombros, 57, has served as our President and Chief Executive Officer and one of our Directors since April 1994. Prior to joining Enzon, Mr. Tombros spent 25 years with Pfizer, Inc., a research-based, global healthcare company headquartered in New York City. From 1986 to March 1994, he served as a Vice President of Pfizer, Inc. in the following areas: Executive Vice President of Pfizer Pharmaceuticals, a division of Pfizer, Inc., corporate strategic planning and investor relations. From 1980 to 1986, Mr. Tombros served as Senior Vice President of Pfizer Pharmaceuticals and general manager for the Roerig division of Pfizer, Inc. Mr. Tombros currently serves on the Board of Trustees of Cancer Care and the National Cancer Care Foundation and Dominican College. He has been a Director of the American Foundation of Pharmaceutical Education since 1980 and served as Chairman for three of those years. Mr. Tombros serves on the Board of Directors of NPS Pharmaceuticals, Inc. and Alpharma, Inc.

Kenneth J. Zuerblis, 40, has served as Chief Financial Officer since January 1996 and as Vice President, Finance since April 1994. From July 1991 to April 1994, Mr. Zuerblis served as our Controller. From January 1982 to July 1991, Mr. Zuerblis was employed by KPMG LLP in various positions, the last being senior manager. He became a certified public accountant in 1985.

John A. Caruso, 55, has served as Vice President, Administration since May 1998, our General Counsel since July 1994 and as our Secretary since July 1989. From January 1991 to May 1998, Mr. Caruso served as Vice President of Business Development. From January 1991 to July 1994, Mr. Caruso served as Vice President, Legal Affairs of Enzon. From the time he joined us in September 1987 through December 1990, Mr. Caruso served as our Corporate Counsel. From 1979 through 1987, Mr. Caruso was employed at Baxter Travenol Laboratories in Deerfield, Illinois as corporate counsel.

Randy H. Thurman, 50, has served as Chairman of the Board since April 1996 and as one of our Directors since April 1993. Mr. Thurman is Chairman and Chief Executive Officer of Strategic Reserves, LLC, a company he founded in 1996. Mr. Thurman is the founder of Health Care Strategies

2000, a global consulting firm, and has been Chairman of the Board since 1995. During 1996, Mr. Thurman also served as a principal of Spencer Stuart Inc. From 1993 to 1995, Mr. Thurman served as Chairman and Chief Executive Officer of Corning Life Sciences. From 1985 to 1993, Mr. Thurman served as Corporate Executive Vice President and a Director of Rhone-Poulenc Rorer, Inc. and President of Rhone-Poulenc Rorer Pharmaceuticals, Inc. He is also Chairman of the Board of UTC International, a wholly owned subsidiary of Donaldson Lufkin Jenrette, and also serves on the Board of Directors of Closure Medical, Inc. and Curagen Corporation.

David S. Barlow, 43, has served as one of our Directors since June 1999. From 1995 to September 1999, Mr. Barlow was President of Pharmaceuticals at Sepracor, Inc. From 1993 to 1995, Mr. Barlow served as the General Manager of Pharmaceuticals at Sepracor, Inc. Prior to 1993, Mr. Barlow held several senior level positions at Rhone-Poulenc Rorer, Inc., including Vice President, World Wide Marketing and Business Development at Armor Pharmaceutical Company, a subsidiary of Rhone-Poulenc Rorer, Inc.



Rolf A. Classon, 54, has served as one of our Directors since January 1997. Mr. Classon is currently an Executive Vice President of Bayer Corporation and President of Bayer Diagnostics. From 1991 to 1995, Mr. Classon was an Executive Vice President in charge of Bayer Diagnostics' Worldwide Marketing, Sales and Service operations. From 1990 to 1991, Mr. Classon was President and Chief Operating Officer of Pharmacia Biosystems A.B. Prior to 1991, Mr. Classon served as President of Pharmacia Development Company Inc. and Pharmacia A.B.'s Hospital Products Division.

Dr. Rosina B. Dixon, 57, has served as one of our Directors since August 1994. Dr. Dixon has been a consultant to the pharmaceutical industry since 1987. Prior to such time she held senior positions at Ciba-Geigy Pharmaceuticals, a division of Ciba-Geigy Corporation, and Schering-Plough Corporation. She received her M.D. from Columbia University, College of Physicians and Surgeons and is certified by the National Board of Medical Examiners and the American Board of Internal Medicine. She is a member of the American College of Clinical Pharmacology, American Society for Clinical Pharmacology and Therapeutics and the National Association of Corporate Directors and currently serves as a Director of Church & Dwight Co., Inc. and Cambrex Corporation.

Dr. David W. Golde, 59, has served as one of our Directors since March 1998. Dr. Golde has been the Physician-In-Chief at Memorial Sloan-Kettering Cancer Center since 1996. From 1991 to 1996, Dr. Golde served as Head of the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center. Prior to 1991, Dr. Golde was a professor of medicine and Chief of the Division of Hematology and Oncology at UCLA, Director of the UCLA AIDS Center and Director of the UCLA Clinical Research Center. Dr. Golde serves as a director of Cypress Biosciences.

Robert LeBuhn, 67, has served as one of our Directors since August 1994. Mr. LeBuhn was chairman of Investor International (U.S.), Inc., a subsidiary of Investor A.B., part of Sweden's Wallenberg Group from June 1992 until his retirement in September 1994, and was our President from August 1984 through June 1992. Mr. LeBuhn is a Director of US Airways Group, Inc., Acceptance Insurance Companies, Inc. and Cambrex Corporation. He is President and a trustee of the Geraldine R. Dodge Foundation.

A.M. 'Don' MacKinnon, 75, has served as one of our Directors since 1990. Mr. MacKinnon was President and Chief Operating Officer of Ciba-Geigy Corporation from 1980 until his retirement in 1986. He was a member of the Board of Directors of Ciba-Geigy Corporation from 1970 until he reached the mandatory retirement age in December 1994. Over the last nine years, Mr. MacKinnon has served on the Board of Directors of several biopharmaceutical companies.

Our Board is divided into three classes for purposes of election. One class is elected at each annual meeting of stockholders to serve for a three-year term.

#### KEY EMPLOYEES

Dr. Josef Bossart, 48, has served as our Vice President of Business Development and the President of SCA Ventures, a subsidiary of Enzon that focuses on commercializing our extensive SCA Protein technology, since March 1999. From March 1997 to March 1999, Dr. Bossart was Vice President and Chief Business Officer of GeneMedicine, Inc. Prior to March 1997, Dr. Bossart also spent more than 14

years with Rhone-Poulenc Rorer, Inc. in various business and marketing positions. Dr. Bossart holds a Ph.D. in medicinal chemistry from the Ohio State University, College of Pharmacy and a B.Sc. from Carleton University.

Joseph Fischer, 51, has served as our Vice President Manufacturing, since April 1996. From June 1993 to April 1996, Mr. Fischer served as the Vice President of Operation at Osteotech, Inc. a medical device company. Mr. Fischer has 28 years of experience in operations with companies such as A.H. Robins and American Home Products. Mr. Fischer is a member of the Parental Drug Association, the International Society for Pharmaceutical Engineering and the

Institute of Packaging Professionals. He holds a B.S. in management from Rutgers University.

Dr. Jeffrey McGuire, 49, has served as our Vice President, Research and Development and Chief Scientific Officer since 1997. From 1995 until 1997, Dr. McGuire served as our Director, Business Development. From 1991 to 1997, Dr. McGuire was responsible for our SCA-Binding protein licensing program and intellectual property portfolio. From 1980 until 1991, Dr. McGuire was employed by the Genex Corporation, where he held various research, business development and management positions. Dr. McGuire holds a B.S. in Life Sciences from the Massachusetts Institute of Technology and a Ph.D. in Life Sciences, with a concentration in molecular biology, from the University of Delaware. He also conducted post-doctoral research at Harvard Medical School.

PRINCIPAL STOCKHOLDERS

The following table sets forth information regarding the beneficial ownership of our common stock as of February 15, 2000, and as adjusted to reflect the sale of common stock in this offering by (1) each stockholder who is known by us to beneficially own more than 5% of our common stock, (2) each director and executive officer, and (3) all directors and executive officers as a group. All shares listed are common stock. Except as discussed below, none of these shares are subject to rights to acquire beneficial ownership, as specified in Rule 13d-13(d)(1) under the Securities Exchange Act of 1934, as amended, and the beneficial owner has sole voting and investment power, subject to community property laws where applicable.

NAME AND ADDRESS OF BENEFICIAL OWNER(1) -----	SHARES BENEFICIALLY OWNED PRIOR TO OFFERING -----	PERCENT OF SHARES BENEFICIALLY OWNED -----	
		BEFORE OFFERING (2)	AFTER OFFERING
Janus Capital Corporation(3) ..... 100 Fillmore Street Denver, Colorado 80206	4,394,985	11.5%	11.0%
Peter G. Tombros(4).....	1,138,300	2.9%	2.8%
Kenneth J. Zuerblis(5).....	213,200	*	*
John A. Caruso(6).....	222,692	*	*
Randy H. Thurman(7).....	195,977	*	*
Dr. Rosina B. Dixon(8).....	148,556	*	*
Dr. David W. Golde(9).....	94,368	*	*
David S. Barlow(10).....	10,190	*	*
Rolf A. Classon(11).....	76,398	*	*
Robert LeBuhn(12).....	138,049	*	*
A.M. 'Don' MacKinnon(13).....	118,700	*	*
All directors and executive officers as a group (10 persons).....	2,356,430	5.9%	5.6%

-----

\* Less than 1% of the outstanding stock

- (1) The address of all current executive officers and directors listed above is in the care of Enzon.
- (2) Gives effect to 38,049,632 shares of common stock and 27,000 shares of Series A preferred stock which were issued and outstanding as of February 15, 2000. Generally, the Series A preferred stock and common stock will vote as one class of stock. Each share of common stock and each share of Series A preferred stock is entitled to one vote. The percentage of voting stock outstanding for each stockholder is calculated by dividing (i) the number of shares deemed to be beneficially held by such stockholder as of February 15, 2000 by (ii) the sum of (A) the number of

shares of common stock outstanding as of February 15, 2000 plus (B) the number of shares of Series A preferred stock outstanding as of February 15, 2000 plus (C) the number of shares issuable upon exercise of options or warrants held by such stockholder which were exercisable as of February 15, 2000 or which will become exercisable within 60 days after February 15, 2000.

- (3) The information concerning the stock ownership of the Janus Capital Corporation is based solely on a Schedule 13G/A filed by the Janus Capital Corporation with the SEC for the period ended December 31, 1999.
- (4) Includes 1,108,000 shares subject to options which were exercisable as of February 15, 2000 or which will become exercisable within 60 days after February 15, 2000.
- (5) Includes 210,000 shares subject to options which were exercisable as of February 15, 2000 or which will become exercisable within 60 days after February 15, 2000 and 600 shares owned by Mr. Zuerblis' IRA.
- (6) Consists of 220,392 shares subject to options which were exercisable as of February 15, 2000 or which will become exercisable within 60 days after February 15, 2000.
- (7) Consists of 180,000 shares subject to options which were exercisable as of February 15, 2000 or which will become exercisable within 60 days after February 15, 2000.

(footnotes continued on next page)

(footnotes continued from previous page)

- (8) Includes 121,664 shares subject to options which were exercisable as of December 31, 1999 or which will become exercisable within 60 days after February 15, 2000, 500 shares held by Dr. Dixon's husband and 100 shares held by Dr. Dixon's son. Dr. Dixon disclaims beneficial ownership as to shares held by her husband and son.
- (9) Includes 53,320 shares subject to options which were exercisable as of February 15, 2000, or which will become exercisable within 60 days after February 15, 2000, 32,500 shares held by a revocable trust for Dr. Golde, 2,600 shares held by a separate trust for Dr. Golde's daughter and 1,000 shares beneficially owned by Dr. Golde's wife.
- (10) Includes 9,996 shares subject to options which were exercisable as of February 15, 2000 or which will become exercisable within 60 days after February 15, 2000.
- (11) Includes 70,000 shares subject to option which were exercisable as of February 15, 2000 which will become exercisable within 60 days after February 15, 2000.
- (12) Includes 116,664 shares subject to options which were exercisable as of February 15, 2000 or which will become exercisable within 60 days after February 15, 2000.
- (13) Includes 20,000 shares subject to options which were exercisable as of February 15, 2000 or which will become exercisable within sixty days after February 15, 2000, 54,350 shares held by trusts of which he is a trustee, 24,750 shares held by trusts of which his wife is a trustee, and 19,600 shares held by National Financial Services Corporation pending transfer to a charitable trust. Mr. MacKinnon disclaims beneficial ownership as to 41,550 of the above-referenced shares.

## DESCRIPTION OF CAPITAL STOCK

Our authorized capital stock consists of 60,000,000 shares of common stock, par value \$.01 per share, and 3,000,000 shares of preferred stock, par value \$.01 per share. Unless otherwise designated by our board of directors, all issued shares shall be deemed common stock with equal rights and preferences.

### COMMON STOCK

As of February 15, 2000, there were 38,049,632 shares of our common stock outstanding. Based upon the number of shares outstanding as of that date and giving effect to the issuance of the 2,000,000 shares of common stock offered by us in this offering, there will be 40,049,632 shares of common stock outstanding upon the closing of this offering. In addition, as of February 15, 2000, we had outstanding stock options and warrants to purchase an aggregate of 3,662,867 shares of common stock.

Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Directors are elected by a plurality of the votes of the shares present in person or represented by proxy at the annual meeting and entitled to vote in such election. Holders of our common stock are entitled to receive ratably the dividends, if any, as may be declared by the board of directors out of legally available funds. These rights are subject to the prior rights of any preferred stock then outstanding.

Upon our liquidation, dissolution or winding up, the holders of common stock are entitled to receive ratably our net assets available after the payment of all debts and other liabilities, and after the satisfaction of the rights of any outstanding preferred stock. Holders of the common stock have no preemptive, subscription, redemption or conversion rights, nor are they entitled to the benefit of any sinking fund. The outstanding shares of common stock are, and the shares offered by us in this offering will be, when issued and paid for, validly issued, fully paid and non-assessable. The rights, powers, preferences and privileges of holders of common stock are subordinate to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock whether outstanding or issued in the future.

### PREFERRED STOCK

Our board of directors has the authority to issue up to 3,000,000 shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative rights thereof without any further vote of shareholders. The voting powers of holders of common stock could be diluted by the issuance of this preferred stock. The issuance of this preferred stock could also have the effect of delaying, deferring or preventing a change in our control. The issuance of this preferred stock could decrease the amount of earnings and assets available for distribution to holders of our common stock or adversely affect the rights and powers, including voting rights, of the holders of our common stock.

### SERIES A PREFERRED STOCK

As of February 15, 2000, there were 27,000 shares of our Series A preferred stock outstanding. Shares of our Series A preferred stock are convertible into common stock at a conversion price of \$11.00 per share. The value of the shares of Series A preferred stock for conversion purposes is \$25.00 per share. Holders of the Series A preferred stock are entitled to an annual dividend of \$2.00 per share, payable semiannually, but only when and if declared by our board of directors, out of funds legally available. Dividends on the Series A preferred stock are cumulative and accrue and accumulate but will not be paid, except in liquidation or upon conversion, until such time as the board of directors deems it appropriate in light of our then current financial condition. No dividends are to be paid or set apart for payment on our common stock, nor are any shares of common stock to be redeemed, retired or otherwise acquired for valuable consideration unless we have paid in full or made appropriate provision for the payment in full of all dividends which have then accumulated on the Series A preferred stock. Holders of the Series A preferred stock are entitled to one vote per share on matters to be voted upon by our stockholders and except as required by Delaware law, our Series A preferred stock votes together with our common stock as a single class on all matters which come to a vote of our stockholders. As of February 15, 2000, undeclared accrued dividends in arrears were \$521,000 or \$19.30

per share of Series A preferred stock. All shares of common stock are junior in rank to the Series A preferred stock with respect to the preferences as to dividends, distributions and payments upon our liquidation, dissolution or winding up.

#### COMMON STOCK WARRANTS

In July 1998, we issued warrants to purchase 200,000 shares of our common stock at an exercise price of \$6.50 per share, the closing price of the common stock on the date of grant. The warrants were issued as consideration for consulting services to be rendered through February 2002 by certain persons affiliated with Evolution Capital, Inc. The warrants expire on August 18, 2004. In connection with the March 1996 private placement of our common stock, we issued five-year warrants to purchase 206,227 shares of our common stock at an exercise price of \$5.63 per share. In January 1996, we paid a finders fee in cash and issued five-year warrants to purchase 51,504 shares of our common stock at an exercise price of \$4.11 per share in connection with the 1996 private placements. These warrants were outstanding as of February 15, 2000 and have been adjusted for standard anti-dilution provisions which are still in place, including adjustments for stock splits, reverse stock splits and stock dividends, adjustments for capital reorganizations, and, with certain exceptions, adjustments for the issuance of common stock or the issuance of options, warrants, or convertible securities, with an exercise or conversion price below the market price of the common stock as determined in accordance with the warrants.

#### REGISTRATION RIGHTS

There are demand and/or piggyback registration rights on 457,731 shares of our common stock underlying warrants outstanding as of February 15, 2000. We have granted Schering-Plough piggyback registration rights with respect to 847,489 shares of our common stock. In addition, two persons affiliated with Evolution Capital have piggyback and demand registration rights with respect to the shares underlying their warrants to purchase 200,000 shares of our common stock. The demand rights give these warrant holders a one-time right to require us to register, upon their request, that number of shares underlying such warrants. We granted the Carson Group, Inc. and two of its principals piggyback registration rights with respect to the shares underlying their warrants to purchase an aggregate of 51,504 shares of our common stock as consideration for finder's services that were provided to us. Transferees of Clearwater Fund IV were also granted piggyback registration rights under a registration rights agreement with us with respect to the 206,227 shares of common stock issuable under warrants they hold, 200,000 of which shares are currently covered by an effective registration statement. Absent any contractual limitations, the holders of these rights could cause a significant number of shares of our common stock to be registered and sold in the public market. Such sales, or the perception that these sales could occur, may have an adverse effect on the market price for our common stock and could impair our ability to raise capital through an offering of equity securities. We have obtained waivers of all such piggyback registration rights applicable to this offering.

We originally registered the resale of approximately 3,983,000 shares of our common stock owned by stockholders who purchased such shares in a private placement of shares of our common stock that closed in July 1998. We are required to maintain the effectiveness of this registration statement until the earlier of the date that all of the shares are sold or July 2000.

We originally registered the resale of approximately 4,122,317 shares of our common stock owned by stockholders who purchased such shares in a private placement of shares of our common stock that closed in January and March 1996. We are required to maintain the effectiveness of this registration statement until the earlier of the date that all of the shares are sold or March 15, 2004.

#### INDEMNIFICATION AND LIMITATION OF LIABILITY

Our charter documents provide that our directors and officers shall be indemnified by us to the fullest extent permitted by Delaware law, as it now exists or may in the future be amended, against all expenses and liabilities

reasonably incurred in connection with their service for or on behalf of us. In addition, our certificate of incorporation provides that our directors will not be personally liable for monetary damages to us for breaches of their fiduciary duty as directors, unless they violated their duty

56

of loyalty to either us or our stockholders, acted in bad faith, knowingly or intentionally violated the law, authorized illegal dividends or redemptions or derived an improper personal benefit from their action as directors. We have insurance which insures our directors and officers against certain losses and which insures us against our obligations to indemnify our directors and officers. Our officers and directors have executed indemnity agreements with us which supplement the protections provided by our certificate of incorporation and by-laws.

These agreements require us to pay for any damages, judgments, settlements, costs and expenses for the defense of legal actions, claims, proceedings and appeals due to any actual or alleged breach of duty, neglect, error, misstatement, misleading statement, omission or other act done, suffered or wrongfully attempted by the officer or director. If we do not pay such costs and expenses within 90 days after we receive a written claim, such officers or directors may bring a suit against us to recover the unpaid amount of the claim. If such officer or director is successful, we will be required to pay for the expenses incurred relating to the claim.

#### PROVISIONS OF OUR CERTIFICATE OF INCORPORATION, BY-LAWS AND STATE LAW PROVISIONS WITH POTENTIAL ANTITAKEOVER EFFECTS

Certain provisions of our certificate of incorporation and by-laws, as well as Delaware law, may operate in a manner that could discourage or render more difficult a takeover of our company or the removal of our management or may limit the price certain investors may be willing to pay for shares of our common stock.

Our by-laws provide for the division of the board of directors into three classes as nearly equal in size as possible with staggered three-year terms. In addition, it provides that directors may be removed only for cause by the affirmative vote of the holders of a majority of our outstanding shares of capital stock entitled to vote. Any vacancy on the board of directors, however occurring, including a vacancy resulting from an enlargement of the Board, may only be filled by vote of a majority of the directors then in office. The likely effect of the classification of the board of directors and the limitations on the removal of directors and filling of vacancies is an increase in the time required for the stockholders to change the composition of the board of directors. For example, because only three directors may be replaced by stockholder vote at each annual meeting of stockholders, stockholders seeking to replace a majority of the members of the board of directors will need at least two annual meetings of stockholders to effect this change. In addition, our board of directors has the authority to issue up to 3,000,000 shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative rights thereof without any further vote of our stockholders. The voting powers of holders of our common stock could be diluted by the issuance of this preferred stock. The issuance of this preferred stock could also have the effect of delaying, deferring or preventing a change in control. In addition, the issuance of this preferred stock could decrease the amount of earnings and assets available for distribution to holders of our common stock or adversely affect the rights and powers, including voting rights, of the holders of our common stock.

The provisions of Section 203 of the General Corporation Law of Delaware will prohibit us from engaging in a 'business combination' with an 'interested stockholder' for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:

before such person became an interested stockholder, the board of directors of the corporation approved the transaction in which the interested stockholder became an interested stockholder or approved the business combination,

upon the closing of the transaction that resulted in the interested stockholder becoming such, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares held by directors who are also officers of the corporation and shares held by employee stock plans, or

following the transaction in which such person became an interested stockholder, the business combination is approved by the board of directors of the corporation and authorized at a meeting of stockholders by the affirmative vote of the holders of at least two-thirds of the outstanding voting stock of the corporation not owned by the interested stockholder.

57

A 'business combination' includes mergers, asset sales, consolidations and other transactions resulting in a financial benefit to the interested stockholder. An 'interested stockholder' is defined as a person who, at the time of determination whether a person is an interested stockholder:

beneficially owns 15% or more of our common stock, or

is an affiliate or associate of ours and beneficially owned 15% or more of our common stock at any time within three years of the date of determination.

A Delaware corporation may 'opt out' of Section 203 with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or by-laws resulting from an amendment approved by holders of at least a majority of the outstanding voting stock. Neither our certificate nor our by-laws contain any such exclusion.

#### TRANSFER AGENT AND REGISTRAR

The transfer agent and registrar for our common stock is Continental Stock Transfer & Trust Company. Its address is Two Broadway, 19th Floor, New York, New York 10004.

58

#### MATERIAL U.S. FEDERAL TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF COMMON STOCK

The following is a general discussion of the material U.S. federal income and estate tax consequences of the ownership and disposition of common stock by a beneficial owner that is a Non-U.S. Holder, or a person or entity that, for U.S. federal income tax purposes, is a non-resident alien individual, a foreign corporation, a foreign partnership or a foreign estate or trust.

This discussion is based on the Internal Revenue Code of 1986, as amended, or the Code, and administrative interpretations as of the date of this prospectus, all of which are subject to change, including changes with retroactive effect. This discussion does not address all aspects of U.S. federal income and estate taxation that may be relevant to Non-U.S. Holders in light of their particular circumstances and does not address any tax consequences arising under the laws of any state, local or foreign jurisdiction. Prospective holders should consult their tax advisors with respect to the particular tax consequences to them of owning and disposing of common stock, including the consequences under the laws of any state, local or foreign jurisdiction.

#### DIVIDENDS

Enzon does not currently intend to pay cash dividends on shares of common stock. In the event dividends are paid to a Non-U.S. Holder of common stock, they will generally be subject to withholding tax at a 30% rate or a reduced rate specified by an applicable income tax treaty. For purposes of determining

whether tax is to be withheld at a reduced rate under an income tax treaty, Enzon will presume that dividends paid on or before December 31, 2000 to an address in a foreign country are paid to a resident of that country unless it has knowledge that the presumption is not warranted.

In order to obtain a reduced rate of withholding for dividends paid after December 31, 2000, a Non-U.S. Holder will be required to provide an Internal Revenue Service, or IRS, Form W-8BEN certifying its entitlement to benefits under a treaty. In addition, in certain cases where dividends are paid to a Non-U.S. Holder that is a partnership or other pass-through entity, persons holding an interest in the entity may need to provide the required certification.

The withholding tax does not apply to dividends paid to a Non-U.S. Holder that provides a Form 4224 or, after December 31, 2000, a Form W-8ECI, certifying that the dividends are effectively connected with the Non-U.S. Holder's conduct of a trade or business within the United States. Instead, the effectively connected dividends will be subject to regular U.S. income tax as if the Non-U.S. Holder were a U.S. resident. A non-U.S. corporation receiving effectively connected dividends may also be subject to an additional 'branch profits tax' imposed at a rate of 30% (or a lower treaty rate) on an earnings amount that is net of the regular tax.

#### GAIN ON DISPOSITION OF COMMON STOCK

A Non-U.S. Holder generally will not be subject to U.S. federal income tax on gain realized on a sale or other disposition of common stock unless:

the gain is effectively connected with a trade or business of the Non-U.S. Holder in the United States,

in the case of certain Non-U.S. Holders who are non-resident alien individuals and hold the common stock as a capital asset, the individuals are present in the United States for 183 or more days in the taxable year of the disposition,

the Non-U.S. Holder is subject to tax under the provisions of the Code regarding the taxation of U.S. expatriates, or

Enzon is or has been a U.S. real property holding corporation at any time within the five-year period preceding the disposition or the Non-U.S. Holder's holding period, whichever period is shorter.

The tax relating to stock in a U.S. real property holding corporation does not apply to a Non-U.S. Holder whose holdings, actual and constructive, at all times during the applicable period, amount to 5% or less of the common stock of a U.S. real property holding corporation, provided that the common stock is regularly traded on an established securities market. Generally, a corporation is a U.S. real

property holding corporation if the fair market value of its U.S. real property interests, as defined in the Code and applicable regulations, equals or exceeds 50% of the aggregate fair market value of its worldwide real property interests and its other assets used or held for use in a trade or business. Enzon may, prior to a Non-U.S. Holder's disposition of common stock, become a U.S. real property holding corporation.

#### INFORMATION REPORTING REQUIREMENTS AND BACKUP WITHHOLDING

Enzon must report to the IRS the amount of dividends paid, the name and address of the recipient, and the amount of any tax withheld. A similar report is sent to the Non-U.S. Holder. Under tax treaties or other agreements, the IRS may make its reports available to tax authorities in the recipient's country of residence. Dividends paid on or before December 31, 2000 at an address outside the United States are not subject to backup withholding, unless the payor has knowledge that the payee is a U.S. person. However, a Non-U.S. Holder may need to certify its non-U.S. status in order to avoid backup withholding at a 31% rate on dividends paid after December 31, 2000 or dividends paid on or before



that date at an address inside the United States.

U.S. information reporting and backup withholding generally will not apply to a payment of proceeds of a disposition of common stock where the transaction is effected outside the United States through a non-U.S. office of a non-U.S. broker. However, a Non-U.S. Holder may need to certify its non-U.S. status in order to avoid information reporting and backup withholding at a 31% rate on disposition proceeds where the transaction is effected by or through a U.S. office of a broker. In addition, U.S. information reporting requirements may apply to the proceeds of a disposition effected by or through a non-U.S. office of a U.S. broker, or by a non-U.S. broker with specified connections to the United States.

Backup withholding is not an additional tax. Rather, the tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. When withholding results in an overpayment of taxes, a refund may be obtained if the required information is furnished to the IRS.

#### FEDERAL ESTATE TAX

An individual Non-U.S. Holder who is treated as the owner of, or has made certain lifetime transfers of, an interest in the common stock will be required to include the value of the stock in his gross estate for U.S. federal estate tax purposes, and may be subject to U.S. federal estate tax unless an applicable estate tax treaty provides otherwise.

60

#### UNDERWRITERS

Under the terms and subject to the conditions contained in an Underwriting Agreement dated the date of this prospectus, the underwriters named below, for whom Morgan Stanley & Co. Incorporated, CIBC World Markets Corp. and SG Cowen Securities Corporation are acting as representatives, have severally agreed to purchase, and Enzon, Inc. has agreed to sell to them, severally, the number of shares listed below:

NAME	NUMBER OF SHARES
----	-----
Morgan Stanley & Co. Incorporated.....	546,700
CIBC World Markets Corp. ....	546,650
SG Cowen Securities Corporation.....	546,650
Arnhold and S. Bleichroeder, Inc. ....	40,000
First Union Securities, Inc. ....	40,000
Gerard Klauer Mattison & Co., Inc. ....	40,000
ING Barings LLC.....	40,000
Edward D. Jones & Co., L.P. ....	40,000
Leerink Swann & Company.....	40,000
Legg Mason Wood Walker, Incorporated.....	40,000
Thomas Weisel Partners LLC.....	40,000
U.S. Bancorp Piper Jaffray Inc. ....	40,000
	-----
Total.....	2,000,000
	-----
	-----

The Underwriting Agreement provides that the obligations of the several underwriters to pay for and accept delivery of the shares of common stock offered hereby are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the shares of common stock offered by this prospectus (other than those covered by the underwriters' over-allotment option described below) if any of those shares are taken.

The underwriters initially propose to offer part of the shares of common stock directly to the public at the public offering price set forth on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of \$1.74 a share under the public offering price. After the initial offering of the shares of common stock, the offering price and other selling terms may from time to time be varied by the representatives.

We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to an aggregate of 300,000 additional shares of common stock at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. The underwriters may exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the shares of common stock offered in this prospectus. To the extent that the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase approximately the same percentage of such additional shares of common stock as the number set forth next to that underwriter's name in the table above bears to the total number of shares of common stock set forth next to the names of all underwriters in the table above. If the underwriters' option is exercised in full, the total price to the public would be \$102,350,000, the total underwriters' discounts and commission would be \$6,141,000 and total proceeds to the company would be \$96,209,000.

Enzon and each of its directors and officers has agreed that, without the prior written consent of Morgan Stanley & Co. Incorporated on behalf of the underwriters, they will not during the period ending 90 days after the date of this prospectus:

offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock, or

61

enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock

whether any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise.

The restrictions described above do not apply to:

the sale of shares to the underwriters,

the issuance by the company of shares of common stock upon the exercise of an option or a warrant or the conversion of a security outstanding on the date of this prospectus of which the underwriters have been advised in writing,

transactions by any person other than the company relating to shares of common stock or other securities acquired in open market transactions after the completion of the offering of the shares,

the issuance of options under our existing stock option plans, provided that such options are not exercisable during the 90-day period after the date of this prospectus,

the issuance of shares to our directors under our existing independent directors' stock plan, or

certain shares beneficially owned by A.M. 'Don' MacKinnon.

In order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the common stock. Specifically, the underwriters may over-allot in connection with the offering, creating a short position in the common stock for their own account. In addition, to cover over-allotments or to stabilize the

price of the common stock, the underwriters may bid for, and purchase, shares of common stock in the open market. Finally, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the common stock in the offering, if the syndicate repurchases previously distributed common stock in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the common stock above independent market levels. The underwriters are not required to engage in these activities and may end any of these activities at any time.

The underwriters and dealers may engage in passive market making transactions in the common stock in accordance with Rule 103 of Regulation M promulgated by the SEC. In general, a passive market maker may not bid for, or purchase, the common stock at a price that exceeds the highest independent bid. In addition, the net daily purchases made by any passive market maker generally may not exceed 30% of its average daily trading volume in the common stock during a specified two month prior period, or 200 shares, whichever is greater. A passive market maker must identify passive market making bids as such or maintain the market price of the common stock above independent market levels. Underwriters and dealers are not required to engage in passive market making and may end passive market making activities at any time.

We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act.

#### LEGAL MATTERS

The validity of the issuance of shares of common stock offered by us in this offering will be passed upon for us by Dorsey & Whitney LLP, New York, New York. Certain legal matters related to the offering will be passed upon for the underwriters by Ropes & Gray, Boston, Massachusetts.

#### EXPERTS

Our consolidated financial statements as of June 30, 1998 and 1999 and for each of the years in the three-year period ended June 30, 1999, have been included herein and in the registration statement in reliance on the report of KPMG LLP, independent certified public accountants, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.

#### WHERE YOU CAN FIND MORE INFORMATION

We have filed with the SEC a registration statement on Form S-3 with respect to the common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules which are part of the registration statement. For further information about us and our common stock, you should review the registration statement and exhibits and schedules thereto. You may read and copy any document we file with the SEC at the SEC's public reference room at 450 Fifth Street, NW, Washington, DC 20549, as well as at the SEC's regional offices located at 7 World Trade Center, Suite 1300, New York, NY 10048 and Citicorp Center, 500 West Madison Street, Suite 1400, Chicago, IL 60661. Please call the SEC at 1-800-SEC-0330 for further information about its public reference facilities and copy charges. Our filings are also available to the public from the SEC's web site at <http://www.sec.gov>.

We file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information are available for inspection and copying at the SEC's public reference room and the regional offices listed above and can be obtained through the SEC's web site.

The SEC allows us to 'incorporate by reference' information into this prospectus. This allows us to disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, except for any information superseded by information contained directly in this prospectus.

The documents that we are incorporating by reference are:

our annual report on Form 10-K, as amended, for the fiscal year ended June 30, 1999,

our quarterly reports on Form 10-Q for the fiscal quarter ended September 30, 1999 and December 31, 1999, as amended on February 25, 2000,

our proxy statement dated October 28, 1999, filed in connection with our annual meeting of stockholders held on December 7, 1999,

our current reports on Form 8-K filed on January 11, 2000, February 22, 2000, February 23, 2000, and March 20, 2000, and

our Form 8-A, filed on October 29, 1984, as amended by Form 8 filed on October 15, 1990, with respect to our common stock.

We also are incorporating by reference any future filings made by us with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act until the completion of this offering. The most recent information that we file with the SEC automatically updates and supercedes more dated information.

You can obtain a copy of any documents which are incorporated by reference in this prospectus, except for exhibits that are not specifically incorporated by reference into those documents, at no cost, by writing or telephoning us at Investor Relations, Enzon, Inc., 20 Kingsbridge Road, Piscataway, NJ 08854, (732) 980-4517.

[THIS PAGE INTENTIONALLY LEFT BLANK]

ENZON, INC. AND SUBSIDIARIES  
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

	PAGE
	----
Audited Consolidated Financial Statements:	
Independent Auditors' Report.....	F-2
Consolidated Balance Sheets -- June 30, 1999 and 1998...	F-3
Consolidated Statements of Operations -- Years ended June 30, 1999, 1998 and 1997.....	F-4
Consolidated Statements of Stockholders' Equity -- Years ended June 30, 1999, 1998 and 1997.....	F-5
Consolidated Statements of Cash Flows -- Years ended June 30, 1999, 1998 and 1997.....	F-6
Notes to Consolidated Financial Statements -- Years ended June 30, 1999, 1998 and 1997.....	F-7
Unaudited Consolidated Financial Statements:	
Consolidated Condensed Balance Sheet -- December 31, 1999.....	F-19
Consolidated Condensed Statements of Operations -- Six months ended December 31, 1999 and 1998.....	F-20
Consolidated Condensed Statements of Cash Flows -- Six months ended December 31, 1999 and 1998.....	F-21
Notes to Consolidated Condensed Financial Statements....	F-22

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Stockholders  
 ENZON, INC.:

We have audited the consolidated financial statements of Enzon, Inc. and subsidiaries as listed in the accompanying index. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Enzon, Inc. and subsidiaries as of June 30, 1999 and 1998, and the results of their operations and their cash flows for each of the years in the three-year period ended June 30, 1999, in conformity with generally accepted accounting principles.

KPMG LLP

Short Hills, New Jersey  
 September 8, 1999

F-2

ENZON, INC. AND SUBSIDIARIES  
 CONSOLIDATED BALANCE SHEETS  
 JUNE 30, 1999 AND 1998

	1999	1998
	----	----
ASSETS		
Current assets:		
Cash and cash equivalents.....	\$ 24,673,636	\$ 6,478,459
Accounts receivable.....	4,604,847	2,300,046
Inventories.....	1,326,601	1,022,530
Prepaid expenses and other current assets.....	1,034,327	447,952
	-----	-----
Total current assets.....	31,639,411	10,248,987
	-----	-----
Property and equipment.....	12,054,505	15,134,075
Less accumulated depreciation and amortization.....	10,649,661	13,368,330
	-----	-----
	1,404,844	1,765,745
	-----	-----
Other assets:		
Investments.....	68,823	69,002
Deposits and deferred charges.....	753,683	464,747
Patents, net.....	1,049,554	1,192,897
	-----	-----
	1,872,060	1,726,646

Total assets.....	\$ 34,916,315	\$ 13,741,378
-----		
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable.....	\$ 1,716,089	\$ 1,711,856
Accrued expenses.....	6,261,640	4,375,822
-----		
Total current liabilities.....	7,977,729	6,087,678
-----		
Accrued rent.....	634,390	727,160
Royalty advance -- RPR.....	728,977	--
-----		
	1,363,367	727,160
-----		
Commitments and contingencies		
Stockholders' equity:		
Preferred stock -- \$.01 par value, authorized 3,000,000 shares; issued and outstanding 107,000 shares in 1999 and 1998 (liquidation preference aggregating \$4,659,000 in 1999 and \$4,445,000 in 1998).....	1,070	1,070
Common stock -- \$.01 par value, authorized 60,000,000 shares; issued and outstanding 36,488,684 shares in 1999 and 31,341,353 shares in 1998.....	364,886	313,414
Additional paid-in capital.....	146,970,289	123,453,874
Accumulated deficit.....	(121,761,026)	(116,841,818)
-----		
Total stockholders' equity.....	25,575,219	6,926,540
-----		
Total liabilities and stockholders' equity.....	\$ 34,916,315	\$ 13,741,378
-----		

The accompanying notes are an integral part of these consolidated financial statements.

F-3

ENZON, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF OPERATIONS  
YEARS ENDED JUNE 30, 1999, 1998 AND 1997

	1999	1998	1997
	----	----	----
Revenues:			
Sales.....	\$12,855,995	\$12,312,730	\$11,595,985
Contract revenue.....	302,212	2,331,302	1,131,067
-----			
Total revenues.....	13,158,207	14,644,032	12,727,052
-----			
Costs and expenses:			
Cost of sales.....	4,309,956	3,645,281	3,840,198
Research and development expenses.....	6,835,521	8,653,567	8,520,366
Selling, general and administrative expenses.....	8,133,366	6,426,241	5,528,174
-----			
Total costs and expenses.....	19,278,843	18,725,089	17,888,738
-----			
Operating loss.....	(6,120,636)	(4,081,057)	(5,161,686)
-----			
Other income (expense):			
Interest and dividend income.....	1,145,009	460,922	584,384
Interest expense.....	(8,348)	(13,923)	(14,891)
Other.....	64,767	16,925	35,168
-----			
	1,201,428	463,924	604,661
-----			
Net loss.....	\$ (4,919,208)	\$ (3,617,133)	\$ (4,557,025)
-----			

Basic and diluted net loss per common share.....	\$ (0.14)	\$ (0.12)	\$ (0.16)
	-----	-----	-----
	-----	-----	-----
Weighted average number of common shares outstanding.....	35,699,133	31,092,369	29,045,605
	-----	-----	-----
	-----	-----	-----

The accompanying notes are an integral part of these consolidated financial statements.

F-4

ENZON, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY  
YEARS ENDED JUNE 30, 1999, 1998 AND 1997

	PREFERRED STOCK			COMMON STOCK		
	AMOUNT PER SHARE	NUMBER OF SHARES	PAR VALUE	AMOUNT PER SHARE	NUMBER OF SHARES	PAR VALUE
	-----	-----	-----	-----	-----	-----
Balance, July 1, 1996.....		169,000	\$1,690		27,706,396	\$277,064
Common stock issued for exercise of non-qualified stock options.....	--	--	--	\$ 2.36	11,219	112
Common stock issued for Independent Directors' Stock Plan.....	--	--	--	2.97	25,903	259
Consulting expense for issuance of stock options.....	--	--	--	--	--	--
Common stock issued on conversion of Series B Preferred Stock.....	\$ 1.95	(40,000)	(400)	1.95	2,038,989	20,390
Common stock issued on conversion of Series D Preferred Stock.....	1.97	(20,000)	(200)	1.97	1,015,228	10,152
Net Loss.....	--	--	--	--	--	--
		-----	-----		-----	-----
Balance, June 30, 1997.....		109,000	1,090		30,797,735	307,977
Common stock issued for exercise of non-qualified stock options.....	--	--	--	2.23	505,072	5,051
Common stock issued on conversion of Series A Preferred Stock.....	25.00	(2,000)	(20)	11.00	4,544	45
Dividends issued on Series A Preferred Stock.....	--	--	--	11.00	2,848	29
Common stock issued for Independent Directors' Stock Plan.....	--	--	--	4.11	16,904	169
Common stock issued for consulting services.....	--	--	--	4.77	14,250	143
Consulting expense for issuance of stock options.....	--	--	--	--	--	--
Net Loss.....	--	--	--	--	--	--

Balance, June 30, 1998.....		-----	-----		-----	-----
		107,000	1,070		31,341,353	313,414
Common stock issued for exercise of non-qualified stock options.....	--	--	--	4.40	1,000,919	10,009
Common stock issued on exercise of common stock warrants.....	--	--	--	2.50	150,000	1,500
Net proceeds from Private Placement, July 1998.....	--	--	--	4.75	3,983,000	39,830
Common stock issued for Independent Directors' Stock Plan.....	--	--	--	8.88	8,514	84
Common stock options and warrants issued for consulting services.....	--	--	--	--	--	--
Common stock issued for consulting services.....	--	--	--	6.13	4,898	49
Net loss.....	--	--	--	--	--	--
		-----	-----		-----	-----
Balance, June 30, 1999.....		107,000	\$1,070		36,488,684	\$364,886
		-----	-----		-----	-----

	ADDITIONAL PAID-IN CAPITAL -----	ACCUMULATED DEFICIT -----	TOTAL -----
Balance, July 1, 1996.....	\$121,272,024	\$(108,636,320)	\$12,914,458
Common stock issued for exercise of non-qualified stock options.....	26,499	--	26,611
Common stock issued for Independent Directors' Stock Plan.....	76,598	--	76,857
Consulting expense for issuance of stock options.....	80,984	--	80,984
Common stock issued on conversion of Series B Preferred Stock.....	(19,993)	--	(3)
Common stock issued on conversion of Series D Preferred Stock.....	(9,953)	--	(1)
Net Loss.....	--	(4,557,025)	(4,557,025)
	-----	-----	-----
Balance, June 30, 1997.....	121,426,159	(113,193,345)	8,541,881
Common stock issued for exercise of non-qualified stock options.....	1,653,557	--	1,658,608
Common stock issued on conversion of Series A Preferred Stock.....	(42)	--	(17)
Dividends issued on Series A Preferred Stock.....	31,300	(31,340)	(11)
Common stock issued for Independent Directors' Stock Plan.....	69,231	--	69,400
Common stock issued for consulting			



services.....	67,854	--	67,997
Consulting expense for issuance of stock options.....	205,815	--	205,815
Net Loss.....	--	(3,617,133)	(3,617,133)
	-----	-----	-----
Balance, June 30, 1998.....	123,453,874	(116,841,818)	6,926,540
Common stock issued for exercise of non-qualified stock options.....	4,396,477	--	4,406,486
Common stock issued on exercise of common stock warrants.....	373,500	--	375,000
Net proceeds from Private Placement, July 1998.....	17,510,265	--	17,550,095
Common stock issued for Independent Directors' Stock Plan.....	75,539	--	75,623
Common stock options and warrants issued for consulting services.....	1,130,683	--	1,130,683
Common stock issued for consulting services.....	29,951	--	30,000
Net loss.....	--	(4,919,208)	(4,919,208)
	-----	-----	-----
Balance, June 30, 1999.....	\$146,970,289	\$(121,761,026)	\$25,575,219
	-----	-----	-----

The accompanying notes are an integral part of these consolidated financial statements.

F-5

ENZON, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
YEARS ENDED JUNE 30, 1999, 1998 AND 1997

	1999	1998	1997
	----	----	----
Cash flows from operating activities:			
Net loss.....	\$(4,919,208)	\$(3,617,133)	\$(4,557,025)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation and amortization.....	835,503	1,217,423	1,653,331
(Gain) loss on retirement of assets.....	(38,521)	97,037	(35,168)
Non-cash expense for issuance of common stock, warrants, and options.....	1,236,306	343,212	157,841
Changes in assets and liabilities:			
(Increase) decrease in accounts receivable.....	(2,304,801)	133,716	(310,071)
(Increase) decrease in inventories.....	(304,071)	(162,657)	125,505
(Increase) decrease in prepaid expenses and other current.....	(586,375)	(360,220)	346,586
(Increase) decrease in other assets.....	(288,936)	(430,172)	21,370
Increase (decrease) in accounts payable.....	4,233	(198,881)	(168,187)
Increase (decrease) in accrued expenses.....	2,691,353	796,403	(522,761)
Decrease in accrued rent.....	(92,770)	(142,852)	(110,896)
Decrease in royalty advance -- RPR.....	(76,558)	(1,101,501)	(780,081)
Decrease in other liabilities.....	--	--	(1,728)
	-----	-----	-----

Net cash used in operating activities.....	(3,843,845)	(3,425,625)	(4,181,284)
Cash flows from investing activities:			
Capital expenditures.....	(424,670)	(160,940)	(873,754)
Proceeds from sale of equipment.....	131,932	83,129	680,481
Decrease in investments.....	179	9,291	--
Net cash used in investing activities.....	(292,559)	(68,520)	(193,273)
Cash flows from financing activities:			
Proceeds from issuance of common stock, preferred stock and warrants.....	22,331,581	1,658,580	26,607
Principal payments of obligations under capital leases.....	--	(1,728)	(2,348)
Net cash provided by financing activities.....	22,331,581	1,656,852	24,259
Net increase (decrease) in cash and cash equivalents.....	18,195,177	(1,837,293)	(4,350,298)
Cash and cash equivalents at beginning of period...	6,478,459	8,315,752	12,666,050
Cash and cash equivalents at end of period.....	\$24,673,636	\$ 6,478,459	\$ 8,315,752

The accompanying notes are an integral part of these consolidated financial statements.

F-6

ENZON, INC. AND SUBSIDIARIES  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  
YEARS ENDED JUNE 30, 1999, 1998 AND 1997

(1) COMPANY OVERVIEW

Enzon, Inc. ('Enzon' or 'Company') is a biopharmaceutical company that develops, manufactures and markets enhanced therapeutics for life-threatening diseases through the application of its proprietary technologies. The Company was originally incorporated in 1981. To date, the Company's sources of cash have been the proceeds from the sale of its stock through public offerings and private placements, sales of ADAGEN'r', sales of ONCASPAR'r', sales of its products for research purposes, contract research and development fees, technology transfer and license fees and royalty advances. The manufacturing and marketing of pharmaceutical products in the United States is subject to stringent governmental regulation, and the sale of any of the Company's products for use in humans in the United States will require the prior approval of the United States Food and Drug Administration ('FDA'). To date, ADAGEN and ONCASPAR are the only products of the Company which have been approved for marketing by the FDA.

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances are eliminated in consolidation. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

INVESTMENTS

Cash equivalents include investments which consist primarily of debt securities and time deposits. The Company invests its excess cash in a portfolio of marketable securities of institutions with strong credit ratings and U.S. Government backed securities.

The Company classifies its investment securities as held-to-maturity. Held-to-maturity securities are those securities which the Company has the ability and intent to hold to maturity. Held-to-maturity securities are recorded at cost which approximated the fair value of the investments at June 30, 1999 and 1998.

#### INVENTORY COSTING AND IDLE CAPACITY

Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method and includes the cost of raw materials, labor and overhead.

Costs associated with idle capacity at the Company's manufacturing facility are charged to cost of sales as incurred.

#### PATENTS

The Company has licensed, and been issued, a number of patents in the United States and other countries and has other patent applications pending to protect its proprietary technology. Although the Company believes that its patents provide adequate protection for the conduct of its business, there can be no assurance that such patents will be of substantial protection or commercial benefit to the Company, will afford the Company adequate protection from competing products, or will not be challenged or declared invalid, or that additional United States patents or foreign patent equivalents

F-7

#### ENZON, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

will be issued to the Company. The degree of patent protection to be afforded to biotechnological inventions is uncertain, and the Company's products are subject to this uncertainty.

Patents related to the acquisition of SCA Ventures, Inc., formerly Genex Corporation, were recorded at their fair value at the date of acquisition and are being amortized over the estimated useful lives of the patents ranging from 8 to 17 years. Accumulated amortization as of June 30, 1999 and 1998 was \$1,099,000 and \$956,000, respectively.

Costs related to the filing of patent applications related to the Company's products and technology are expensed as incurred.

#### PROPERTY AND EQUIPMENT

Property and equipment are carried at cost. Depreciation is computed using the straight-line method. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. The cost of repairs and maintenance is charged to operations as incurred; significant renewals and betterments are capitalized.

#### LONG-LIVED ASSETS

The Company reviews long-lived assets for impairment whenever events or changes in business circumstances occur that indicate that the carrying amount of the assets may not be recoverable. The Company assesses the recoverability of long-lived assets held and to be used based on undiscounted cash flows and measures the impairment, if any, using discounted cash flows.

#### REVENUE RECOGNITION

Reimbursement from third party payors for ADAGEN is handled on an individual basis due to the high cost of treatment and limited patient population. Because of the uncertainty of reimbursement and the Company's commitment of supply to the patient regardless of whether or not the Company will be reimbursed, revenues for the sale of ADAGEN are recognized when reimbursement from third party payors becomes likely.

Revenues from the sale of the Company's other products that are sold are recognized at the time of shipment and provision is made for estimated returns. Contract revenues are recorded as the earnings process is completed.

Royalties under the Company's license agreements with third parties are recognized when earned.

#### RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred.

#### STOCKHOLDERS' EQUITY

The Company maintains a Non-Qualified Stock Option Plan (the 'Stock Option Plan') for which it applies Accounting Principles Board ('APB') Opinion No. 25, 'Accounting for Stock Issued to Employees,' and related interpretations in accounting for the Stock Option Plan. Stock options issued to employees are granted with an exercise price equal to the market price and in accordance with APB No. 25, compensation expense is not recognized.

#### CASH FLOW INFORMATION

The Company considers all highly liquid securities with original maturities of three months or less to be cash equivalents.

F-8

#### ENZON, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

During the year ended June 30, 1998, 2,000 shares of Series A Cumulative Convertible Preferred Stock ('Series A Preferred Stock' or 'Series A Preferred Shares') were converted to 4,544 shares of Common Stock. Accrued dividends of \$31,000 on the Series A Preferred Shares that were converted were settled by issuing 2,848 shares of Common Stock and cash payments totaling \$28 for fractional shares. There were no conversions of Series A Preferred Stock for the years ended June 30, 1999 and 1997.

Cash payments for interest were approximately \$8,000, \$14,000 and \$15,000 for the years ended June 30, 1999, 1998 and 1997, respectively. There were no income tax payments made for the years ended June 30, 1999, 1998 and 1997.

#### NET LOSS PER COMMON SHARE

Basic and diluted loss per common share is based on the net loss for the relevant period, adjusted for cumulative, undeclared Series A Preferred Stock dividends of \$214,000, \$216,000 and \$218,000 for the years ended June 30, 1999, 1998 and 1997, respectively, divided by the weighted average number of shares issued and outstanding during the period. For purposes of the diluted loss per share calculation, the exercise or conversion of all dilutive potential common shares is not included, due to the net loss recorded for the years ended June 30, 1999, 1998 and 1997. As of June 30, 1999, the Company had approximately 5,857,000 dilutive potential common shares outstanding that could potentially dilute future earnings per share calculations.

#### COMPREHENSIVE INCOME

Effective July 1, 1998, the Company adopted Statement of Financial Accounting Standards No. 130 ('SFAS 130'), Reporting Comprehensive Income. SFAS 130 establishes new rules for the reporting and display of comprehensive income and its components. The adoption of SFAS 130 had no impact on the Company's results of operations for the years ended June 30, 1999, 1998 and 1997. The net loss is equal to the comprehensive loss for those periods.

#### (3) INVENTORIES

Inventories consist of the following:

	JUNE 30,	
	1999	1998
Raw materials.....	\$ 503,000	\$ 510,000
Work in process.....	548,000	398,000
Finished goods.....	276,000	115,000
	<u>\$1,327,000</u>	<u>\$1,023,000</u>

(4) PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

	JUNE 30,		ESTIMATED
	1999	1998	USEFUL LIVES
Equipment.....	\$ 8,024,000	\$ 8,647,000	3-7 years
Furniture and fixtures.....	1,438,000	1,501,000	7 years
Vehicles.....	24,000	29,000	3 years
Leasehold improvements.....	2,569,000	4,957,000	3-15 years
	<u>\$12,055,000</u>	<u>\$15,134,000</u>	

F-9

ENZON, INC. AND SUBSIDIARIES  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

During the year ended June 30, 1999, the Company's fixed asset disposals were approximately \$3,504,000. The disposals were primarily attributable to the Company's consolidation of research operations and the elimination of its leased facility at 40 Cragwood Road. Depreciation and amortization charged to operations, relating to property and equipment, totaled \$692,000, \$1,063,000 and \$1,499,000 for the years ended June 30, 1999, 1998 and 1997, respectively.

(5) STOCKHOLDERS' EQUITY

During the year ended June 30, 1999, the Company sold 3,983,000 shares of Common Stock in a private placement to a small group of investors. The private placement resulted in gross proceeds of approximately \$18,919,000 and net proceeds of approximately \$17,550,000.

During the year ended June 30, 1997, all of the outstanding shares of Series B Preferred Stock were converted into Common Stock. The 40,000 shares of Series B Preferred Stock which were converted resulted in the issuance of 2,038,989 shares of Common Stock.

During March 1997, all of the outstanding Series C Preferred Stock was exchanged for newly issued Series D Preferred Stock. The Series D Preferred Stock contained the same provisions as the Series C Preferred Stock, with the exception of the elimination of a restriction on the maximum number of shares which could be held by the holding institution. During March 1997, all of the outstanding Series D Preferred Stock was converted into Common Stock. The 20,000 shares of Series D Preferred Stock which were converted resulted in the issuance of 1,015,228 shares of Common Stock.

SERIES A PREFERRED STOCK

The Company's Series A Preferred Shares are convertible into Common Stock at a conversion rate of \$11 per share. The value of the Series A Preferred Shares for conversion purposes is \$25 per share. Holders of the Series A Preferred Shares are entitled to an annual dividend of \$2 per share, payable semiannually, but only when and if declared by the Board of Directors, out of funds legally available. Dividends on the Series A Preferred Shares are cumulative and accrue and accumulate but will not be paid, except in liquidation or upon conversion, until such time as the Board of Directors deems it appropriate in light of the Company's then current financial condition. No dividends are to be paid or set apart for payment on the Company's Common Stock, nor are any shares of Common Stock to be redeemed, retired or otherwise acquired for valuable consideration unless the Company has paid in full or made appropriate provision for the payment in full of all dividends which have then accumulated on the Series A Preferred Shares. Holders of the Series A Preferred Shares are entitled to one vote per share on matters to be voted upon by the stockholders of the Company. As of June 30, 1999 and 1998, undeclared accrued dividends in arrears were \$1,984,000 or \$18.54 per share and \$1,770,000 or \$16.54 per share, respectively. All Common Shares are junior in rank to the Series A Preferred Shares, with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution or winding up of the Company.

During the year ended June 30, 1998, 2,000 shares of Series A Preferred Shares were converted to 4,544 shares of Common Stock. Accrued dividends of \$31,000 were settled by issuing 2,848 shares of Common Stock and cash payments totaling \$16 for fractional shares. There were no conversions of Series A Preferred Shares during the years ended June 30, 1999 or 1997.

COMMON STOCK

Holders of shares of Common Stock are entitled to one vote per share on matters to be voted upon by the stockholders of the Company.

ENZON, INC. AND SUBSIDIARIES  
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

As of June 30, 1999, the Company has reserved its common shares for special purposes as detailed below:

Shares issuable upon conversion of Series A Preferred	
Shares.....	424,000
Shares issuable upon exercise of outstanding warrants.....	1,089,000
Non-Qualified Stock Option Plan.....	4,344,000
	-----
	5,857,000
	-----
	-----

COMMON STOCK WARRANTS

During the year ended June 30, 1999, 150,000 warrants were exercised to purchase 150,000 shares of the Company's Common Stock at \$2.50 per share. These warrants were issued during the year ended June 30, 1996, as part of the commission due to a real estate broker in connection with the termination of the Company's former lease at 40 Kingsbridge Road.

During the year ended June 30, 1999, the Company issued 200,000 five-year warrants to purchase Enzon Common Stock at \$6.50 per share, the closing price of the Common Stock on the date of grant. The warrants are consideration for consulting services to be rendered through February 2002. The estimated fair value of the warrants of approximately \$917,000 is being amortized over the service period of three years. The unamortized portion is included as a component of other assets with the corresponding current portion included in other current assets on the consolidated balance sheet as of June 30, 1999.

SERIES B AND C PREFERRED STOCK WARRANTS

As of June 30, 1999 and 1998, warrants to purchase 688,686 shares of Common Stock at \$4.11 and 200,000 shares of Common Stock at \$5.63, issued in connection with the private placements of Series B and C Preferred Shares, were outstanding.

(6) INDEPENDENT DIRECTORS' STOCK PLAN

On December 3, 1996, the stockholders voted to approve the Company's Independent Directors' Stock Plan, which provides for compensation in the form of quarterly grants of Common Stock to non executive, independent directors serving on the Company's Board of Directors. Each independent director is granted shares of Common Stock equivalent to \$2,500 per quarter plus \$500 per Board of Director's meeting attended. The number of shares issued is based on the fair market value of Common Stock on the last trading day of the applicable quarter. During the years ended June 30, 1999, 1998 and 1997, the Company issued 8,514, 16,904 and 25,903 shares of Common Stock, respectively, to independent directors, pursuant to the Independent Directors' Stock Plan.

(7) NON-QUALIFIED STOCK OPTION PLAN

In November 1987, the Company's Board of Directors adopted a Non-Qualified Stock Option Plan (the 'Stock Option Plan'). The number of shares reserved for issuance upon adoption of the Company's Stock Option Plan was 6,200,000. As of June 30, 1999, 4,344,000 shares of Common Stock were reserved for issuance pursuant to options which may be granted to employees, non-employee directors or consultants to the Company. The exercise price of the options granted must be at least 100% of the fair market value of the stock at the time the option is granted. Options may be exercised for a period of up to ten years from the date they are granted. The other terms and conditions of the options generally are to be determined by the Board of Directors, or an option committee appointed by the Board, at their discretion.

The Company has adopted the disclosure-only provisions of Statement of Financial Accounting Standards No. 123 ('SFAS No. 123'), 'Accounting for Stock-Based Compensation'. The Company

F-11

ENZON, INC. AND SUBSIDIARIES  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

continues to use APB No. 25, 'Accounting for Stock Issued to Employees,' to account for the Stock Option Plan. All options granted under the Stock Option Plan are granted with exercise prices which equal or exceed the fair market value of the stock at the date of grant. Accordingly, there is no compensation expense recognized for options granted to employees. The Company records compensation expense equal to the value of stock options granted for consulting services rendered to the Company by non-employees. The value of the options granted to non-employees is determined by the Black-Scholes option-pricing model.

The following pro forma financial information shows the effect and the Company's net loss and loss per share, had compensation expense been recognized consistent with SFAS No. 123.

	1999 ----	1998 ----	1997 ----
Net loss -- as reported.....	\$(4,919,000)	\$(3,617,000)	\$(4,557,000)
Net loss -- pro forma.....	\$(7,289,000)	\$(5,638,000)	\$(5,927,000)
Loss per share -- as reported.....	\$(0.14)	\$(0.12)	\$(0.16)
Loss per share -- pro forma.....	\$(0.21)	\$(0.19)	\$(0.21)

The pro forma effect on the loss for the three years ended June 30, 1999 is not necessarily indicative of the pro forma effect on earnings in future years

since it does not take into effect the pro forma compensation expense related to grants made prior to the year ended June 30, 1996. The fair value of each option granted during the three years ended June 30, 1999 is estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions: (i) dividend yield of 0%, (ii) expected term of five years, (iii) expected volatility of 86%, 84%, and 82%, and (iv) a risk-free interest rate of 5.06%, 5.57%, and 6.45% for the years ended June 30, 1999, 1998, and 1997, respectively. The weighted average fair value at the date of grant for options granted during the years ended June 30, 1999, 1998 and 1997 was \$9.68, \$5.85 and \$2.78 per share, respectively.

The following is a summary of the activity in the Company's Stock Option Plan:

	SHARES	WEIGHTED AVERAGE EXERCISE PRICE	RANGE OF PRICES
	-----	-----	-----
Outstanding at July 1, 1996.....	3,558,000	\$4.75	\$1.88 to \$14.88
Granted at exercise prices which exceeded the fair market value on the date of grant.....	3,000	2.81	\$2.81
Granted at exercise prices which equaled the fair market value on the date of grant.....	1,469,000	2.78	\$2.31 to \$3.41
Exercised.....	(11,000)	2.37	\$2.00 to \$2.63
Canceled.....	(822,000)	6.26	\$2.00 to \$14.25
	-----		
Outstanding at June 30, 1997.....	4,197,000	3.77	\$1.88 to \$14.88
Granted at exercise prices which equaled the fair market value on the date of grant.....	719,000	5.85	\$2.03 to \$6.56
Exercised.....	(305,000)	2.73	\$2.06 to \$5.13
Canceled.....	(189,000)	6.69	\$2.09 to \$14.88
	-----		
Outstanding at June 30, 1998.....	4,422,000	4.06	\$1.88 to \$10.88
Granted at exercise prices which equaled the fair market value on the date of grant.....	455,000	9.68	\$4.88 to \$15.75
Exercised.....	(1,001,000)	4.40	\$2.00 to \$9.88
Canceled.....	(172,000)	7.25	\$2.81 to \$14.50
	-----		
Outstanding at June 30, 1999.....	3,704,000	4.51	\$1.88 to \$15.75
	-----		

F-12

ENZON, INC. AND SUBSIDIARIES  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

As of June 30, 1999, the Plan had options outstanding and exercisable by price range as follows:

RANGE OF EXERCISE PRICES	OPTIONS OUTSTANDING	WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE	WEIGHTED AVERAGE EXERCISE PRICE	OPTIONS EXERCISABLE	WEIGHTED AVERAGE EXERCISE PRICE
-----	-----	----	-----	-----	-----
\$1.88 to \$ 2.63.....	535,000	6.22	\$2.34	535,000	\$2.34
\$2.69 to \$ 2.81.....	793,000	6.95	\$2.75	793,000	\$2.75
\$2.88 to \$ 3.50.....	582,000	6.79	\$3.19	482,000	\$3.24
\$3.56 to \$ 4.50.....	576,000	5.40	\$4.25	576,000	\$4.25
\$4.56 to \$ 6.00.....	669,000	7.89	\$5.76	427,000	\$5.68
\$6.13 to \$15.75.....	549,000	8.71	\$9.29	78,000	\$8.28
	-----			-----	
\$1.88 to \$15.75.....	3,704,000	7.01	\$4.51	2,891,000	\$3.64



(8) INCOME TAXES

The Company adopted Statement of Financial Accounting Standards No. 109 (SFAS No. 109), 'Accounting for Income Taxes' as of July 1, 1993. Under the asset and liability method of SFAS No. 109, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under SFAS No. 109, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The effects of adopting SFAS No. 109 were not material to the financial statements at July 1, 1993.

At June 30, 1999 and 1998, the tax effects of temporary differences that give rise to the deferred tax assets and deferred tax liabilities are as follows:

	1999	1998
	----	----
Deferred tax assets:		
Inventories.....	\$ 272,000	\$ 111,000
Investment valuation reserve.....	86,000	86,000
Contribution carryover.....	20,000	19,000
Compensated absences.....	127,000	115,000
Excess of financial statement over tax		
depreciation.....	1,031,000	827,000
Royalty advance -- RPR.....	371,000	402,000
Non-deductible expenses.....	1,497,000	543,000
Federal and state net operating loss carryforwards...	44,531,000	2,133,000
Research and development and investment tax credit		
carryforwards.....	8,176,000	7,447,000
	-----	-----
Total gross deferred tax assets.....	56,111,000	51,683,000
Less valuation allowance.....	(55,405,000)	(50,977,000)
	-----	-----
Net deferred tax assets.....	706,000	706,000
	-----	-----
Deferred tax liabilities:		
Step up in basis of assets related to acquisition of		
Enzon Labs Inc. ....	(706,000)	(706,000)
	-----	-----
Total gross deferred tax liabilities.....	(706,000)	(706,000)
	-----	-----
Net deferred tax.....	\$ 0	\$ 0
	-----	-----

A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The net change in the total valuation allowance for the years

ended June 30, 1999 and 1998 was an increase of \$4,428,000 and \$2,221,000, respectively. The tax benefit assumed using the Federal statutory tax rate of 34% has been reduced to an actual benefit of zero due principally to the aforementioned valuation allowance. Subsequently recognized tax benefits as of June 30, 1999 of \$1,677,000 relating to the valuation allowance for deferred tax assets will be allocated to additional paid-in capital.

At June 30, 1999, the Company had federal net operating loss carryforwards of approximately \$114,639,000 for tax reporting purposes, which expire in the years 2000 to 2019. The Company also has investment tax credit carryforwards of approximately \$1,900 and research and development tax credit carryforwards of approximately \$6,696,000 for tax reporting purposes which expire in the years 2000 to 2019.

As part of the Company's acquisition of Enzon Labs Inc., the Company acquired the net operating loss carryforwards of Enzon Labs Inc. As of June 30, 1999, the Company had a total of \$55,731,000 of acquired Enzon Labs net operating loss carryforwards, which expire between December 31, 1999 and October 31, 2006. As a result of the change in ownership, the utilization of these carryforwards is limited to \$613,000 per year.

#### (9) SIGNIFICANT AGREEMENTS

##### SCHERING AGREEMENT

The Company and Schering Corporation ('Schering'), a subsidiary of Schering-Plough, entered into an agreement in November 1990 (the 'Schering Agreement') to apply the Company's PEG Process to develop a modified form of Schering-Plough's INTRON'r'A (interferon alfa 2b), a genetically-engineered anticancer and antiviral drug with longer activity. A PEG-modified version of INTRON A ('PEG-Intron'TM') is currently in four large scale Phase III clinical trials in the United States, Europe and Japan for hepatitis C and cancer as well as earlier stage trials for cancer and certain leukemias. The trials call for administration of PEG-Intron once per week as compared to the current regimen for unmodified INTRON A of three times per week. PEG-Intron utilizes the Company's Second Generation PEG Technology.

Under the license agreement, which was amended in 1995 and 1999, the Company will receive royalties on worldwide sales of PEG-Intron, if any. Schering is responsible for conducting and funding the clinical studies, obtaining regulatory approval and marketing the product worldwide on an exclusive basis. During 1999, the Company and Schering amended the agreement that resulted in an increase in the effective royalty rate in return for Enzon's exclusive U.S. manufacturing rights for the product and a license under one of the Company's Second Generation PEG patents for Branched or U-PEG. The license for Branched PEG gives Schering the ability to sublicense the patent for a competing interferon product.

Enzon is entitled to an additional \$3,000,000 in payments from Schering, subject to the achievement of certain milestones in the product's development. The Schering Agreement terminates, on a country-by-country basis, upon the expiration of the last to expire of any future patents covering the product which may be issued to Enzon, or 15 years after the product is approved for commercial sale, whichever shall be the later to occur. This agreement is subject to Schering's right of early termination if the product does not meet specifications, if Enzon fails to obtain or maintain the requisite product liability insurance, or if Schering makes certain payments to Enzon. If Schering terminates the agreement because the product does not meet specifications, Enzon may be required to refund certain of the milestone payments. Revenue will not be recognized on these payments until the product is deemed to meet specification.

F-14

#### ENZON, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

##### RHONE-POULENC RORER AGREEMENT

Under the Company's Amended RPR U.S. License Agreement, Enzon granted an exclusive license to RPR to sell ONCASPAR in the U.S. Enzon has received licensing payments totaling \$6,000,000 and is entitled to a base royalty of 23.5% until 2008, on net sales of ONCASPAR up to agreed upon amounts. Additionally, the Amended RPR U.S. License Agreement provides for a super royalty of 43.5% until 2008, on net sales of ONCASPAR which exceed certain agreed upon amounts, with the limitation that the total royalties earned for any such year shall not exceed 33% of net sales. The Amended RPR U.S. License

Agreement also provides for a payment of \$3,500,000 in advance royalties, which was received in January 1995.

The payment of base royalties to Enzon under the Amended RPR U.S. License Agreement will be offset by an original credit of \$5,970,000, which represents the royalty advance plus reimbursement of certain amounts due to RPR under the original RPR U.S. License Agreement and interest expense. Super royalties will be paid to the Company when earned. The royalty advance is shown as a long term liability, with the corresponding current portion included in accrued expenses on the Consolidated Balance Sheets as of June 30, 1999 and 1998. The royalty advance will be reduced as base royalties are recognized under the agreement.

The Amended RPR U.S. License Agreement prohibits RPR from selling a competing PEG-asparaginase product anywhere in the world during the term of such agreement and for five years thereafter. The agreement terminates in December 2008, subject to early termination by either party due to a default by the other or by RPR at any time upon one year's prior notice to Enzon. Upon any termination all rights under the Amended RPR U.S. License Agreement revert to Enzon. A separate supply agreement with RPR requires RPR to purchase from Enzon all ONCASPAR requirements for sales in North America.

The Company and RPR are currently in discussions related to a disagreement over the purchase price of ONCASPAR under the supply agreement between the two companies. RPR has asserted that the Company has overcharged RPR under the supply agreement in the amount of \$2,329,000. The Company believes its costing and pricing of ONCASPAR to RPR complies with the terms of the supply agreement. RPR has also asserted that the Company should be responsible for its lost profits while ONCASPAR is under the temporary labeling and distribution modifications agreed to by the Company and the FDA. RPR contends that its lost profits due to this matter, through June 30, 1999 were \$2,968,000. The Company does not agree with RPR's claim.

Under a separate license, RPR has exclusive rights to sell ONCASPAR in Canada and Mexico. These agreements provide for RPR to obtain marketing approval of ONCASPAR in Canada and Mexico and for the Company to receive royalties on sales of ONCASPAR in these countries, if any.

The Company also has a license agreement with RPR for the Pacific Rim region, specifically, Australia, New Zealand, Japan, Hong Kong, Korea, China, Taiwan, Philippines, Indonesia, Malaysia, Singapore, Thailand and Viet Nam (the 'Pacific Rim'). The agreement provides for RPR to purchase ONCASPAR for the Pacific Rim from the Company at certain established prices which increase over the ten year term of the agreement. Under the agreement, RPR is responsible for obtaining additional approvals and indications in the licensed territories. The agreement also provides for minimum purchase requirements for the first four years of the agreement.

#### MEDAC AGREEMENT

The Company has also granted an exclusive license to MEDAC to sell ONCASPAR in Europe and Russia. The agreement provides for MEDAC to purchase ONCASPAR from the Company at certain established prices which increase over the initial five year term of the agreement. Under the agreement, MEDAC is responsible for obtaining additional approvals and indications in the licensed territories,

F-15

#### ENZON, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

beyond the currently approved hypersensitive indication in Germany. Under the agreement, MEDAC is required to meet certain minimum purchase requirements.

#### (10) COMMITMENTS AND CONTINGENCIES

The Company is being sued by a former financial advisor asserting that under a May 2, 1995, letter agreement ('Letter Agreement') between Enzon and LBC Capital Resources Inc. ('LBC'). LBC claims it was entitled to a commission in connection with the Company's January and March 1996 private placements, comprised of \$500,000 and warrants to purchase approximately 1,000,000 shares of

Enzon common stock at an exercise price of \$2.50 per share. LBC has also asserted that it is entitled to an additional fee of \$175,000 and warrants to purchase 250,000 shares of Enzon common stock when and if any of the warrants obtained pursuant to the private placements are exercised. LBC has claimed \$3,000,000 in compensatory damages, plus punitive damages, counsel fees and costs for the alleged breach of the Letter Agreement. The Company believes that no such commission was due under the Letter Agreement and denies any liability under the Letter Agreement. The Company intends to defend this lawsuit vigorously and believes the ultimate resolution of this matter will not have a material adverse effect on the financial position of the Company.

In the course of normal operations, the Company is subject to the marketing and manufacturing regulations as established by the Food and Drug Administration ('FDA'). During the year ended June 30, 1999, the Company and the FDA agreed to temporary labeling and distribution modifications for ONCASPAR due to increased levels of particulates in certain batches of ONCASPAR, which were manufactured by the Company. The Company, rather than its marketing partner, Rhone-Poulenc Rorer ('RPR'), will temporarily distribute ONCASPAR directly to patients, on an as needed basis, and will conduct the additional inspection and labeling procedures prior to distribution. During May 1999, the FDA placed additional restrictions on ONCASPAR, which specified ONCASPAR was to be distributed only to those patients who are hypersensitive to native L-asparaginase.

The Company has been able to manufacture several batches of ONCASPAR which contain acceptable levels of particulates and anticipates a final resolution of the problem during fiscal 2000. It is expected that RPR will resume distribution of ONCASPAR at that time. There can be no assurance that this solution will be acceptable to the FDA. If the Company is unable to resolve this problem it is possible that the FDA may not permit the Company to continue to distribute this product. An extended disruption in the marketing and distribution of ONCASPAR could have a material adverse impact on future ONCASPAR sales.

The Company maintains a separate supply agreement with RPR, under which RPR purchases from Enzon all of RPR's requirements for ONCASPAR at a price defined in the supply agreement. The Company and RPR are currently in discussions related to a disagreement over the purchase price of ONCASPAR under the supply agreement between the two companies. RPR has asserted that the Company has overcharged RPR under the supply agreement in the amount of \$2,329,000. The Company believes its costing and pricing of ONCASPAR to RPR complies with the supply agreement.

RPR has also asserted that the Company should be responsible for its lost profits while ONCASPAR is under the temporary labeling and distribution modifications. RPR contends that its lost profits through June 30, 1999 were \$2,968,000. The Company does not agree with RPR's claim for these two issues. The Company does not believe the ultimate resolution of these matters will have a material adverse effect on the financial results or operations of the Company.

The Company has agreements with certain members of its upper management which provide for payments following a termination of employment occurring after a change in control of the Company. The Company also has a 3-year employment agreement, dated April 5, 1997, with its Chief Executive Officer which provides for severance payments in addition to the change in control provisions discussed above.

F-16

ENZON, INC. AND SUBSIDIARIES  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

(11) LEASES

The Company has several leases for office, warehouse, production and research facilities and equipment.

Future minimum lease payments, net of subleases, for noncancelable operating leases with initial or remaining lease terms in excess of one year as of June 30, 1999 are:

YEAR ENDING JUNE 30, -----	OPERATING LEASES -----
2000.....	\$ 979,000
2001.....	952,000
2002.....	819,000
2003.....	765,000
2004.....	765,000
Later years, through 2007.....	2,752,000
	-----
Total minimum lease payments.....	\$7,032,000
	-----
	-----

Rent expense amounted to \$1,394,000, \$1,768,000 and \$1,608,000 for the years ended June 30, 1999, 1998 and 1997, respectively.

For the years ended June 30, 1999, 1998 and 1997, rent expense is net of subrental income of \$110,000, \$221,000 and \$233,000, respectively. As of June 30, 1999, the Company no longer subleases a portion of its facilities.

#### (12) RETIREMENT PLANS

The Company maintains a defined contribution, 401(k) pension plan for substantially all its employees. The Company currently matches 50% of the employee's contribution of up to 6% of compensation, as defined. The Company's match is invested solely in a fund which purchases the Company's Common Stock in the open market. Total company contributions for the years ended June 30, 1999, 1998 and 1997 were \$115,000, \$100,000 and \$105,000, respectively.

#### (13) ACCRUED EXPENSES

Accrued expenses consist of:

	JUNE 30, -----	
	1999	1998
	----	----
Accrued wages and vacation.....	\$1,074,000	\$ 695,000
Accrued Medicaid rebates.....	1,114,000	1,083,000
Current portion of royalty Advance -- RPR.....	200,000	1,006,000
Contract and legal accrual.....	3,328,000	1,000,000
Other.....	546,000	592,000
	-----	-----
	\$6,262,000	\$4,376,000
	-----	-----
	-----	-----

#### (14) BUSINESS AND GEOGRAPHICAL SEGMENTS

Effective July 1, 1998, the Company adopted SFAS No. 131, 'Disclosures about Segments of an Enterprise and Related Information.' The Company manages its business in one business segment in one location.

During the years ended June 30, 1999, 1998 and 1997, the Company had export sales of \$3,075,000, \$2,641,000 and \$2,377,000 respectively. Of these amounts, sales to Europe represented \$2,559,000, \$2,117,000 and \$1,937,000 during the years ended June 30, 1999, 1998 and 1997, respectively. Included as

a component of European sales are sales to France which were \$1,108,000, \$994,000 and \$663,000; and sales to Italy which were \$1,201,000, \$879,000 and \$441,000 for the years ended June 30, 1999, 1998 and 1997.

ADAGEN sales represent approximately 90% of the Company's total net sales for the year ended June 30, 1999. ADAGEN's Orphan Drug designation under the Orphan Drug Act expired in March 1997. The Company believes the expiration of ADAGEN's Orphan Drug designation will not have a material impact on the sales of ADAGEN. Approximately 49%, 48% and 54% of the Company's ADAGEN sales for the years ended June 30, 1999, 1998 and 1997, respectively, were made to Medicaid patients.

F-18

ENZON, INC. AND SUBSIDIARIES  
 CONSOLIDATED CONDENSED BALANCE SHEET  
 DECEMBER 31, 1999  
 (UNAUDITED)

ASSETS

Current assets:

Cash and cash equivalents.....	\$ 23,261,685
Accounts receivable.....	4,701,186
Inventories.....	1,423,507
Other current assets.....	1,738,367

-----  
 Total current assets..... 31,124,745  
 -----

Property and equipment.....	11,951,345
Less accumulated depreciation and amortization.....	10,497,269
	-----
	1,454,076 -----

Other assets:

Investments.....	68,823
Other assets, net.....	807,711
Patents, net.....	977,883
	-----
	1,854,417 -----

-----  
 Total assets..... \$ 34,433,238  
 -----

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable.....	\$ 1,783,726
Accrued expenses.....	8,232,526
	-----

-----  
 Total current liabilities..... 10,016,252  
 -----

Accrued rent.....	621,152
Royalty advance -- RPR.....	815,583
	-----
	1,436,735 -----

Commitments and contingencies

Stockholders' equity:

Preferred stock-.01 par value, authorized 3,000,000 shares: issued and outstanding 27,000 shares at December 31, 1999 (liquidation preference aggregating \$1,189,000 at December 31, 1999).....	270
Common stock-.01 par value, authorized 60,000,000	

shares; issued and outstanding 37,209,146 shares at December 31, 1999.....	372,091
Additional paid-in capital.....	149,371,514
Accumulated deficit.....	(126,763,624)
	-----
Total stockholders' equity.....	22,980,251
	-----
Total liabilities and stockholders' equity.....	\$ 34,433,238
	-----
	-----

The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.

F-19

ENZON, INC.  
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS  
SIX MONTHS ENDED DECEMBER 31, 1999 AND 1998  
(UNAUDITED)

	1999	1998
	----	----
Revenues		
Sales.....	\$ 6,616,903	\$ 6,718,113
Contract revenue.....	61,982	67,475
	-----	-----
Total revenues.....	6,678,885	6,785,588
	-----	-----
Costs and expenses		
Cost of sales.....	1,971,482	2,338,796
Research and development expenses.....	3,590,252	3,422,911
Selling, general and administrative expenses.....	5,136,409	3,643,655
	-----	-----
Total costs and expenses.....	10,698,143	9,405,362
	-----	-----
Operating loss.....	(4,019,258)	(2,619,774)
	-----	-----
Other income (expense)		
Interest and dividend income.....	599,222	602,881
Interest expense.....	(3,884)	(8,055)
Other.....	(36,274)	39,834
	-----	-----
	559,064	634,660
	-----	-----
Net loss.....	\$ (3,460,194)	\$ (1,985,114)
	-----	-----
	-----	-----
Basic and diluted loss per common share.....	\$ (0.09)	\$ (0.06)
	-----	-----
	-----	-----
Weighted average number of common shares issued and outstanding.....	36,835,399	35,181,937
	-----	-----
	-----	-----

The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.

F-20

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS  
SIX MONTHS ENDED DECEMBER 31, 1999 AND 1998  
(UNAUDITED)

	1999	1998
	----	----
Cash flows from operating activities:		
Net loss.....	\$(3,460,194)	\$(1,985,114)
Adjustment for depreciation and amortization.....	243,212	559,869
Loss (gain) on retirement of equipment.....	36,274	(39,834)
Non-cash expense for issuance of common stock and stock options.....	207,770	242,497
Decrease in accrued rent.....	(13,238)	(79,533)
Increase (decrease) in royalty advance -- RPR.....	5,219	(110,507)
Changes in assets and liabilities.....	1,168,597	(1,906,039)
	-----	-----
Net cash used in operating activities.....	(1,812,360)	(3,318,661)
	-----	-----
Cash flows from investing activities:		
Capital expenditures.....	(257,047)	(137,875)
Proceeds from sale of equipment.....	--	129,872
	-----	-----
Net cash used in investing activities.....	(257,047)	(8,003)
	-----	-----
Cash flows from financing activities:		
Proceeds from issuance of common stock, net.....	2,199,860	20,583,850
Dividends paid on Series A Preferred Stock.....	(1,542,404)	--
	-----	-----
Net cash provided by financing activities.....	657,456	20,583,850
	-----	-----
Net (decrease) increase in cash and cash equivalents....	(1,411,951)	17,257,186
Cash and cash equivalents at beginning of period.....	24,673,636	6,478,459
	-----	-----
Cash and cash equivalents at end of period.....	\$23,261,685	\$23,735,645
	-----	-----

The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.

F-21

ENZON, INC. AND SUBSIDIARIES  
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS  
(UNAUDITED)

(1) ORGANIZATION AND BASIS OF PRESENTATION

The unaudited consolidated condensed financial statements have been prepared from the books and records of Enzon, Inc. and subsidiaries in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting only of normal and recurring adjustments) considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of the results that may be expected for the year.

(2) LOSS PER COMMON SHARE

Basic and diluted loss per common share is based on the net loss for the relevant period, adjusted for cumulative undeclared preferred stock dividends of \$27,000 and \$107,000 for the six months ended December 31, 1999 and 1998, respectively, divided by the weighted average number of shares issued and outstanding during the periods. Due to the net loss recorded for the six months ended December 31, 1999 and 1998, the exercise or conversion of all dilutive potential common shares is not included for purposes of the diluted loss per



share calculation. As of December 31, 1999, the Company had 6,842,000 common stock equivalents outstanding that could potentially dilute future diluted earnings per share calculations.

(3) INVENTORIES

The composition of inventories at December 31, 1999 is as follows:

Raw materials.....	\$ 240,000
Work in process.....	1,017,000
Finished goods.....	167,000
	-----
	\$1,424,000
	-----
	-----

(4) CASH FLOW INFORMATION

Highly liquid securities with original maturities of three months or less are considered to be cash equivalents. Cash payments for interest were approximately \$4,000 for the six months ended December 31, 1999 and \$8,000 for the six months ended December 31, 1998. There were no income tax payments made for the six months ended December 31, 1999 and 1998. During the six months ended December 31, 1999, 80,000 shares of Series A Cumulative Convertible Preferred Stock ('Series A Preferred Stock') were converted to 181,818 shares of Common Stock. Accrued dividends on the converted preferred shares of \$1,542,000 were settled by a cash payment. There were no conversions of Series A Preferred Stock during the six months ended December 31, 1998.

(5) NON-QUALIFIED STOCK OPTION PLAN

On December 7, 1999 the stockholders voted to increase the number of shares reserved for issuance under our Non-Qualified Stock Option Plan from 6,200,000 to 7,900,000. During the six months ended December 31, 1999, we issued 209,000 stock options at an average exercise price of \$29.07 per share under our Non-Qualified Stock Option Plan, as amended, of which 77,000 were granted to executive officers as part of a bonus plan for the year ended June 30, 1999. None of the options granted during the period are exercisable as of December 31, 1999. All options were granted with exercise prices that equaled or exceeded the fair market value of the underlying stock on the date of grant.

F-22

ENZON, INC. AND SUBSIDIARIES  
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS -- (CONTINUED)  
(UNAUDITED)

(6) BUSINESS SEGMENTS

A single management team that reports to the Chief Executive Officer comprehensively manages our business operations. We do not operate separate lines of business or separate business entities with respect to any of our approved products or product candidates. In addition, we do not conduct any operations outside of the United States. We do not prepare discrete financial statements with respect to separate product areas. Accordingly, we do not have separately reportable segments as defined by Statement of Financial Accounting Standards No. 131, 'Disclosures about Segments of an Enterprise and Related Information'.

(7) COMPREHENSIVE LOSS

The net loss of \$3,460,000 and \$1,985,000, recorded for the six months ended December 31, 1999 and 1998, respectively, is equal to the comprehensive loss for those periods.

(8) COMMITMENTS AND CONTINGENCIES

We are being sued, in the United States District Court for the District of New Jersey, by a former financial advisor asserting that under a May 2, 1995 letter agreement between us and LBC Capital Resources Inc., LBC was entitled to a commission in connection with our January and March 1996 private placements, comprised of \$500,000 and warrants to purchase 1,000,000 shares of our common stock at an exercise price of \$2.50 per share. LBC has claimed \$3,000,000 in compensatory damages, plus punitive damages, counsel fees and costs for the alleged breach of the letter agreement. We have entered into an agreement with LBC (Stipulation of Damages) that if we are found liable to LBC in this suit the damages for these claims would be limited to \$2,750,000 in cash. LBC has also asserted that it is entitled to an additional fee of \$175,000 and warrants to purchase 250,000 shares of our common stock to the extent the warrants issued to investors in the private placements are exercised. We believe that no compensation is due to LBC under the letter agreement and deny any liability under the letter agreement. We intend to defend this lawsuit vigorously and believe the ultimate resolution of this matter will not have a material adverse effect on our financial position. However, if we were required to issue warrants to LBC we would be required to incur a non-cash expense for each warrant issued equal to the difference between the exercise price of the warrants (\$2.50) and the then current market price of our common stock.

In January 2000, Hoffmann-La Roche filed lawsuits in both the U.S. and France against Schering-Plough alleging that PEG-Intron infringes certain patents held by Hoffmann-La Roche. The validity and scope of Hoffmann-La Roche's patents in this segment of the industry could be judicially determined during these proceedings. The litigation is at a very early stage and we are not in a position to predict its outcome. If Schering-Plough does not prevail in this litigation, Hoffmann-La Roche may completely block Schering-Plough from commercializing PEG-Intron and we will not receive any royalties on the sales of PEG-Intron. This would have a material adverse effect on our business, financial condition and results of operations.

In the course of normal operations, we are subject to the marketing and manufacturing regulations as established by the Food and Drug Administration ('FDA'). We have agreed with the FDA to temporary labeling and distribution modifications for ONCASPAR due to increased levels of particulates in certain batches of ONCASPAR, which we manufactured. We, rather than our marketing partner, Rhone-Poulenc Rorer ('RPR'), will temporarily distribute ONCASPAR directly to patients, on an as needed basis. We will conduct additional inspection and labeling procedures prior to distribution.

We have manufactured several batches of ONCASPAR which contain acceptable levels of particulates and anticipate a final resolution of the problem during fiscal 2000. It is expected that RPR

F-23

ENZON, INC. AND SUBSIDIARIES  
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS -- (CONTINUED)  
(UNAUDITED)

will resume distribution of ONCASPAR at that time. There can be no assurance that this solution will be acceptable to the FDA. If we cannot resolve this problem it is possible that the FDA may not permit us to continue to distribute this product. An extended disruption in the marketing and distribution of ONCASPAR could have a material adverse impact on future ONCASPAR sales.

We maintain a separate supply agreement with RPR, under which RPR purchases from us all of RPR's requirements for ONCASPAR at a price defined in the supply agreement. We are currently in discussions with RPR related to a disagreement over the purchase price of ONCASPAR under the supply agreement we have with RPR. RPR has asserted that we have overcharged them under the supply agreement in the amount of \$2,329,000. We believe our costing and pricing of ONCASPAR to RPR complies with the supply agreement.

RPR has also asserted that we should be responsible for its lost profits while ONCASPAR is under the temporary labeling and distribution modifications. RPR contends that its lost profits through December 31, 1999 were \$5,194,000. We do not agree with RPR's claim for over charges under the supply agreement and lost profits. We do not believe the ultimate resolution of these matters will

have a material adverse effect on our financial results or operations, though it could have a material adverse effect on our financial position.

(9) SCHERING AGREEMENT

During December 1999, our development partner for PEG-Intron, Schering-Plough submitted a U.S. marketing application to the FDA for the use of PEG-Intron in the treatment of chronic hepatitis C. We are entitled to a \$1 million milestone payment upon the FDA's acceptance of this filing.

Schering-Plough has also reported that it has submitted a centralized Marketing Authorization Application for PEG-Intron to the European Union's (EU) European Agency for the Evaluation of Medicinal Products (EMEA).

Under the Company's licensing agreement with Schering-Plough, we are entitled to royalties on worldwide sales of PEG-Intron. We will receive an additional \$2 million milestone payment upon FDA approval of PEG-Intron.

(10) SUBSEQUENT EVENT

During January 2000, all of the outstanding Series B Preferred Stock warrants to purchase 657,895 shares of Common Stock were exercised. This exercise resulted in net proceeds of approximately \$2,625,000.

F-24

[THIS PAGE INTENTIONALLY LEFT BLANK]

[THIS PAGE INTENTIONALLY LEFT BLANK]

[Logo]

STATEMENT OF DIFFERENCES

-----

The trademark symbol shall be expressed as..... 'TM'  
The registered trademark symbol shall be expressed as..... 'r'